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The projects described in this thesis investigate the psychophysical properties and 
neural correlates of cutaneous and muscle pain in healthy volunteers and in a 
small patient group.
A total of four experiments are reported; two in healthy volunteers and two in 
patients with lateral epicondylitis.
The first experiment investigated psychophysical differences between intradermal, 
subcutaneous and intramuscular pain induced by hypertonic saline injections. The 
pain descriptors used by the subjects were different between the three injections. 
The profile of pain, including the intensity and time course and response to each 
single injection, was similar between intradermal and intramuscular injections 
whereas results were inconsistent with subcutaneous injections.
The second study, employing the methods developed in the first, used functional 
magnetic resonance imaging (fMRI) of the brain to undertake a comparison of the 
neural activation patterns associated with intradermal and intramuscular pain.
The results reveal commonalities but also distinct differences between the two 
tissue types, including more prominent activations following intramuscular 
injections in some brain areas including prefrontal cortex and caudate nucleus. In 
addition, peak activation following intramuscular injection was observed to be 
more rostral in a key component of the pain circuitry, anterior insula.
The third study compared brain activations in a clinical pain population with 
results suggesting that pain processing in this population involves ventrobasal 
structures (amygdala and hippocampus) which was not seen in healthy subjects in 
study 2. Activation in secondary somatosensory cortex appeared more posterior 
than in healthy subjects.
Innocuous and painful compression of the painful area in two subjects also 
revealed unique brain activations.
Taken together the studies reveal differences in both perceptual qualities and 
neural correlates of cutaneous and muscle pain; both in healthy volunteers and in 
clinical pain patients.
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Chapter one: Introduction to the thesis
This first chapter serves to provide an introduction to the thesis and the topics 
covered therein.
It begins with a background to the topics presented; providing first a historical 
aspect of and then generic overview of pain; aiming to set the context for the 
investigations later presented.
The chapter concludes with a brief overview of the individual chapters contained 
within the rest of the thesis.
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1.1 Historical perspective on pain
Historically the overriding theory of pain was the specificity theory proposed by 
Rene Descartes in the 17th century. Descartes argued that the human body worked 
akin to a machine thereby allowing its study using methods of physics (Melzack 
1999). Although Descartes argued that humans did have a soul, it was separate 
from the body; the latter being a machine, rather like an animal’s body. Pain he 
argued was therefore the result of a simple one way, un-modifiable system that 
occurred when a peripheral external stimulus sent a signal to the ‘pain pathway , 
this signal being transmitted along the pathway to a single ‘pain centre’ within the 
brain.
This specificity theory dominated not just scientific investigation but also medical 
therapeutic practice for some time, persisting well into the 21st century.
Melzack and Wall (1970) in a review of pain related investigations and 
experiments conducted in the first half of the 20th century note that these 
predominately focused on the search for specific pain fibres, pathways and a pain 
centre in the brain. Thus the concept of pain as a specific straight through sensory 
projection system was accepted.
Several theories of pain however did follow, the major opponent to the specificity 
theory being pattern theories which although described as vague and inaccurate 
are considered to have ‘set the stage’ for the emergence of the gate control theory 
proposed by Melzack and Wall (1965).
However none of these successive theories considered an explicit role for the 
brain in pain other than as being a passive recipient for incoming information. 
Although they did signal a shift of focus in the direction from the periphery to the 
central nervous system albeit at the level of the spinal cord.
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Melzack and Wall’s proposal of the gate control theory of pain was the first to 
truly recognise that not only is the awareness of pain not directly linked to the 
degree of noxious stimulus presented i.e. that the signal could in some way be 
modulated but that this modulation may be driven by higher cognitive centres.
They proposed that transmission of nerve impulses from afferent fibres in the 
periphery to spinal cord transmission (T) cells is subject to modulation by a spinal 
gating mechanism within the dorsal horn. Further this spinal gating would be 
affected by activity in large and small diameter fibres; large fibre activity having 
an inhibitory effect on transmission i.e. would ‘close’ the gate whilst activity in 
the small fibres would have a facilitatory influence or ‘open’ the gate. The theory 
contended that this spinal gating mechanism is influenced by nerve impulses that 
descend from the brain via a specialised system of large diameter fibres that 
activate selective cognitive processes that influence, via descending fibres the 
properties of the spinal gating mechanism.
At the time of the proposal the gate control theory caused much debate and was 
seen as the catalyst to a great deal of research seeking to support or disprove the 
theory. Although the concept has been modified over the proceeding 30 years 
many principles of the gate control theory hold true today (Gifford 1998) and the 
concept is included in every major textbook on pain.
1.2 Definition of pain
Pain has been defined by the International Association for The Study of Pain 
(IASP, 1979) as ‘an unpleasant sensory and emotional experience associated with 
actual tissue damage or expressed in such terms’ i.e. pain is ultimately a 
perception; a perception determined by a number of factors, both internal and 
external to the person experiencing the pain, such factors may include previous 
experience / exposure to pain, the environment in which it occurs and the potential 
impact the pain may have on an individual’s life.
The term pain should be differentiated from nociception; the latter refers to the 
mechanisms by which the nervous system handles noxious or unpleasant
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information whereas the former refers to the actual physical and emotional 
sensation that an individual experiences.
Pain, both experimental and clinical, in common with any form of somatic 
sensation, is now considered to be the integration of sensory, cognitive and 
affective components (Melzack & Casey 1968); these three components 
accounting for the multidimensional complexity of pain. Sensory attributes 
include location, magnitude and spatiotemporal properties; affective properties 
include the hedonic aspect -  i.e. the degree of unpleasantness of the sensation and 
a motivational aspect -  producing the motivation to limit the experience of the 
noxious stimulus (Sewards et al., 2002). It has been argued that the hedonic and 
sensory aspects of somatic sensation are represented and processed in parallel but 
distinct pathways throughout the nervous system. Cognitive aspects of pain 
include the interpretation and meaning of the pain to the individual and again are 
subject to many factors including past experience and environmental situation 
(Sewards et al., 2002).
1.2.1 Taxonomy of pain
The taxonomy of pain over the years has been the subject of much debate 
(Merskey and Bogduk, 1994). Researchers and clinicians alike have sought to 
define pain syndromes both for academic and clinical progression. Pain may be 
classified as ‘experimental pain’ or ‘clinical pain’; both of which however are 
generic and cover a broad spectrum of both normal physiology and 
pathophysiology. Experimental pain involves stimulation of nociceptors through 
the introduction of a noxious stimulus; stimuli may be chemical, thermal, 
electrical or ischaemic (Arendt Nielsen et al., 2001). Typically both the stimulus 
and the response will be relatively short lasting, causing little or no tissue damage 
and the effects of which are totally reversible. Experimental pain investigations 
are frequently undertaken in animal studies or healthy volunteers although 
increasingly these are also being applied in patient populations.
The term ‘clinical pain’ refers to a pain condition arising from injury or disease; 
typically where actual tissue damage has occurred. Clinical pain is frequently
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further categorised based on temporal characteristics into acute or chronic pain 
and / or employing a tissue based classification into neuropathic, nociceptive or 
visceral pain (Merskey and Bogduk, 1994). The term ‘acute’ is typically 
employed in the early stages of injury e.g. post fracture or surgical operation, 
whilst ‘chronic’ pain has been defined as ‘pain which persists past the normal 
time of healing’ (Bonica 1953).
Neuropathic pain is defined as ‘pain initiated or caused by a primary lesion or 
dysfunction in the nervous system’ (Merskey and Bogduk, 1994). Further sub - 
classifications of neuropathic pain being peripheral neuropathic or central 
neuropathic pain; this relates to whether the symptoms originate from or are 
mediated predominantly by the peripheral or the central nervous system. Visceral 
pain is that which arises from the viscera whilst nociceptive pain typically arises 
from the musculoskeletal system (Merskey and Bogduk, 1994).
1.3 Generic mechanisms of pain
The development of the gate control theory developed by Melzack and Wall in the 
late sixties led to an upsurge in pain research and a greater understanding of the 
complexity of pain perception. In the periphery, the initial noxious stimulus 
(mechanical, thermal or chemical) activates primary sensory nerve cells with 
receptive properties, which are tuned to noxious stimuli (Julius and Basbaum 
2001) but only if these stimuli are of sufficient intensity to cause actual or 
potential damage to tissue (Woolf and Ma 2007). These specialised nerve cells, 
nociceptors, rapidly receive, transduce and integrate noxious information (Hucho 
and Levine 2007), allowing the organism to take defensive or avoidant action. A8 
nociceptors, which are thinly myelinated and of medium diameter, belong to two 
main classes -  type I are polymodal, responding to heat, mechanical and chemical 
stimuli (Meyer et al 2006) while type II fibres are less responsive to mechanical 
stimuli, respond more slowly to heat (with a slower conduction velocity than Type 
I fibres) yet are credited with the first pain sensation from a noxious heat stimulus. 
C-fibre nociceptors which are unmyelinated, polymodal and of small diameter, 
respond to noxious chemical, thermal and mechanical stimuli (Julius and 
Basbaum 2001). A5 fibres, because of their larger size and more rapid
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transduction (with a conduction velocity of 6 -25 ms'1), are thought to be 
responsible for the immediate “first” sharp pain sensation, whilst the smaller C- 
fibres, firing more slowly (at a conduction velocity of less than 1.0 ms’1) are the 
candidates for the transmission of the slower dull, more disseminated “second” 
pain sensation (Julius and Basbaum 2001). The first pain is perceived within 0.84 
seconds whereas the second pain evolves over the next 2.1 seconds (Handwerker 
and Kobal 1993).
Nociceptive activity is modulated by mediators in the extracellular tissue fluid 
(Hucho and Levine 2007). When the peripheral terminals of C-fibres are 
stimulated enough to fire, they cause an immediate rise in the concentration of 
glutamate in the injured tissue which reaches a peak within a 2 hour period and 
transiently re-activates nociceptive nerve fibres (Ro at al., 2005). In addition to 
the release of glutamate there is a range of chemicals that act on the peripheral 
terminals of C-fibres, sensitising them and causing them to fire in response to 
innocuous, low-intensity stimuli, so that the pain sensation continues (Woolf and 
Ma 2007). These chemicals have been termed the “inflammatory soup”; these 
surround the area of tissue damage, and include cytokines, amines, prostanoids, 
growth factors, kinins and chemokinines. Nociceptive neurons, in common with 
all sensory neurons are capable of long-term plastic change in response to this 
chemical sensitisation, contributing to the experience of persistent pain (Hucho 
and Levine 2007).
Nociceptive afferent fibres terminate predominantly in the dorsal horn of the 
spinal cord and synapse with projection neurons located in lamina I and 
intemeurons in lamina I and lamina II (Graham et al., 2007). A subset of these 
neurons, wide dynamic range neurons, responds to stimuli that are both noxious 
and non-noxious (Basbaum and Jessell, 2000).
Nociceptive signals then project to the brain via five key ascending pathways: 
spinothalamic, spinomesencephalic, cervicothalamic and the spinohypothalamic 
(Basbaum and Jessell, 2000). The spinothalamic tract is central to pain 
processing; lamina V dorsal horn neurons predominantly project A8 and C 
nociceptor input directly to lateral thalamic nuclei via the contralateral
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The thalamus is the main relay location for the passage of nociceptive signals to 
the cortex not only for the relaying of ascending signals, but also for the relaying 
of descending, pain modulating signals (Weiss et al., 2005)
Julius and Basbaum (2001) acknowledge that most of the work on primary 
nociceptive afferents has been done using a model of skin pain, as these are most 
accessible. However, nociceptors are spread widely throughout the body, 
innervating the skin, muscle, joints and the viscera and in each area of the body 
are specialised to respond to different stimuli, for example to light touch over the 
cornea, or to any stimulus to the teeth. Visceral silent nociceptors have a firing 
threshold that is dramatically reduced by inflammation and chemicals. (Basbaum 
and Jessell, 2000).
1.3.1 Modulation of pain
The descending pain modulatory system comprises a cerebral, spinal and 
peripheral network, such that pain may be either reduced or enhanced (Fields et al, 
2006). Pain modulation is mediated in the main by endogenous opioid peptides 
that are ubiquitous in the pain matrix but particularly in the periaqueductal grey 
(PAG) and the rostral ventromedial medulla (RVM). Endogenous opioid release, 
and subsequent pain relief, is dependent upon behavioural triggers, sensory 
stimuli and the mediating action of neurotransmitters such as GABA and 
glutamate (Fields et al., 2006).
In addition, Yoshimura and Furue (2006) have discussed the analgesic effects of 
noradrenaline and serotonin release by the membrane hyperpolarisation, reducing 
the excitatory effect of nociceptive fibres, and stimulating the release the 
inhibitory transmitters, GABA and glycine.
spinothalamic tract, whilst Lamina I-II dorsal horn neurons of the
spinomesencephalic and spinoreticular tracts mainly relay C nociceptor input to
parabrachial, midbrain, and medial thalamic nuclei (Hunt and Mantyh, 2001).
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1.4 Why do we feel pain?
Wall (1979) describes the sensation of acute pain as being the ‘conscious signal of 
a physical threat’; as such pain may serve as a warning, a major purpose of which, 
in addition to producing the emotional reaction of fear and or anger, is to provide 
the motivation that may bring about an appropriate behavioural response 
facilitating both survival and healing. Depending upon the type of stimulus, the 
tissue involved, environmental factors and previous experience behavioural 
response may vary.
The initial response therefore of acute pain is purposeful; bringing about 
behaviours that remove the body from danger thereby reducing further damage 
and promoting healing. Behaviours can also bring about assistance — e.g. a child s 
cry or a back pain sufferer’s grimace. When pain persists however the ensuing 
behaviour often no longer serves a purpose, indeed the opposite is frequently true. 
Protective or avoidant behaviours associated with chronic pain may contribute to 
the persistence of pain and its resistance to therapeutic interventions.
When faced with an actual or perceived physical insult a number of physiological 
responses occur, of which the perception of pain may or may not be one. Issues of 
bodily survival take precedent over the perception of pain and its associated 
illness behaviour (Gray 1987) as seen for example in the battlefield situation 
where injured American service personnel did not report pain in the immediate 
post trauma time period (Beecher 1946).
Indeed the suppression of pain by the CNS may be a survival strategy to prevent 
pain impinging on our consciousness (Fields & Basbaum 2006). Conversely pain 
experienced may far outweigh actual or potential tissue injury with respect to the 
stimulus.
Hence it is now well established that the reported experience in terms of severity 
and unpleasantness does not always correlate with the degree of noxious input / 
stimulation and / or tissue damage (Wall 2000). Nociceptors may fire with very 
little reported pain and conversely severe pain may be reported in the absence of
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excessive noxious stimulus. Pain experienced and / or reported by an individual is 
frequently disproportionate to the magnitude of the actual nociceptive stimulus.
Previously, those who presented with pain that either persisted beyond the 
expected healing time after trauma or reported pain that far out weighed the actual 
bodily harm may have been dismissed as being malingerers or have 
psychosomatic pain.
The apparent dichotomy between reported pain and tissue insult and the work of 
Melzack and Wall has increasingly led researchers to investigate the role of the 
central nervous system in initiating and/or maintaining chronicity in a number of 
clinical pain syndromes. Psychological factors are now seen as an integral 
component of pain processing and are the subject of much investigation of their 
role in not only maintaining chronic pain but also as the target of therapeutic 
intervention (Gifford 1998).
1.5 Investigating pain
Variability in the sensory manifestations and both temporal and behavioural 
characteristics render investigation of clinical pain complex (Woolf 1997); the 
individual and subjective nature of chronic pain making it difficult to define, 
quantify and hence ultimately treat effectively.
Experimental pain in healthy volunteers is easier than clinical pain to both control 
and standardise therefore is appealing to pain researchers (Arendt-Nielson & 
Svensson., 2001). This very standardisation, however, is perhaps also what 
contributes to the limitations of experimental models when extrapolating results to 
a clinical population.
How similar an experimental model tested in healthy volunteers is to a clinical 
condition in a patient population has been questioned (Staahl et al., 2006).
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Reliable reproduction of clinical pain syndromes however has proved difficult 
therefore application of experimental pain in a clinical population may be a useful 
compromise.
Although frequently quoted that cutaneous pain and muscle pain differ in their 
respective psychophysical properties (Svensson et al., 1997); direct comparisons 
of respective differences within the literature are scarce (Witting et al., 2001).
1.6 Soft tissue pain
Pain in the muscles is a common phenomenon affecting most people on occasion 
(Bennett 2007), usually occurring because of injury or strain, and settling down 
quickly once the affected muscle is rested. Myofascial pain is a common 
condition characterised by trigger points in a muscle which cause spontaneous 
pain and are painful to light compression (Yap 2007). A recent survey suggests up 
to 20% of the adult population in Europe, particularly women and the elderly may 
be affected by chronic musculoskeletal pain (Breivik et al., 2006). Although it is 
usually self-limiting, it is a causative or contributing factor in up to 30% of 
patients with chronic pain attending a pain clinic (Bennett 2007). Muscle pain 
can be difficult to localise, is variously described as cramping or aching in nature, 
and is frequently referred to other tissues (Mense 2003).
Svenssen et al., (1997c) suggest a commonality of central processing for muscle 
and skin pain as nociceptive afferents from both skin and muscle converge onto 
wide dynamic range neurons in the spinal dorsal horn, although other researchers 
emphasise the differences in skin and muscle pain processing throughout the 
central nervous system. This is also evident when comparisons are made between 
visceral and skin pain, with nociceptive responses from both visceral and 
cutaneous tissue converging on the dorsal horn such that the spinothalamic 
pathway contains neurons which respond to noxious events in both types of tissue 
(Strigo et al., 2003). These researchers did demonstrate a difference in cerebral 
processing between visceral pain (an increase in primary somatosensory and 
motor cortical processing) and skin pain (increased activation in anterior cingulate 
cortex and ventrolateral prefrontal cortex).
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Muscle nociceptors are classified as group III (with similar properties to A5 
fibres, including a thin layer of myelination) and Group IV (unmyelinated and 
with similar properties to C-fibres, Graven-Niel sen and Mense, 2001). Group IV 
fibres have been shown to end exclusively in free nerve endings, while group IV 
fibres, in addition to free nerve endings, also have some other receptors such as 
paciniform corpuscles (Graven-Nielsen and Mense, 2001). Group III fibres have a 
conduction velocity of 2.5 -  30 ms'1 (measured in cats) whereas the velocity of 
Group IV fibres is slower at 2.5ms'1; these figures are comparable to the 
conduction velocities of A8 and C-fibres respectively.
In addition to differences in the physical properties of peripheral afferents 
mediating noxious stimuli from skin and muscle, differences are also reported in 
the processing of impulse transmission at various levels of the central nervous 
system. Small diameter muscle afferents do not terminate in lamina III of the 
dorsal horn where cutaneous afferents are numerous (Molander and Grant, 1987; 
Mense 2003). Central terminals of unmyelinated muscle afferents cover a larger 
area in the dorsal horn than those of cutaneous afferents while their density is 
lower (Ling et al., 2003).
In the thalamus, muscle nociceptor input into the ventrolateral and dorsal nuclei 
are more pronounced than from the skin (Gholami et al., 2006). The descending 
dorsal column pathways appear to impose a stronger inhibitory action on dorsal 
horn neurones processing noxious input from muscle than skin (Yu and Mense 
1990). These anatomic and physiological differences suggest a functional 
differentiation that may sub serve specific behavioural patterns. For example, 
stimulation of group III and IV afferents, using hypertonic saline injection, has 
been shown to facilitate motoneurone activity, while depressing motor cortex 
activity (Martin et al., 2008), arguably allowing the muscle to rest while healing 
takes place.
Much of the research on muscle pain has been done with animal models, with the 
limitation of results not always being applicable to clinical pain conditions.
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1.7 Differences in clinical phenomenology
Referral of pain is a typical characteristic of muscle pain (Capra and Ro 2004); for 
example injection of hypertonic saline into temporalis muscle elicits referred pain 
in the teeth (Jensen and Norup 1992) and into tibialis major causes ankle pain 
(Graven-Nielsen et al., 1997a).
In contrast noxious stimulation of the skin leads to secondary hyperalgesia 
characterised by a stinging, burning sensation and a visible, local “flare” 
surrounding the injured area of skin (Geber et al., 2007). This flare occurs because 
of the dual action of stimulated c-fibres -  first, to activate the pain network, and 
secondly to indirectly stimulate the release of neuropeptides. *
Easy access to the skin and controllability increases the appeal of cutaneous 
models of experimental pain, however how closely these models reflect clinical 
pain has been particularly questioned (Staahl et al., 2006). Experimental muscle 
pain has been shown to closely mimic clinical musculoskeletal pain in both 
subjective quality and motor performance (Arendt-Nielsen et al., 1996) and in 
response to pharmacological intervention (Curatolo et al., 2000). As such may 
provide a better model of clinical pain for investigation.
Various methods have been developed to evoke experimental pain in the skin and 
in muscles in healthy volunteers and animal studies. They typically have a rapid, 
short mode of action and no lasting effects, so are considered safe for use in 
experimental models. A constraint of many studies comparing muscle and skin 
pain lies in the use of different methods to stimulate a painful response (e.g. 
Svenssen et al., 1997a) using electrical stimulation to elicit muscle pain and laser 
stimulation to elicit skin pain).
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1.8 Brain imaging investigations of pain
Advances in brain imaging techniques have allowed the central determinants of 
pain to be investigated. Although differences are observed, activation in multiple 
discrete cortical and subcortical areas has been observed dispelling the belief that 
the cortex is not involved in pain processing (Treede et al., 1999). These 
consistently include SII, thalamus, anterior cingulate cortex (ACC) and insula 
(Peyron 2000). Less consistent but still frequent areas where activation during a 
painful stimulus has been reported include SI / MI, prefrontal cortex (PFC), 
cerebellum and basal ganglia (Apkarian 2005). Areas even less frequently 
reported include amygdala and hippocampus.
Manipulation of various parameters including attention (Brooks et al., 2002, 
Bantick et al., 2002), intensity (Derbyshire et al., 1997), unpleasantness (Rainville 
et al., 2002), expectation (Plogaus et al., 2003) and hypnotic induction 
(Derbyshire et al., 2004) will all influence areas of activation observed.
Studies utilising experimental phasic cutaneous pain in healthy volunteers 
dominate the imaging and pain literature; investigations of the central nervous 
system during experimental muscle pain are sparse; perhaps due to perceived 
controllability, particularly in relation to the ability to control phasic muscle pain. 
There is also a lack of brain imaging studies investigating clinical pain syndromes 
although these are increasing.
Chronic pain affects a significant proportion of the population, causing distress 
and disability to the sufferer in addition to being a socio-economic burden in 
terms of both health care and welfare. Muscle and soft tissue pain conditions are 
amongst the most commonly seen, but under-investigated; epidemiological 
studies suggesting the incidence being 2 -  9% of the population at any given time 
(Mense 2003). Despite this there is a paucity of imaging research investigating 
musculoskeletal pain.
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The author’s clinical experience of treating chronic musculoskeletal pain and the 
paucity of research utilising human experimental muscle pain models in brain 
imaging studies provided the impetus for the studies described in this thesis.
The thesis will address the following questions:
1. When experimental muscle and cutaneous pain are induced in healthy 
volunteers utilising the same methodology and intensity matching, are the 
psychophysical properties sufficiently different to enable clear distinction between 
pain originating in the two tissue types.
2. Are differences in psychophysical properties of experimental muscle and 
cutaneous pain induced in healthy volunteers reflected in observed brain 
activation patterns?
3. Does the presence of a pre-existing clinical pain condition (tennis elbow) 
enhance or negate differences observed in healthy volunteers.
4. How does clinical pain compare to experimental pain induced in contralateral 
but similar tissue.
1.9 Hypotheses
Hypotheses are based primarily on the expected differing behavioural response, 
the knowledge that muscle pain is consistently considered to be more unpleasant 
than cutaneous pain (Rainville et al., 1992, Svensson et ah, 1997a) and what is 
known from the small number of imaging studies utilising muscle pain.
The human brain must have the ability to differentiate between when ‘fight / 
flight’ is appropriate and when a ‘stop and protect signal’ in fact is required. 
Cutaneous pain predominantly arises from an external threat; whether that is 
pinprick, heat, cold or chemical. The response is fight, i.e. to defend oneself 
against attack or flight or in other words to distance oneself from the danger. 
Important information that the brain must process is the source, site and severity 
of damage therefore it is hypothesised that the lateral or direct pain pathway is 
likely to predominate.
Conversely pain arising from deep tissue, including muscle is likely to arise from 
an internal threat e.g. damage, disease or infection of deep tissue and initiates an
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altogether different behavioural response -  one of stop and protect i.e. to reduce 
activity, evaluate, prevent further damage and facilitate healing. In this scenario 
fight is of no purpose as the ‘fight’ per se is internal and flight would involve the 
use and therefore potentially further damage to the already injured / diseased 
tissue. Whilst sensory discriminative components will also have a role, it is 
proposed that the evaluative components are of greater importance.
Furthermore pain arising from muscle tissue will typically have a less apparent 
origin that the external insult that results in cutaneous pain hence it is expected 
that muscle pain will result in greater activity in cognitive processing and may 
induce a more fearful response. Therefore it is hypothesised that the medial pain 
pathway will predominate.
Through comparisons with the literature the hypothesis that experimental muscle 
pain rather than experimental cutaneous pain is more reflective of clinical pain 
will be tested.
Imaging predictions
1. Widespread activation will be observed in the ‘pain matrix’ during both muscle 
and cutaneous pain conditions.
2. Greater / more extensive activation will be observed in SI, posterior insula and 
lateral thalamus during cutaneous pain when compared to muscle pain reflecting 
greater activity in the lateral pain pathways.
3. Greater more extensive activation with be observed in rostral ACC, rostral 
anterior insula and the prefrontal cortex during muscle pain compared to 





Chapter 2 presents a review of the literature in relation to three key areas of pain; 
experimental models of pain, the role of the brain in pain processing in response 
to experimental pain and role of the brain in relation to clinical pain processing. 
The chapter serves to introduce the background for the four experiments described 
later in the thesis.
Chapter 3
Chapter three presents the methodology and results of Experiment One; a 
laboratory based investigation of the psychophysical properties of hypertonic 
saline induced pain in muscle (MS), intradermal (ID) and subcutaneous (SC) 
tissues.
The key aims of experiment one was (i) determine whether the psychophysical 
properties of deep and superficial pain differ when pain of similar intensity is 
induced using the same method of noxious stimulus and (ii) to investigate the 
applicability and reliability of the hypertonic saline model to consider its use in 
the planned fMRI studies.
Chapter 4
Chapter four begins with an overview of fMRI and methodology providing the 
background for the fMRI methods applied in three experiments described in the 
thesis.
The chapter then continues with the methodology specific to experiment two; 
fMRI undertaken in 18 healthy volunteers during hypertonic saline induced 
muscle and cutaneous pain. The results of this experiment are then presented. The 
chapter concludes with a brief discussion of the findings.
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Chapter 5
Chapter five describes two experiments carried out in three patients with a clinical 
diagnosis of lateral epicondylitis (tennis elbow).
The first experiment, in which all three patients participated, replicates the 
methods employed in the healthy volunteer experiment described in Chapter 4.
The second experiment, in which two patients participated, was also an fMRI 
study in which patients were subjected to both innocuous and noxious pressure 
stimuli to both the affected and unaffected arms.
The results of the experiments are presented then the chapter concludes with a 
brief discussion of the findings.
Chapter six
This final discussion chapter begins with a summary of the findings, followed by 
a review of associated methodological issues and further discussion and 
interpretation of the results of each experiment presented in the thesis in turn.
The chapter concludes with a discussion regarding the implications of the findings 
of all three experiments and makes recommendation for future investigations.
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Chapter 2: Literature review
This chapter reviews the literature with reference to what is currently known in 
regards to three key areas related to pain; experimental models of pain, the role of 
the brain in pain processing in response to experimental pain and role of the brain 
in relation to clinical pain processing.
The chapter begins with experimental pain, reviewing methods of induction 
(electrical, thermal, ischaemic, pressure, chemical), reliability and validity of the 
models, similarities and differences between models and tissue types and finally 
measurement.
There follows a brief overview of imaging techniques available; then continues to 
describe the so called ‘pain matrix’ and discusses the main components of the 
pain matrix. Studies involving experimental muscle pain are then specifically 
reviewed and an overview of cognitive and effective modulation of brain activity 
presented before a discussion on the functional division of pain pathways into 
medial and lateral components is presented.
Finally the chapter considers the literature that has employed brain imaging 
techniques to investigate clinical pain syndromes.
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2.1 Background: Experimental models of pain
Progress with regards to management of pain is contingent upon treatment being 
targeted at the mechanism(s) that operates to produce a patient’s symptoms 
(Woolf and Mannion, 1999). Variability in the sensory manifestations and 
temporal and behavioural characteristics however, render investigation of clinical 
pain complex. Clinical pain can rarely be standardised; some clinical conditions 
are episodic with intermittent quiescent periods of variable duration. Others may 
report a near constant background pain with frequent or infrequent exacerbations 
of varying duration and intensity. Clinical pain may be stimulus dependent or 
independent; be affected by temperature, circadian rhythms, menstrual cycle in 
women and a range of psychological factors. The latter includes anxiety and 
depression levels, previous pain experience, and situational and environmental 
factors (Keefe et al., 2005). In summary investigation of clinical pain is complex 
particularly when investigating effectiveness of a therapeutic intervention.
Experimental studies in healthy volunteers may therefore be useful, (Arendt- 
Nielson & Svensson 2001). How closely experimental models reflect the clinical 
situation however has been questioned (Petersen and Rowbotham, 1999).
A number of experimental models, particularly cutaneous pain have been 
described in the literature employing a variety of techniques utilising thermal, 
electrical, mechanical, chemical or ischaemic stimuli. Although these have added 
much to our knowledge base of the physiology of pain the models, particularly 
cutaneous ones are not without limitations. Cutaneous models however are 
particularly well developed; a possible reason for this being the ease of access to 
skin to introduce noxious stimuli.
The cutaneous models do have many advantages -  ease of application, 
repeatability and ability to switch pain ‘on’ and ‘off. However these very 
advantages also contribute to their limitations. Typically studies have been of a 
block design, utilising phasic pain stimuli; clinical pain however rarely happens in 
15 second bursts, nor is it often limited to cutaneous tissue. However 
experimental models do exist which produce a stimulus that is more tonic in
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nature therefore arguably more closely aligned to the clinical situation (Mork et 
al. 2003).
Arendt-Nielsen and Sumikura (2002) defined the ‘ideal’ experimental pain 
stimulus in humans as having the following characteristics:
• Non-invasive; producing no tissue damage
• Specificity -  the stimulus stimulates the nociceptive system specifically 
rather than sensory-motor systems
• Sensitivity -  the ability to measure pain within a range that is both 
ethically and physiologically acceptable to the participant
• Measurable -  showing a relationship between stimulus and reported pain 
intensity
• Variable - the response shows an inherent variability from zero to 
maximum tolerable levels
• Reproducible -  the stimulus produces a response that is repeatable over a 
number of repetitions and time
2.2 Experimental models; methods of pain induction
In order to elicit peripheral pain, small diameter afferent fibres must be activated. 
These fibres are classified as either thin myelinated (A8 in cutaneous, group III in 
muscle) with fast conduction velocities (Meyer et al 2006) or unmyelinated (C- 
fibre in cutaneous, group IV in muscle) or further classified according to their 
conduction velocities.
2.2.1 Electrical stimulation
Electrical stimulation has been frequently employed in both human and animal 
models of experimental pain (Handwerker and Kobal 1993) to evoke either 
cutaneous or muscle pain (Graven-Nielsen and Mense 2001).
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Nociceptors are stimulated by the insertion of fine electrodes into either the 
intradermal / subcutaneous tissue or the belly of a muscle; the later may result in 
electrical stimulation of the electrodes causing painful twitching of the muscle 
(Svenssen et al,. 1997); this twitching can itself introduce a confound into 
investigations employing this method. Geber et al., (2007) however did 
demonstrate good test-retest reliability using an intradermal model of electrical 
stimulation in healthy volunteers.
Onset and offset of electrical stimulation is well defined (Gregersen et al., 2007) 
which can eliminate the latency to stimulation of afferent fibres that may occur 
with other pain induction methods. Parameters of electrical stimulation apparatus 
may be adjusted thereby allowing a variety of stimulation patterns to be delivered 
which provides some degree of selectivity in exciting different primary afferent 
neurons and hence evoking different types of pain
Electrical stimulation of the nociceptive pathway however, bypasses nociceptor 
transduction, depolarising the primary afferent fibre directly. Furthermore 
electrical stimulation acts on a broad spectrum of afferents both non-painful 
(group I and II fibres) and painful (group III and IV fibres) with lower stimulation 
intensities required to activate thick myelinated (non-nociceptive) afferents than 
unmyelinated nociceptive fibres. Electrical stimuli therefore are not specifically 
nociceptive (Thunberg et al., 2005) however a number of studies have employed 
electrical stimulation to the cutaneous (Svensson et al., 1997), muscle ( Vecchiet 
et al., 1999, Arendt Nielsen et al., 1997) and visceral ( Drewes et al., 2006) 
tissues.
The overriding problem associated with electrical stimulation therefore is its 
inherent non-specificity; the threshold for electrical stimulation is related to the 
sensory fibre diameter therefore at intensities sufficient to excite small diameter 
fibres, large diameter fibres will also be excited. These include non-noxious 
sensory fibres and also muscle efferent fibres, potentially resulting in local muscle 




A contact Peltier thermode is placed on a body part and temperature is increased 
at a fixed rate, typically 1°C / second activating both Ad and C fibres (Hughes et 
al., 2002). Heat pain threshold, tolerance and suprathreshold levels maybe tested.
Temperature increases induced in the skin are dependent on a number of factors 
including reflectance, transmission, and absorption of the epidermis (Bromm and 
Treede 1991, Le Bars et al., 2001) which gives rise to variability between 
individual subjects. The advantages of contact heat include controllability of the 
pain induced allows the pain to be switched on and off with a rapid onset and 
offset time.
Thermode application activates small myelinated Adelta and unmyelinated C- 
fibres however also low-threshold mechanosensitive afferent fibres, which can 
modulate the spinal transmission of nociceptive and thermal information; thereby 
potentially excerpting an inhibitory influence on the pain mechanisms (Staahl and 
Drewes 2004).
2.2.2.2 Laser induced heat
Cutaneous pain can be evoked using a high energy CO2 laser beam to direct 
radiant heat to a small area of skin (Svenssen at al., 1997), causing a stinging and 
burning sensation. A limitation of laser beams is that, because it induces rapid 
heating of the skin, it is likely that, as well as stimulating C-fibres, there is also 
the possibility that sensitive mechanoreceptors will also be excited (Handwerker 
and Kobal (1993).
CO2 lasers operate in the far infrared range (10-6 pm), hence avoid some of the 
problems associated with contact heat (Plaghki and Mouraux., 2003). 
Temperature increases are extremely fast; activating nociceptors within a few 
milliseconds. As skin absorption is almost 100%, energy is confined to the upper 
cutaneous layers i.e. where nociceptors are located.
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C 02 laser has the further advantage of allowing selective stimulation of specific 
fibre classes; stimulation parameters may be adjusted to target small myelinated 
and unmyelinated fibres without concomitant activation of Abeta fibres or C- 
fibres without Adelta fibres (Plaghki and Mouraux., 2003; Magerl et al., 1999; 
Tran et al., 2001).
It has been suggested however that as laser stimulation produces a synchronised 
fast onset it may feel subjectively different from other more natural pain stimuli 
(Kupers and Kehlet, 2006).
2.2.2.3 Cold pain
The cold pressor test evokes pain by plunging an extremity -  either the foot or the 
hand into a receptacle of ice - saturated water (0-2°C) (Curatolo et al., 2000). The 
exact mechanism by which the pain is mediated is unclear. Initial immersion 
induces cutaneous vasoconstriction hence cold receptors will indeed be stimulated 
however the cold also induces a marked vasoconstriction (Wilson et al., 2007) 
resulting in ischaemic pain. The cold pressor test has also been shown to be 
unreliable in clinical testing (Blasco and Bayes 1988).
Cooling and therefore cold pain is now more typically induced by application of a 
Peltier thermode and decreasing the temperature in the same manner as above 
(Liem et al., 2005). Cooling may also be achieved by topical application of ice, 
alcohol, menthol or ether (Staahl and Drewes 2004).
One group of investigators have explored heat as a noxious muscle stimulus 
through injection of isotonic saline at temperatures of 48°C (Graven Nielsen et al.,
2003). Pain was induced however this was only mild (peak VAS 3.2). 
Furthermore there are methodological issues associated with maintenance of 
saline temperature and safety issues regarding maximum temperature required to 
induce pain.
In summary thermal pain models provide a valid and reliable model of pain 
induction for cutaneous pain. A limitation in terms of comparison however is the 
lack of an appropriate comparator model in muscle.
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2.2.3 Ischaemia induced pain
Ischaemia-induced muscle pain is a long-standing method induced by the use of a 
tourniquet (Graven-Nielsen and Arendt-Nielsen 2003). This pain, involving the 
whole limb, is caused by deprivation of oxygen in all tissues distal to the 
tourniquet during the temporary (15-20min) occlusion of blood supply to the limb. 
It is followed by a variable degree of post ischaemic paraesthesia (Pertovaara et al 
1984). The pain induced by the tight tourniquet is of similar severity to the 
ischaemic pain (Pertovaara et al., 1984). These features significantly reduce the 
applicability of ischaemic pain to study cutaneous and deep tissue pain separately. 
Ischemia has also been used in animal models of visceral pain (Ness and Gebhart, 
1990) however is not considered an acceptable model for investigation of visceral 
pain in humans (Drewes et al., 2006)
2.2.4 Chemical pain
In an attempt to reproduce some of the features of clinical pain a number of 
chemical agents have been employed to induce pain -  again in both cutaneous and 
muscle tissue. The most common of these agents is capsaicin (Witting et al., 
2001) .
Capsaicin, extracted from chilli peppers, is used either as a local application to 
evoke skin pain, or by injection -  subcutaneous or intradermal to evoke skin pain, 
and intramuscular to evoke muscle pain (Capra and Ro 2004), producing 
moderate pain and inflammation.
Intradermal administration of capsaicin also causes secondary allodynia and 
hyperalgesia (LaMotte et al., 1991), its action mediated through vanilloid 
receptors (VR1) found on heat nociceptors (Tominaga et al., 1998)
Due to a prolonged period of action it may be avoided in human experiments 
requiring short durations of pain stimulus.
Concerns have also arisen regarding toxicity effects of injection of algesic agents; 
although a number have been tested in humans, their use is typically more limited 
to animal models.
2.2.5 Mechanically induced pain
Mechanical stimulation may be applied via a pressure algometer allowing 
standardised, measurable graded increases or decrease of pressure to be applied
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evoking mechanical muscle (Graven-Nielsen and Arendt-Nielsen 2003) pain. This 
method of pain induction has been shown to yield good reliability (Nussbaum et 
al., 1998; Vatine et ah, 1993; Antonaci et ah, 1998). The later two groups also 
demonstrated no difference between dominant and non-dominant sides.
Mechanical stimulation however is again non-specific as low threshold 
mechanoreceptors in the skin are also stimulated (Handwerker and Kobal 1993) 
hence it may be difficult to differentiate the effect on muscle and skin separately. 
Kosek et ah, (1999) demonstrated that skin sensitivity did affect pain pressure 
thresholds in a double- blind investigation employing EMLA cream, a local 
anaesthetic. Pre -  application of a topical anaesthetic could perhaps be employed 
to negate the effects of cutaneous stimulation however the depth to which EMLA 
penetrates and therefore the reproducibility of this method has been questioned 
(Kosek et ah, 1999).
The mechanical properties of the gastrointestinal tract are important for its 
function as a digestive organ and the gut contains mechanoreceptors at various 
locations in the wall (Ness and Gebhart, 1990). As such visceral mechanical 
models are particularly well developed, the most common of these being 
distension, typically via an inflatable balloon either rectally or via the oesophagus 
(Drewes et ah, 2006).
2.2.6 Hypertonic saline induced pain
Injection of hypertonic saline has been employed extensively in both animal and 
human muscle pain studies. Kellgren (1938) first wrote about its use and the 
technique has been widely investigated since. Intramuscular injection of 
hypertonic saline (HS) is perhaps the most established technique of inducing 
experimental muscle pain, having been extensively studied with regards to 
psychophysical properties (Graven-Nielsen et al 1997). It has proved a useful tool 
in improving understanding about the peripheral mechanisms of muscle pain and 
been shown to closely mimic clinical musculoskeletal pain in both subjective 
quality and motor performance (Arendt-Nielsen et ah, 1996). It has been less well 
utilised in cutaneous studies.
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Injection of hypertonic saline causes a short lasting, reversible, moderate intensity 
pain which has been widely tested, has never been associated with serious 
complications and there are no reports of muscle toxicity (Marchettini et al., 
1996).
Despite the long history of investigators employing HS as a model of 
experimental pain, it is only in recent years that investigations have revealed the 
probable mechanistic basis for the nociceptive effects of HS.
In vitro and in vivo experiments show that hypertonic saline at 2 -  5 % 
concentration stimulates C-fibre afferents (Pedersen et al 1998, Alessandri-Haber
2005); providing the theoretical basis for its use in studies of experimental skin 
and muscle pain (Alessandri-Haber et ah, 2005).
It has been postulated that the pain-inducing effect of hypertonic saline is 
mediated through changes in local osmotic pressure to which a number of ion 
channels located in nociceptors respond. The receptors with the required 
properties are members of the TRPV family (TRPV1, TRPV2, TRPV4, and the 
stretch-inactivated channel, SIC as well as TREK-1, a two pore voltage-gated K+ 
channel). Importantly, TRPV1, TRPV4, SIC and TREK-1 are found in small, 
unmyelinated sensory fibres (Alessandri-Haber et al 2005, Schumacher et al 2000, 
Liu et al 2007, Alloui et al 2006).
TREK-1 is co-localised with TRPV1, the latter able to transduce thermal, 
mechanical and hyperosmolar stimuli (Alloui et al 2006). To date the strongest 
case for this action comes from studies conducted on TRPV4. Hypertonic saline 
injected intradermally in the paw of the rat induced concentration-dependent pain 
behaviour in them (Alessandri-Haber et al 2005). PGE2 enhances this response at 
low concentrations of hypertonic saline but not at higher concentrations (10%). 
Because only very small volumes of hypertonic saline are needed, the changes in 
local tonicity are likely to normalise quickly lessening the capacity of the saline to 
maintain nociceptor activation.
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Initial nociceptor depolarization, via activation of SIC or TRPV4, however may 
induce neurogenic release of glutamate and neuropeptides (Hua et al., 1986 and 
Lawand et al., 2000) which in theory, if injections are give repeatedly may lead to 
a prolonged or heightened response (Coggeshall and Carlton, 1997). 
Alternatively, prolonged stimulation may lead to habituation.
A mechanosensitive non-selective cation channel, known as stretch-inactivated 
channel (SIC), has also been suggested as a potential transducer for HS induced 
pain (Schumacher et al., 2000). SIC is a variant of TRPV1 that is activated by cell 
shrinkage and inhibited by cell swelling (Suzuki et al., 1999). As SIC is expressed 
in small diameter neurons in the DRG (Schumacher et al., 2000), changes in 
osmolarity in the extracellular fluid environment around nociceptive terminals can 
activate SIC upon cell shrinkage and depolarize nociceptors.
Therefore, it is suggested that SIC may function as mechanical transducer 
mediating muscle tenderness, a symptom frequently seen in patients with chronic 
musculoskeletal pain. Hence HS may indeed be a useful model of clinical MSK 
pain conditions.
Hypertonic saline has been employed to induce experimental muscle pain in a 
controlled manner in healthy volunteers (Graven-Nielsen et al., 1997) and the 
technique has been extensively investigated for psychophysical properties, 
particularly in relation to referred muscle pain. Induced pain has been shown to be 
dependent on infusion rate, volume and concentration of the HS introduced 
(Jensen and Norup, 1992).
Graven Nielsen and colleagues have also developed a model of muscle pain 
induction which produces a longer lasting pain response through continuous 
infusion of minute volumes. Whilst this has proved useful in investigations of 
psychophysical properties (Graven Nielsen et al., 1997) and tests of drug 
effectiveness (Curatolo et al., 2000), the infusion model is less suitable for 
investigations requiring pain induced to be of more limited duration; for example 
in a scanning environment.
There is little evidence however that it has been used in cutaneous pain.
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Observations from studies investigating motor effects of (Arendt-Nielsen et al., 
1996) and pharmacological response to (Curatolo et al., 2000) HS also indicate 
that pain elicited by HS injection / infusion reflects acute, clinical muscle pain. Its 
use has never been associated with serious complications and there are no reports 
of muscle toxicity (Marchettini et al., 1996). As the pain lasts for several minutes 
it allows for an accurate collection of the subject’s impressions of sensory and 
motor effects, including the phenomenon of referred pain.
Taken together the evidence would suggest that hypertonic saline can be injected 
safely and repeatedly, induces a relatively short-lasting reversible pain and may 
serve as a reasonable surrogate model of clinical musculoskeletal pain in healthy 
volunteers
2.2.7 Combined experimental models
Whilst the controlled environment of experimental pain and healthy volunteers 
has great appeal, there is recognition of the limitation particularly in that they tell 
us about physiology and not pathophysiology.
A surrogate model of clinical pain is therefore desirable. Petersen and Rowbotham 
(1999) developed such a model; a novel method of pain induction involving pre­
sensitisation of cutaneous tissue with heat prior to topical application of capsaicin 
cream. This produces a thermal hyperalgesia i.e. a lowering of the threshold of 
heat pain. The model is said to replicate heat allodynia seen in many clinical 
neuropathic pain conditions.
Capsaicin-induced heat allodynia is thought to depend largely on the activity of C 
nociceptors because it persists when the conduction of A fibres is selectively 
blocked (Torebjòrk et al., 1992). There is however some evidence of the 
involvement of a unique subgroup of A6 nociceptors by the capsaicin-induced 
heat allodynia (Ringkamp et al., 2001).
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Some C nociceptors are also exclusively responsive to heat following the 
application of irritants, such as capsaicin or mustard oil (Handwerker and Kobal, 
1993).
Heat allodynia is also distinct from ‘normal’ heat pain in that different spinal 
mechanisms are thought to be involved; heat allodynia involving the sensitisation 
of spinal cord projection neurons, characterised by the enhancement of their 
response to heat and enlargement of their receptive fields (Woolf and Salter,
2000).
It is suggested therefore that heat allodynia following chemical irritants may 
involve the recruitment of a class of nociceptors that are functionally distinct, 
conveying information regarding pathophysiology of the tissue rather than the 
actual or potential threat of heat damage.
Since its initial development the heat -  capsaicin model has been extensively 
tested in experimental studies, drug efficacy investigations and brain imaging 
studies. The model shows initial promise, appearing to more closely reflect the 
psychophysical properties and cerebral correlates of heat hyperalgesia observed in 
some patients with neuropathic pain.
2.3 Interpretation of the measured response
Pain is a subjective sensation; as such it is not possible therefore to directly 
measure, however certain components can be measured, which combined, provide 
information regarding the pain experienced by an individual.
Perceived intensity and quality, both unpleasantness and descriptive semantics are 
the main aspects frequently measured. Combinations of these factors provide 
some information with regards to the working of the nociceptive system. Under 
experimental conditions on healthy volunteers, stimulus modality, duration and 
intensity can be defined and hence controlled.
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Visual analogue scales (VAS) are typically employed to take a measure of pain 
intensity; consisting of a 10cm long line, the extremes are labelled to represent the 
extremes of a potential painful response. That is the left anchor is typically 
labelled ‘no pain’ whilst the right anchor is labelled ‘pain as bad as could be’ or 
‘worst possible pain’ (Jenson et al., 1986). Visual analogue scales have been 
found to correlate well with other measures of pain self report (Jensen et al., 1989; 
Paice and Cohen, 1997) and observed behaviour responses (Gramling and Elliot, 
1992.) Ahles et al., (1984) also demonstrated that VAS measurements are distinct 
from measures of other subjective components of pain experienced.
Whilst visual analogue pain scales provide a reliable measure of perceived pain 
intensity they fail to capture the multidimensional aspect of pain. The McGill Pain 
Questionnaire (MPQ) therefore provides a method of investigating these 
(Melzack, 1975). The scale includes descriptive words of sensory, affective and 
evaluative aspects of pain; whilst the usefulness of the scale has been 
demonstrated in a number of clinical and some laboratory based investigations, its 
length and therefore time taken to complete preclude its usefulness in 
experimental pain studies investigating relatively short-lasting stimuli.
A Short-Form MPQ (SF-MPQ) was subsequently developed by the originator of 
the MPQ (Melzack, 1987), and recommended for use in specific research and 
clinical settings when the time to obtain information is limited (Melzack and Katz
2006). The SF-MPQ consists of 15 descriptors of pain, 11 from the sensory and 4 
from the affective categories of the MPQ. Words were selected on the basis of 
endorsement by patients with a variety of acute, intermittent, and chronic pains 
(Melzack and Katz, 2001).
Sensory and affective factor scores have been show to correlate highly with those 
from the MPQ (Melzack 1987) and factorial validity shown to have good internal 
consistency estimates for both the sensory and affective dimensions (Wright et al.,
2001)
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2.4 Comparisons of cutaneous and muscle pain.
The suggestion that muscle and skin pain are different is not a new one, Thomas 
Lewis having written on the subject of perceptual and behavioural differences 
(Lewis, 1942). Pain of cutaneous origin is typically described as possessing a 
sharp, prickly or burning sensation and is easily localised. Behaviourally the 
expected response is one of fight or flight i.e. removal of oneself from the source 
of the pain and therefore limit further danger or damage. Muscle pain on the other 
hand is frequently described as dull, aching, throbbing sensation which is difficult 
to localise, and may evoke a characteristic passive coping manner.
Despite the prevailing view that pain arising from cutaneous and muscle pain 
show different characteristics, direct comparisons in the literature of pain from 
these two tissue types, evoked by the same stimulus are rare.
Rainville et al (1992) undertook a comparison of the psychophysical properties of 
four different stimulus modalities; contact heat, electrical, cold-pressor and 
ischaemic exercise induced pain. They clearly demonstrated that the 
psychophysical properties of a painful response relative to the intensity of a 
stimulus vary according to the type of stimulus modality employed. The results, 
they suggest indicate ischaemic exercise and cold pressor pain may be a better 
model of clinical pain having higher levels of unpleasantness induced whereas the 
lower levels of unpleasantness of contact heat may suggest this model is better for 
dissociating sensory discriminative aspects of pain.
Svensson et al (1997) also investigated stimulus response curves of cutaneous and 
muscle pain; reporting that although these were similar in form, unpleasantness / 
intensity ratios of muscle and cutaneous pain were different; muscle pain having a 
relatively higher ratio than cutaneous pain. Interestingly both of these groups of 
investigators report the intensity component of the ratio as a function of stimulus 
intensity rather than response. Although increasing intensity of pain does indeed 
follow increasing intensity of stimuli, the response is not necessarily linear.
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Caution therefore should be taken when the authors interpret their findings as 
evidence that pain arising from muscle tissue is more unpleasant than that from 
cutaneous stimulation.
Witting et al., (2001) also undertook a direct comparison of cutaneous and muscle 
pain using capsaicin injections. The focus of their investigation however was on 
differences in referred symptoms which they duly found; referred sensations were 
frequently reported in muscle but not cutaneous pain.
A direct comparison of psychophysical properties of subcutaneous, intradermal 
and muscle pain induced by hypertonic saline has not been undertaken, to the best 
of the author’s knowledge.
2.5 Summary of experimental pain
Pain, in common with any form of somatic sensation, is typically described in 
terms of sensory, cognitive and affective aspects. Sensory aspects generally 
include location, magnitude and spatiotemporal properties. Affective components 
include the hedonic aspect -  i.e. the degree of unpleasantness of the sensation and 
a motivational aspect -  producing the motivation to limit the experience of the 
noxious stimulus (Sewrads et al., 2002).
It has been argued that the hedonic and sensory aspects of somatic sensation are 
represented and processed in parallel but distinct pathways throughout the nervous 
system and may reflect differences in psychophysical properties of cutaneous and 
muscle pain.
The sensory-discriminative and affective-motivational aspects of pain differ 
according to the forebrain targets of ascending pathways (Melzack and Casey 
1968; Price 2000 and Hunt and Mantyh 2001). Therefore, the central processing 
of cutaneous and muscle pain, according to the types of nociceptors and spinal 
projections mediating these sensations may also differ.
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In order for a direct comparison of either the psychophysical or cerebral properties 
of muscle and cutaneous pain to be undertaken; pain must be elicited via the same 
method of induction. Reviewing the evidence suggests that hypertonic saline can 
be injected safely and repeatedly into either muscle or cutaneous tissue, induces a 
relatively short-lasting reversible pain and therefore would appear to be the most 
appropriate model to utilise if indeed aim is to carry out a comparative study of 
relative psychophysical properties of the se two tissue types.
2.5. Background: Neural processing of pain
Advances in brain imaging techniques have led to a number of methods becoming 
available for the safe, non-invasive study of both normal and pathological pain 
processing in humans. Techniques include electroencephalographic dipole source 
analysis (EEG), magnetoencephalography (MEG), positron emission tomography 
(PET), single photon emission computed tomography (SPECT) and functional 
magnetic resonance imaging (fMRI). Each method has inherent strengths and 
weaknesses in relation to sensitivity, spatial and temporal resolution however all 
provide a utility for measuring either directly or indirectly neuronal activity.
Electrophysiologic techniques provide direct measurements of neuronal activity 
with millisecond temporal resolution therefore allow the means to study dynamic 
nociceptive processing. However relatively poor localization in the brain to the 
origin of the signal is a significant weakness.
PET provides the means to measure both metabolic and neurochemical aspects of 
brain processing and allows for the identification and investigation of the roles of 
neurotransmitters and receptor systems involved in acute and chronic pain. As 
PET requires injection however of a radioactive tracer, dose restraints do limit the 
number of scans that may be acquired.
FMRI measures metabolic and haemodynamic responses to neuronal activity and 
provides better spatial and temporal resolution than PET for localizing brain
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regions that are activated during pain processing, and for probing possible 
functional connections between activated regions. A further important advantage 
of fMRI is that due to the non- requirement for radioactive tracers there is not the 
same constraints placed in terms of repeating scans allowing longitudinal e.g. pre 
and post intervention studies to be undertaken.
2.5.1 The Pain Matrix
Melzack (1989) first proposed the idea of a pain ‘neuromatrix’ in an attempt to 
explain the possible mechanisms underlying phantom limb pain. He put forward 
his idea that phantom pain may be mediated by a network of neurons, the 
‘neuromatrix’, involving three major neural circuits in the brain and incorporating 
the sensory, cognitive, affective and motor aspects of pain.
Subsequently, functional brain imaging studies have reported a widely distributed 
set of cortical and sub-cortical brain areas that are activated during a variety of 
experimental pain conditions. Despite some inconsistencies between studies, often 
attributed to differences in study design, a fairly robust set of structures 
considered to play a significant role in pain have become collectively know as the 
‘pain matrix’ rather than Melzack’s (1997) ‘neuromatrix’. It is however accepted 
that the term has evolved from Melzack’s original proposal (Derbyshire, 2000)
The pain matrix consistently includes primary and secondary somatosensory 
cortices (SI and SII), Anterior Cingulate Cortex (ACC), insular cortex, primary 
motor and premotor cortices, prefrontal cortex (PFC), and thalamus in addition to 
posterior parietal cortices, amygdala, basal ganglia, midbrain (periaqueductal grey 
matter), and cerebellum (Peyron et al., 2000).
A systematic review of pain imaging literature by Apkarian et al (2005) revealed 




Primary somatosensory cortex (SI)
The primary somatosensory cortex (SI), located in the posterior gyrus of the 
parietal lobe receives sensory information via projections from the ventral 
posterior medial (VPM) nucleus of the thalamus. Four cytoarchitectonical areas 
(Brodmann areas 3a, 3b, 1, and 2) have been defined in SI of primates and more 
recently humans (Kurth et al 2000); although the four areas are extensively 
interconnected, each contains a separate representation of the body surface and 
also a different functional role in sensory processing (Iwamura 1998). Areas 3b 
and 1 receive information from cutaneous sensory receptors whilst areas 3 a and 2 
receive proprioceptive information from joints and muscles.
Although its role in relation to pain processing continues to be a matter of debate, 
SI is thought to encode for intensity and location of pain despite containing only a 
relatively low number of nociceptive driven neurons (Svenson et al., 1997c), of 
which less than 10% receive input from deep (i.e. non cutaneous) tissue.
Nociceptive neurons in areas 3 a, 3b, and 1 have been identified in macaque 
monkeys through electrophysiologic recordings (Kenshalo 1983). Ploner et al., 
(2002) however report serial activations in Brodmann areas 3b, 1 and posterior 
parietal cortex during touch but only activation of area 1 during nociceptive 
stimulation in humans suggesting that although SI appears to have a role in 
sensory-discriminative aspects of pain, the processing of pain would seem less 
hierarchically organised than tactile processing.
In a comprehensive review of pain imaging studies Apkarian found that over 50% 
of studies report SI activation in response to a painful stimulus. The lack of SI 
activation in the other pain studies may be in part due to insufficient intensity of 
pain produced (Svensson et al 1997), small body surface area stimulated (Peyron 
et al., 2000) or as suggested by Brooks et al., (2002) due to other affective or 
cognitive aspects of the individual and the environment of the experiment taking 
place.
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Somatotopic reorganisation observed in phantom limb pain patients (Flor et al., 
1997; Lotze et al., 1999) and Complex Regional Pain Syndrome (CRPS) patients 
(Maihofner et al., 2003) has also led to increased interest in SI. However although 
the extent of SI re-organisation has been shown to correlate with intensity of pain 
(Flor et al., 1997) and also reverse after successful rehabilitation (Maihofner et al.,
2004) the exact role of SI remains unclear.
In summary multiple lines of evidence exist to indicate the involvement of SI in 
nociceptive processing; the predominant role being sensory discriminative. 
However the specific roles of each area during pain processing and its relationship 
with tactile system still need further investigation.
Secondary somatosensory cortex (SII)
The secondary somatosensory cortex (SII), located in the parietal operculum in 
the upper bank of the Sylvian fissure, receives projections from each of the four 
SI areas. SII neurones project to the insular cortex, in turn innervating regions of 
the temporal lobe believed to be important for tactile learning and memory 
(Mishkin 1979).
Despite the findings of Robinson et al (1980) that in macaques less than 3% of 
neurons recorded from SII respond to noxious stimuli, many human imaging 
studies consistently report activation of SII during experimentally induced pain 
(Peyron 2000). SII activation has been reported during contact heat in both PET 
(Talbot et al., 1991, Casey et al., 1996, Craig et al 1996, Rainville et al 1997, 
Svensson et al 1997c, Coghill et al., 1999) and fMRI (Davis et al., 1998, Apkarian 
et al., 1999; Becerra et al., 1999; Gelnar et al., 1999) studies.
MEG studies provide further evidence of SII activation during pain processing 
(Hari et al., 1997; Huttunen 1986; Kakigi 1995).
Lenz et al., (1998) recorded laser evoked potentials directly from SII via subdural 
electrodes implanted in three subjects suffering intractable epilepsy providing 
direct evidence of nociceptive input to the human parasylvian cortex.
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Clinical observations in patients with SII lesions also point to SII having a role in 
pain perception; these patients demonstrating elevated pain thresholds to pin-prick 
stimulation (Greenspan and Winfield 1992, Greenspan et al., 1999). Ploner et al., 
(1999) in a single case study of a patient with an ischaemic lesion in the parietal 
operculum report the inability to recognise both the nature and location of an 
intense noxious stimulus. Despite this the patient did report an intense unpleasant 
sensation.
2.5.1.2 Insular cortices
The insular cortices, both posterior and anterior, have received much attention in 
the pain literature and are reported to be the most consistently activated regions 
during painful stimuli (Peyron 2000). Insula activation has been reported during a 
number of different noxious stimuli including painful heat (Casey et al., 1996, 
Coghill et al., 1994, Derbyshire et al., 1997), electrical stimulation (Svensson et al 
1997, Oshiro et al., 1998, Niddam et al., 2002), pressure pain (Farina et al., 2002, 
Rolls et al., 2003) and both oesophageal (Aziz et al., 1997) and rectal (Mertz et 
al., 2000) painful distension. It is suggested that the insula may be seen as a site 
of sensory and affective integration (Brooks and Tracey 2007).
Functional and cytoarchitectonical differences in the insula
The insula may be split into anterior and posterior segments at both a 
cytoarchitectonical level and a functional level; posterior and anterior insular 
cortices change from granular in the posterior portion to agranular in the anterior 
portion. It also receives differential cortical and thalamic input along its length. 
Anterior insula receives direct projections from the basal part of the ventral 
medial nucleus (VMb) of the thalamus and large inputs from the central nucleus 
of the amygdala with reciprocal projections.
The posterior insula connects reciprocally with the secondary primary sensory 
cortex (S2) and receives input from spinothalamically activated ventral posterior 
inferior (VPI) thalamic nuclei.
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Functionally the posterior insula would seem to have a sensory discriminative 
role, contributing to localisation of pain; somatotopy during painful stimulus has 
been demonstrated (Dunckley et al., 2005, Brookes et al., 2005) and Ostrowsky et 
al., (2002) demonstrated pain in the contralateral hemibody during direct electrical 
stimulation of the posterior insula.
Anterior insula has been attributed with affective, motivational and memory 
aspects of pain. The area receives inputs from the ventromedial nucleus of the 
thalamus that contains predominantly nociceptive and thermoreceptive neurons 
specialised to convey information such as pain, temperature and itch (Craig et al 
1995).
Activity has also been demonstrated in other non-painful but aversive states e.g 
anxiety, fear. Activation is also enhanced by attending to an aversive stimulus 
(Brookes et al., 2002) and stimulation within insula evokes painful experiences 
(Ostrowsky 2002). Greenspan et al., (1999) also demonstrated that damage to the 
insula results in a change in the affective quality of pain i.e. that pain is still felt 
but the associated unpleasantness is absent.
Schweinhardt et al., (2006) recently proposed a function subdivision of the 
anterior insula into rostral and caudal areas; from a review of the literature they 
reported that clinical pain was preferentially processed in the rostral anterior 
insula (rAI) whereas in experimental pain studies caudal anterior insula (cAI) 
predominated.
They suggest that the cAI may reliably encode the intensity of perceived pain 
whereas the rAI may uniquely reflect the processing of clinical pain; clinical pain 
having a more affective response that experimental pain. The authors do however 
acknowledge that perception of bodily states and also aversive (non-painful) 
stimuli also provoke rAI activation, as does modulation of experimental pain by 
attention. A further consideration should be that the experimental pain studies 




The cingulate cortex, situated in the medial aspect of the cortex, extends from the 
corpus callosum below to the cingulate sulcus above. Based on cytoarchitectonics 
and pattern of projections the anterior cingulate cortex (ACC) can be 
differentiated from the posterior cingulate cortex (PCC) (Vogt et al., 1992). 
Distinct also functionally, the ACC is considered to have an ‘executive’ role 
whilst PCC has an evaluative function (Vogt et al.,1992).
Anterior cingulate cortex (ACC)
The anterior cingulate cortex (ACC) has been divided into the perigenual (or 
rostral) anterior cingulate cortex (pACC) and midcingulate (MCC) cortex, with 
the MCC more recently also having been further divided in to posterior (pMCC) 
and anterior (aMCC) divisions (Vogt et al 2003). The aMCC is both anatomically 
and functionally distinct from the pMCC. The former is considered to be 
primarily concerned with fear and affect whilst the later is thought to be more 
involved with executive function.
Observations that the ACC is one of the structures most frequently activated in 
pain imaging studies suggest that the ACC has a key role in nociceptive 
processing (Derbyshire et al., 2000, Peyron et al., 2000). However there is also 
substantial variation in the exact location within the ACC of activation reported 
(Apkarian et al., 2005) which led Kulkami and colleagues (2005) to suggest that 
the ACC may have both pain specific and non pain specific cognitive functions.
Mid cingulate cortex (MCC)
The MCC receives significant posterior parietal afferents (Vogt et al 1987) and 
contains the cingulate motor areas (CMAs) which project directly to the spinal 
cord and the motor cortices (Dum and Strick 1993, Van Hoesen et al., 1993). 
Functionally the MCC is involved in motor and non-motor response selection and 
behavioural change (Vogt 2003)
Although ACC is considered to code for unpleasantness, rather than intensity of a 
painful stimulus, discrete intensity associated areas have been identified within 
the mid cingulate cortex (Coghill et al., 1999, Derbyshire et al., 1997).
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Perigenual (rostral) ACC (pACC)
Vogt et al., (1996) suggests that the affective or ‘suffering’ component of pain is 
primarily interpreted in the pACC; this area receiving significant input from the 
amygdala. Lenz et al., (1998) measured laser evoked potential directly from ACC 
(BA 24) in five patients with epilepsy via subdural grids demonstrating the 
presence of significant direct nociceptive input to this area. Evoked potentials 
were present bilaterally although stronger contralateral to the stimulus. ACC 
connections have also been reported with the prefrontal cortex, parietal cortex and 
the motor system (Posner & DiGirolamo, 1998). However some studies of 
experimental pain that have manipulated the affective component of the pain 
experience have failed to demonstrate pACC activation (Tolle et al 1999, 
Rainville et al 1997).
Conversely, Jones et al (2002) in a PET study where subjects selectively attended 
to unpleasantness during a painful laser stimulus demonstrated an increase in 
rCBF bilaterally in pACC. Whilst receiving the same stimulus but attending to 
location the increase in rCBF was found in the contralateral SI and inferior 
parietal cortices. Kulkami et al., (2005) also demonstrated significantly greater 
increases in the pACC when subjects attended to the unpleasantness of a painful 
stimulus than when they attended to location of the same stimulus. The authors 
attribute the results to their use of localisation as comparator to unpleasantness 
rather than intensity suggesting that subjectively differentiating between intensity 
and unpleasantness was not as effective as differentiating localisation and 
unpleasantness.
Internally generated emotions activate pACC and significant increases in rCBF in 
the pACC during PET studies of psychiatric patients have been demonstrated in 
those diagnosed with obsessive compulsive disorders (Brieter 1996), phobic 
anxiety (Rauch et al., 1995), post-traumatic stress (Rauch et al., 1996) and mood 
disorders (Drevets et al., 1997) suggesting stress and /or anxiety may be closely 
associated with pACC and it is perhaps this element that is represented during 
pain studies.
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Peyron et al., (2000) suggest that the relative lack of activation in the pACC 
demonstrated during experimental pain studies may be explained by the controlled 
situation leading to minimal stress or anxiety. The authors further point out that 
the opposite may be true for clinical pain where haemodynamic changes have 
been repeatedly reported in this area (see clinical pain section below).
Clinical lesion patients provide further evidence of a role for ACC in pain. After 
cingulotomy, patients with chronic pain report that they continue to have pain, 
which is "not particularly bothersome" (Folz and White 1962).
In patients with confirmed lesions of the cingulate gyrus a reduction in the 
affective response to pain (Ballantine et al., 1967, Davis et al., 1994, Pillay and 
Hassenbusch 1992) has been reported whilst the ability to localise noxious stimuli 
was retained. Results of such lesions however are variable with reported relief of 
chronic pain reported in 23% (Hurt and Ballantine, 1974) to 75% of patients (Folz 
and White, 1962).
Posterior cingulate cortex (PCC)
The PCC corresponds to Brodmann areas 23 and 31 and the restrosplenial cortex 
(RSC) posteriorly (Brodmann area 29) and is considered to have an evaluative 
role in assessing sensory input rather than initiating action in response (Vogt et 
al., 1992).
2.5.1.4 Thalamus
The thalamus, one of the two major subdivisions of the diencephalon, is an 
important link in the transfer of sensory information from afferent input from the 
periphery to a number of cortical areas. Originally considered to act simply as a 
relay station, a number of lines of evidence now point to a gating and modulatory 
role (Kandel et al 2000). Thalamus contains three major nuclear complexes that 
receive somatosensory input from ascending sensory pathways (Sewards and 
Sewards 2002); the ventroposterior complex, the posterior complex and the 
intralaminar thalamic nuclei. The ventrobasal complex is considered a ‘specific’ 
somatic relay, the nuclei receiving precisely organised input from DCN and the 
dorsal horn which is then relayed to the somatosensory cortex.
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Thalamic activation in pain studies is again frequently but inconsistently found 
with studies reporting bilateral (Casey et al 1994, Coghill et al 1999, Vogt et al 
1996,), ipsilateral (Adler et al., 1997, Derbyshire et al., 1998) and contralateral 
(Jones et al., 1991, Derbyshire et al., 1994, Becerra et al., 1999) activation.
Studies investigating attention and vigilance have shown bilateral increase in 
thalamic activation (Frederickson et al., 1995; Portas., et al 1998; Posner et al., 
1994).
The evidence suggests therefore that the thalamus may have both sensory -  
discriminative and cognitive roles in pain processing which Peyron et al (1999) 
suggests may reflect a general ‘arousal’ response to nociceptive input.
2.5.1.5 Amygdala
The role of the amydala in pain processing has also been subject to increasing 
investigation. Nociceptive specific neurons have been observed in the central 
nucleus of the amygdala (Bernard et al., 1992) however it is also thought to have a 
key role in the general stress response (Roozendal et al., 1997, Bohus et al., 1996) 
affecting behavioural and autonomic responses during fear processing (LeDoux et 
al 1988). Activation is frequently observed during stimuli perceived to be 
unpleasant or induce fear (Morris et al., 1999, Lane et al., 1997, Buchel et al 1998, 
Critchley et al., 2002). Electrical stimulation of the amygdala has also been 
shown to evoke feelings of fear and anxiety (Cendes et al., 1994)
Amygdala activation therefore would be expected during pain processing, 
particularly when perceived as extremely unpleasant and/or threatening. However 
conversely a number of studies have reported a decrease in activation observed 
during painful stimulation (Derbyshire et al 1997, Becerra et al 1999, 2001, 
Petrovic et al 1999, 2004). It has been suggested that the observed deactivation 
may reflect a cognitive strategy of attenuation by the amygdala of the perceived 
distress associated with an aversive stimuli (Petrovic 1999).
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2.5.1.6 Cerebellum
The cerebellum, which sits at the base of the brain has three anatomically 
distinguishable lobes; the flocculonodular lobe, the anterior lobe (rostral to the 
primary fissure), and the posterior lobe (dorsal to the primary fissure). The 
anterior and posterior lobes are further divided into a midline cerebellar vermis 
and two cerebellar hemispheres. Neurons in the cerebellar cortex are classified 
into granular, stellate, basket, Golgi, and Purkinje cells, the most abundant type 
being the granule cell (Goldowitz and Hamre, 1998).
There remains some controversy in the literature regarding the role of the basal 
ganglia and cerebellum in pain studies. Not only is activation consistently 
reported across imaging studies utilising a range of painful stimuli in healthy 
volunteers (Casey et al., 1996, Svensson et ah, 1997, Iadorola et al 1998, Coghill 
et ah, 1999, 2001), and patients (Derbyshire et ah, 2002, Becerra et ah, 2006, 
Schweinhardt et al 2006), activation has also been reported during imagined pain 
(Ogino et al 2006), perception of pain in others (Singer 2004), empathy (Jackson 
et al 2005, Moriguchi et al 2007) and anticipation of pain (Ploghaus et al 1999).
Despite the cerebellum being one of the frequently reported areas of activation 
during pain imaging studies (Borsook et ah, 2007), such activation is often 
initially attributed to representing either an actual or planned motor response to 
the induced pain and in early imaging studies received little attention other than to 
report activation. Activation during a painful stimulus was demonstrated in the 
caudal parts of ipsilateral hemispheric lobuli Vi and Crus I/II by Helmchen et ah, 
(2003). This area partly coincides with Larsells hemispheric lobuli VII, previously 
reported to be activated during imagined but not actual hand movement (Lotze et 
ah, 1999), suggesting this activation may reflect motor intention. Furthermore 
Staud et ah, (2007) investigating temporal summation during C-fibre stimulation 
also found increased activation in the cerebellum correlated with premotor 
activation. Jueptner (2001) proposes, from movement studies that the cerebellum 
is specifically concerned with feedback and monitoring of any actual movement 
taking place whilst the basal ganglia have a greater role in actual or planned
43
movement. Bingel et al., (2000) and others however now argue that the 
cerebellum may have a role in nociception that is not motor related.
Helmchen et al., (2003) compared activation patterns during both noxious and 
innocuous heat stimuli. They suggest that activation in the anterior vermis 
(lobules II-V) and both cerebellar hemispheres (III-VI) during noxious heat 
indicates this activation does not reflect pure sensory processing. Additionally the 
degree of activation increased with pain severity suggesting involvement not only 
in nociceptive processing but also pain perception.
Projections from the ventral dentate nucleus of the cerebellum to the dorsal 
prefrontal cortex in primates has been demonstrated (Middleton and Strick 2001) 
providing evidence for the potential role of the cerebellum in cognitive function.
More recently in humans, Allen et al., (2005) found that changes in the MR signal 
in the dentate nucleus correlated with signal fluctuations in cerebellar, thalamic, 
limbic, striatal, and cerebrocortical regions. Correlation was particularly apparent 
in dorsolateral prefrontal cortex. These findings provide further evidence of a 
functional relationship between the cerebellum and other brain regions involved in 
higher cognitive functions.
Whether cerebellar activation seen during pain studies is related to 
somatosensory, nociceptive, pain perception or motor processing remains unclear.
2.5.1.7 Basal ganglia
The basal ganglia comprises; caudate nucleus, putamen, nucleus accumbens, 
globus pallidus, substantia nigra and the subthalamic nucleus.
Animal studies show that the basal ganglia receive noxious and non- noxious 
somatosensory information (Schneider and Lidsky 1981, Chudler et al., 1993) 
although the functional significance of the nociceptive input is unclear. Activation 
of the basal ganglia during pain studies, in common with the cerebellum, whilst 
frequently reported has been attributed to motor planning or intent.
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Work by Bingel et al., (2004) suggests that the putamen encodes for laterality of 
noxious stimuli in a study utilising thulium-YAG laser evoked pain, thereby 
removing any confounding tactile stimuli. The authors reported somatotopic 
organisation of nociceptive information in the contra-lateral putamen. 
Interestingly although activation of the putamen was bilateral, somatotopy was 
only present contralaterally.
2.5.2 Brain imaging of muscle pain
Imaging studies investigating muscle pain are sparse; those published are limited 
and inconclusive. Although unclear from these studies if there are variations 
between the pain matrix for skin and muscle (overlap has been demonstrated), it is 
likely that there are discrete differences (Niddam et al., 2002). Nonetheless the 
evidence does suggest that there may indeed be differences in cortical processing 
of muscle and cutaneous pain. There were until recently only two reports in the 
literature of the intramuscular hypertonic saline technique being utilised in brain 
imaging studies.
Svensson et al., (1997) in a PET study investigating forebrain responses in a 
group of 11 healthy volunteers report the differences between laser evoked 
cutaneous pain and electrically evoked muscle pain. The authors found no reliable 
statistical difference in cerebral activation between the two forms of noxious 
stimulation however report that the ipsilateral premotor cortex, the contralateral 
prefrontal cortex and SII tended to be more activated in the noxious cutaneous 
condition whereas the ACC was more responsive to intramuscular pain. The 
study however has a number of limitations including the fact that only very low 
levels of pain were evoked; it has been demonstrated that an increasing number of 
cortical and subcortical areas are activated with increased levels of pain 
(Derbyshire et al., 1997).
The particular weaknesses of the use of electrical stimulus to induce muscle pain 
have been covered earlier in this chapter however it is worth noting again that 
electrical stimulation is a non specific stimulus therefore afferent input can be
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assumed to be different between HS induced and electrically induced muscle pain 
(Korotkov et al., 2002). It is not possible to conclude whether the reported 
differences between muscle and cutaneous pain in this study therefore can be 
ascribed to tissue type, stimulation type or indeed a combination of both.
Niddam et al., (2002) also used an electrical stimulus in an fMRI study to 
investigate neural correlates of muscle pain. During the painful stimulus (in 
comparison with non-painful stimulus), in addition to areas reported previously by 
Svensson et al., (1997), activity was reported in areas of both hemispheres 
including SMA, SMG, thalamus, claustrum, STG posterior cingulate and posterior 
insula.
The authors conclude that there was substantial overlap between central pain 
matrices for acute muscle pain and that previously documented for cutaneous pain 
however these authors did not themselves undertake a direct comparison of 
muscle and cutaneous pain. Again therefore caution should be used when 
ascribing differences to tissue type when a number of other factors may be 
implicated.
Korotkov and colleagues (2002), also utilising PET investigated the changes in 
regional cerebral blood flow following hypertonic saline induced muscle pain. 
They report a smaller number of areas than reported previously in pain studies and 
suggest that this may be due to the low intensity (NRS = 3.5) and duration of pain 
induced. As Niddam (2002), this group again failed to undertake a direct 
comparison with cutaneous pain. Of interest however is the report of activity in 
the putamen, part of the basal ganglia and considered to be an important element 
of the motor control system.
A more recent PET study (Kupers et al, 2004) reports on HS induced masseter 
muscle pain. Activation during muscle pain was reported in the ACC (mid- 
cingulate and rostral perigenual), anterior insula, cerebellum and inferior 
prefrontal cortex. Interestingly the authors report a decrease in rCBF in the 
amygdala, ventromedial prefrontal cortex and subgenual cingulate cortex.
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Previous studies have reported an increase in amygdala activation during phasic 
pain and a decrease during tonic pain, the authors suggesting this may reflect a 
coping mechanism to reduce the unpleasantness of the ongoing pain.
Mechanical hyperaesthesia, a feature of experimental muscle pain, was also 
included in this study. Whilst muscle pain alone was not associated with any 
thalamic activation, during mechanical stimulation plus muscle pain posterior 
thalamus and anterior subgenual cingulate activation was observed which the 
authors attribute to central sensitisation.
The authors conclude that cerebral processing of jaw muscle pain and cutaneous 
pain may be different however this hypothesis needs to be tested further and 
acknowledge that they did not in fact undertake a direct comparison.
Henderson et al., (2006), utilised fMRI in a study investigating 15 healthy 
volunteers during both HS induced muscle and cutaneous pain; the first group to 
undertake this direct comparison. Subjects received two single HS bolus 
injections, one into the right tibialis anterior muscle and one subcutaneously to the 
overlying skin during two separate scanning runs. Some psychophysical data was 
collected online however this consisted of a buzzer which was pressed by the 
subject at onset of the pain, just after the peak intensity had been reached and 
again when the pain had ceased; A modified Borg scale was used to rate pain 
intensity however it is unclear whether this data was gathered during or after 
scanning. Time course of the pain were plotted post scan. Sensory words from the 
Short Form McGill pain questionnaire were also read out loud to the subjects 
however again it is unclear whether this was peri or post scan.
Despite employing only a single injection into each tissue type the authors report 
significant signal change during both conditions in anterior and posterior mid 
cingulate cortex, posterior insula and SI and MI and during muscle pain only in 
ipsilateral anterior insula and perigenual cingulate cortex; the latter being a 
decrease in signal.
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Changes within SI were localised to the dorsal aspect of the paracentral lobule 
during superficial pain whilst during deep pain this signal intensity increase 
extended to the entire dorso-ventral extent of the paracentral lobule. MI activation 
was also more extensive during deep pain, extending to the paracentral lobule. 
The authors attribute this difference to the greater area of pain referral reported 
during deep compared to superficial pain, reflecting the sensory discriminative 
role of SI.
The findings of ipsilateral insula activation during muscle but not cutaneous pain 
is somewhat surprising; the insula as previously discussed being the region of the 
brain most frequently reported as being activated in previous imaging studies 
employing acute experimental cutaneous pain.
However this group of investigators have also published further studies employing 
the HS model reporting on gender differences between muscle and cutaneous pain 
(Henderson et al., 2008), somatotopy for muscle and cutaneous pain in the insula 
(Henderson et al., 2007) and associated referred pain (Macefield et al., 2007).
2.5.3 Functional divisions within the ‘pain matrix’
The concept of functionally separate medial and lateral components of the human 
brain system, based on cadaver work and also neurosurgical observation was 
proposed prior to the availability of modem neuroimaging techniques (Bowsher, 
1957; Albe-Fessard et al., 1985). Advances in neuroimaging techniques have 
allowed the theory of anatomical and functionally separate pathways to be further 
developed.
The lateral pain system consists of spinothalamic tract neurons projecting to the 
ventrobasal nucleus of the thalamus, which in turn projects to the primary and 
secondary somatosensory cortex and the parietal operculum. This so called lateral 
system is a somatotopically organised, fast, more direct route with fewer synapses 
than the medial system and is considered to subserve the sensory-discriminative
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components of painful experience which include location of the pain, intensity, 
type and duration.
The medial pain system is slower (in comparison to the lateral system), multi- 
synaptic, non-somatotopic and comprises the medial thalamic nuclei, anterior 
cingulate cortex (ACC), prefrontal cortex and insula. The medial pain system 
consists primarily of spinothalamic tract neurons that project to the intralaminar 
and medial thalamic nuclei, which subsequently project to the anterior cingulate 
cortex (ACC), amygdala, hippocampus, and hypothalamus (Sewards and Sewards, 
2002). The medial system is predominantly concerned with motivational-affective 
and cognitive-evaluative aspects of pain processing, memory for pain, and 
autonomic-neuroendocrine responses (Treede 1999).
Division of function has been demonstrated during functional imaging studies 
utilising a variety of methods -  mainly manipulation of attention. Destruction of 
somatosensory cortex greatly impairs painful stimulus localisation without 
altering pain affect; a possible explanation for this being that the medial pain 
system including cingulate is still intact (Ploner et al., 1999). However in studies 
utilising varying pain intensities Coghill et al., (1999) and Derbyshire et al., 
(1997) demonstrated pain intensity coding throughout the pain matrix i.e. it is not 
limited to just the lateral pain system.
Furthermore the insula receives projections from the posterior part of 
ventromedial nucleus (VMpo) and as mentioned above somatotopy has been 
demonstrated in the posterior insula (Ostrowsky et al., 2002, Brooks et al., 2006) 
suggesting that the insula also has a sensory discriminative role. Chen et al 2007 
suggests that this may place the insula in an intermediate position between the 
lateral and medial pain systems
Although the concept of a functionally distinct medial and lateral pain pathway 
may be an oversimplification it provides a theory for hypothesis and discussion.
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2.5.4 Cognitive and affective effects on pain processing.
One of the difficulties and indeed criticisms in interpreting functional imaging 
data is the knowledge that there are many factors that influence brain activity 
rather than just the stimulus itself. Differences reported in activation patterns 
across a number of studies may be due to methodological considerations, in 
particular lack of control. Various authors have sought to manipulate a number of 
attentional and motivational factors to investigate these further.
2.5.4.1 Attention and distraction
Brooks et al., (2002) demonstrated a shift from anterior to posterior insula 
activation during painful contact heat when attention was distracted away from 
the stimulus suggesting that distraction attenuates the affective component of the 
painful stimulus whilst attention enhances it.
Kulkami et al (2005) elegantly investigated the effect of manipulating subjects to 
attend to either the localisation or unpleasantness of a painful stimulus and 
demonstrated a clear difference in functionality of the medial and lateral pain 
systems. During localisation tasks activation in SI and inferior parietal cortices 
were reported whereas activation in perigenual ACC, orbitofrontal cortex (OFC), 
frontal pole, amygdala, posterior insula, MI and hypothalamus was more 
prominent during the attention to unpleasantness.
Ohara et al., (2004) reported on laser evoked potentials measured directly from a 
patient with a subdural grid implanted for the treatment of epilepsy and found 
when the subject attended to the painful stimulus LEP peaks were enhanced in SI, 
parasylvian and medial frontal cortices when compared to a distraction task.
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2.5.4.2 Anticipation
During pain imaging studies subjects may be shown a visual cue indicating the 
beginning of a painful stimulus or during block designed trials they may learn 
when a stimulus is due leading to subjects anticipating the onset of pain. 
Behavioural studies have demonstrated that uncertainty about impending noxious 
stimulation can both modify the perceived unpleasantness of the stimulus and 
decrease pain tolerance (Staub et ah, 1971). Several authors have therefore 
investigated the effects of anticipation by manipulating the context of stimuli 
delivery.
Anticipation of either innocuous touch or painful electrical stimuli to the finger 
resulted in a decrease in rCBF in SI somatosensory area representing the face i.e. 
areas of SI located out with that associated with the body location about to be 
stimulated (Drevets et al., 1995). This would indicate that anticipation not only 
enhances activation in appropriate regions but may generate a generalised 
suppression of background activity in the neighbouring region. Porro et al., (2002) 
report similar findings of increased activation in foot representation area of 
contralateral (SI) during anticipation of a painful stimulus to the foot. The authors 
point to this as providing evidence for top-down modulating cortical systems 
involved in sensory and affective components of pain which may be triggered by 
anticipation even in the absence of actual noxious input.
Decreased amygdala activation was found when subjects anticipated a prolonged 
duration of painful stimulation (i.e. more aversive) when compared to a shorter 
duration despite intensity of pain being matched (Petrovic et al, 2004). The 
authors suggest this deactivation may reflect a cognitive mechanism that exists to 
reduce subjective distress experienced whilst in an experimental “no-escape” 
situation. Anticipation was also associated with an increase in activation in the 
rostral ACC.
Ploghaus et al., (1999) manipulated subjects’ expectations prior to them receiving 
either a noxious or innocuous heat stimulus. During anticipation anterior medial 
frontal cortex, anterior insula and posterior cerebellum activation was observed 
whilst the actual pain stimulus activated caudal ACC, mid insula and anterior
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cerebellum. The authors sensibly advise caution when interpreting pain imaging 
data whereby anticipation has not been controlled for.
In summary, pain is a complex, multi-dimensional experience that comprises 
sensory-discriminative, affective, motivational and evaluative components. 
Multiple cortical and sub-cortical areas of the human brain are involved in the 
recognition, experience and modulation of pain. These areas include primary and 
secondary somatosensory cortices, thalamus, insula, prefrontal cortex, cerebellum, 
basal ganglia. Functionally the pain matrix may be considered as a medial and a 
lateral pathway with separate associated functions. The lateral pathway is 
primarily associated with sensory-discriminative components of the pain sensation 
whilst the medial slower pathway is typically associated with affective and 
evaluative components. Evidence from brain imaging studies to date generally 
support the existence of functionally separate medial and lateral pain pathways 
although it should be recognised that this may be an oversimplification.
2.6 Imaging studies of clinical pain
Investigations utilising brain imaging of pain has been dominated by the use of 
acute experimental pain models (Kupers and Kehlet 2006). Whilst study 
paradigms have evolved and a number of clever manipulations by investigators 
have produced results, which have furthered our understanding of acute 
physiological pain processing; in contrast, investigations involving brain imaging 
in patients with chronic pain are scarce.
Brain activation patterns observed during acute, physiological pain processing 
may not reflect that which happens in chronic pain conditions. It has been 
suggested that a fundamental approach to understanding the pain experience in 
clinical pain is to establish whether patients display altered cerebral 
representations of painful stimuli; if so then what is the role of peripheral and 
central factors in generating this altered representation (Schweinhardt and Tracey 
(2007).
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Increasingly researchers’ have turned their attention to these patient populations; 
assembling a homogenous patient cohort, particularly in respect to matching 
symptom profile, duration of disease, medication history, age distribution, 
aetiology and psychological profile is however often problematic (May, 2007). It 
is perhaps therefore unsurprising that a recent review of clinical pain studies 
(Kupers and Kehlet 2006) suggests that the results are ‘highly incongruenf.
2.6.1 Studies investigating experimental pain in clinical patient populations
On account of the difficulties in reliably inducing / reproducing clinical pain and 
differentiating between evoked and spontaneous pain within a scanning 
environment, early brain imaging studies involving chronic pain conditions 
typically investigated brain activation patterns in patients to an experimental pain 
stimulus, typically employing contact heat or mechanical pressure as the painful 
stimulus and usually in an anatomically distinct body area from the reported 
clinical symptoms.
Jones and Derbyshire (1997) investigated six patients diagnosed with Rheumatoid 
Arthritis, a chronic inflammatory pain condition; undertaking PET scans during 
heat pain. In comparison to age and sex matched controls, the patient group 
showed “remarkably damped cortical and subcortical responses” to a nociceptive 
input. Areas showing reduction included prefrontal and anterior cingulate areas.
The same group later undertook a similar study in another patient group; patients 
with acute, unilateral surgical pain, again applying heat pain to the contralateral 
hand during PET and comparing the responses with the control and RA group 
(Derbyshire et al., 1999). The surgical patients demonstrated significantly 
increased regional cerebral blood flow in the ipsilateral prefrontal cortex (BA 44) 
during heat pain in addition to contralateral increases in the putamen and bilateral 
increases in the insular cortex. In comparison to the control and RA group, 
significantly reduced responses in the anterior cingulate (BA 24), pre-frontal 
medial, and orbito-frontal (BA 9/10/32/47) cortices were shown. They suggest the 
reduced frontal and anterior cingulate responses to the experimental heat pain 
during acute inflammatory pain (left jaw) indicates cortical modulation of
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nociceptive processing that may be related to non-somatotopic, bilateral, 
nociceptive inputs to these areas. However it is difficult to extrapolate the results 
due to the small numbers in each group (N = 6) and the significant difference in 
age between the surgical and other groups.
Derbyshire et al (2002) compared the activation of a number of brain regions 
during application of heat at graded intensities in healthy volunteers compared to 
in patients with chronic low back pain. Only a few small differences were 
observed between the groups that the authors did not consider were sufficient to 
indicate that abnormal nociceptive processing in patient group may be occurring.
Fibromyalgia is a chronic pain condition characterised by reduced pressure pain 
thresholds over 11 of 18 muscle-tendon sites, in the absence of a clinically 
demonstrable peripheral nociceptive cause (Wolfe et al., 1990). Gracely and 
colleagues (2002) investigated cerebral responses to noxious and innocuous 
mechanical pressure in fibromyalgia patients compared to healthy volunteers.
During a matched pressure design patients reported higher levels of pain intensity 
and increased activation was observed in parietal, insula and cingulate cortices. 
However when the pain levels were matched i.e. the patient group had a reduced 
pressure applied, no differences in the level or area of activation was observed 
between patients and volunteers suggesting that in fibromyalgia, augmented 
processing by the CNS of peripheral stimuli occurs. Further evidence to support 
this conclusion of augmented processing in fibromyalgia comes from a recent 
review of the literature by Schweinhardt et al (2008).
The same group of investigators later undertook a similar investigation in patients 
with chronic low back pain (Giesecke et al., 2004) investigating pressure pain at a 
neutral site -  i.e. neither within nor in close proximity to the area of clinical pain. 
During equal pressure, increased activation was observed in pain-related cortical 
areas in the LBP group compared to controls; contralateral primary and secondary 
somatosensory cortices, inferior parietal lobule, cerebellum, and ipsilateral SII. In 
contrast when pain intensity was matched (lower pressure in patient group
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compared to control group) the authors report no significant difference in brain 
activation patterns between the groups.
Cook et al., (2004) in an fMRI study investigated brain activations to both painful 
and non-painful heat stimulus in nine female subjects with FM compared to 
healthy controls. Interestingly during warm stimulation that was non p a in fu l, FM 
subjects compared to controls demonstrated significantly greater activity 
prefrontal, supplemental motor, insular, and anterior cingulate cortices. During 
painful heat stimulus (intensity matched) only contralateral insula showed an 
increase in the FM patient group when compared to the controls.
2.6.2 Surrogate models of clinical pain
Surrogate models of chronic pain have attracted interest of some researchers in an 
attempt to ‘bridge the gap’ between experimental and clinical pain studies whilst 
minimising the confound of heterogeneity in clinical populations.
The heat capscaicin model of heat allodynia described previously is one such 
model employed by Lorenz et al., (2002) in healthy volunteers, demonstrating 
increased activation in medial thalamus, ventral putamen, pACC and prefrontal 
cortex in comparison with heat pain of similar intensity.
2.6.3 Investigations of clinical pain exacerbation
Schweinhardt et al., (2006) studied brain responses to exacerbation of allodynia in 
eight patients with a clinical diagnosis of neuropathic pain, demonstrating 
activation in the rostral anterior insula (rAI) that correlated with perceived 
intensity of provoked allodynia. The authors also undertook a review of the 
literature investigating anterior insula activation in clinical pain studies, 
demonstrating that anterior insula activation reported was more rostral during 
clinical pain than experimental pain.
Kulkami et al., (2006), in a PET study investigated twelve patients with 
osteoarthritis of the knee, undertook scanning during 3 different pain states: 
arthritic knee pain, experimental knee pain, and pain-free. Although activation of
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the pain matrix was seen during both clinical and experimental pain, arthritic pain 
demonstrated greater increase in activity in cingulate cortex, thalamus, and 
amygdala; areas which have been reported pain studies but also involved in the 
processing of fear, emotions, and in aversive conditioning.
Mayer et al., (2005), in a PET study, reported greater activation of limbic and 
paralimbic circuits during rectal distension in patients with IBS compared with 
control subjects or patients with quiescent ulcerative colitis.
Baliki et al., (2006) report on a cleverly designed study investigating brain 
patterns associated with sustained pain compared to spontaneous exacerbations of 
pain and thermal pain in an fMRI study of patients with low back pain. They 
report increased activity in the medial prefrontal cortex, rostral anterior cingulate 
and posterior parietal cortex that was strongly related to intensity of the ongoing 
pain. In contrast to this was during spontaneous exacerbations of LBP the authors 
report activation in brain areas previously reported during acute experimental 
pain.
The authors suggest that their findings of positive correlation between mPFC 
activation and intensity of spontaneous pain in comparison to the similar 
relationship between insula activation and pain intensity during thermal 
stimulation indicates that sustained pain involves specific spatiotemporal neuronal 
mechanisms that are distinct from those observed for acute experimental pain.
2.6.4 Post therapeutic intervention studies
In an early PET study Di Piero et al., (1991) investigated 5 patients with unilateral 
chronic pain due to cancer before and after percutaneous cervical cordotomy; an 
intervention which has been shown to effectively reduce unilateral neuropathic 
pain. They report a decrease in blood flow of the contralateral (to side of pain) 
thalamus pre cordotomy that was normalised post successful cordotomy. They 
also note that they observed no significant changes in the prefrontal or primary 
somatosensory cortex.
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Hsieh et al., (1995), also in a PET study investigated the neural substrates of the 
perception of chronic neuropathic pain in eight patients with painful peripheral 
neuropathy in the lower limb before and after a successful regional nerve block 
lidocaine. The ongoing neuropathic pain resulted in activation of bilateral anterior 
insula, posterior parietal, lateral prefrontal and PCC and right ACC Brodmann 
area (BA) 24, regardless of the side of PMN. A reduction in rCBF was noted in 
the contralateral posterior thalamus but no significant change of rCBF was 
detected in the somatosensory areas, i.e., SI and SII.
2.6.5 Structural brain changes and pain
Voxel-based morphometry investigations have revealed subtle, regionally specific 
changes in grey matter across subjects in a number of chronic pain conditions. 
May et al., (1999), in a study comparing patients with a history of cluster 
headache to age matched controls found in the patient group higher grey-matter 
density in the hypothalamus ipsilateral to the side of the cluster headache attacks. 
The area of increased grey-matter density overlapped with that where increased 
rCBF during a cluster attack was also found; the authors suggesting parallel 
structural and functional changes.
Patients with chronic back pain, again compared with a matched control group 
have been reported as having a 5-11% reduction  in global cortical grey-matter 
density; the decrease correlating with chronicity of pain. (Apkarian et al., 2004). 
More specifically, regional grey matter was also reduced bilaterally in prefrontal 
cortex and right thalamus.
Two further studies investigated CLBP patients; Schmidt-Wilcke et al., (2006) in 
a study of 18 patients compared to age matched controls report a significant 
decrease of gray matter in the brainstem and somatosensory cortex; the change in 
gray matter showing a negative correlation with degree of unpleasantness i.e. the 
higher the degree of reported unpleasantness the lower the gray matter density. 
Conversely they also report a significant in crease  in gray matter bilaterally in the 
basal ganglia and the left thalamus.
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Buckalew et al., (2008) subsequently investigated structural brain differences in 
older adults with chronic low back pain (CLBP) when compared with age 
matched pain-free controls; demonstrating significantly decreased gray matter 
volume in the posterior parietal cortex and middle cingulate white matter volume 
of the left hemisphere in CLBP patients. CLBP participants also had impaired 
attention and mental flexibility. However again the numbers in this study were 
limited (N = 8 in each group).
Other investigators have also reported morphometric changes in chronic tension- 
type headache (Schmidt-Wilcke et al., 2005) and phantom limb pain (Draganski et 
al., 2006). N-acetyl aspartate, found localised within neurons, involved in synaptic 
processes and considered as a neuronal and axonal marker was found to be 
depleted in the prefrontal cortex, specifically the DLPFC, in patients with chronic 
low back pain (Grachev et al., 2000).
However, it remains unclear what the relationship of these changes are to pain; 
similar reductions in grey-matter density have been reported in non pain studies 
including in bipolar depression (Lyoo et al., 2004) and patients with chronic 
fatigue syndrome (de Lange et al., 2004). The adult human brain has also been 
shown to be capable of changes in structure in response to environmental 
demands (Draganski et al., 2004) therefore a key question with regards to the 
findings of cortical morphological changes remains; are these a consequence, 
contributing factor in development or indeed simply an epiphenomenon of chronic 
pain. Longitudinal studies may help answer this question.
2.6.6 Summary of clinical pain studies
Kupers and Kehlet (2006) advocate repeated-measure, prospective-study designs 
carried out in a homogeneous subset of patients before and after a well-described 
surgical intervention as a way forward in investigating clinical pain syndromes. 
They suggest the post-operative pain model has the advantage of pain onset 
predictability and that patients may be designated low or high risk for 
development of chronicity on the basis of their response to an acute pain stimulus 
before surgery. They point out that the fact that both the low and high-risk
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patients undergo the same experimental surgical procedure would allow for the 
study of time by group interactions in the development of chronicity.
The idea that we may be able to ‘track’ the development of chronicity through a 
series of brain imaging studies is certainly appealing, however any such study 
would require careful planning and significant resource to ensure the multi­
factorial nature of chronic pain development is captured.
Published clinical pain studies have used patient populations that differ greatly in 
demographics related to age and sex, cause of pain, duration of pain, levels of 
ongoing spontaneous pain and psychological profile making comparisons 
difficult.
However taken together, a body of evidence exists that in patients with a variety 
of chronic pain syndromes, when compared to healthy volunteers, neuroplastic 
changes and alterations in brain processes occur. These differences include, 
somatotopic re-organisation, augmented (or suppressed) processing of both 
innocuous and noxious stimuli and morphological changes.
The degree to which these factors are a consequence, contributing factor in 
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2. 7 Summary of chapter
Whilst several methods for inducing experimental pain exist, each with relative 
advantages and weaknesses, the key requirement for the planned study was a 
method of induction that may be applied to selectively induce pain in the skin and 
muscle in a repetitive and safe manner, employing a methodology applicable to 
both tissue types and that is compatible within an MRI environment.
It was concluded therefore that injection of hypertonic saline as the method of 
induction of pain offered the best balance.
By far the greatest majority of the pain imaging literature to date has relied on 
acute experimental cutaneous pain induced in healthy volunteers. The small 
number of studies utilising muscle pain, whilst limited are sufficient to suggest 
that pursuing the brain imaging of muscle pain models may be useful in particular 
in relation to perhaps serving as a more reflective model of clinical pain. This will 
be further explored in chapter 6.
Increasingly, researchers have become aware that results of brain imaging studies 
employing experimental pain models may not reflect brain processes involved in 
clinical pain conditions.
Studies involving clinical patients are increasing apace; evidence suggests that 
altered processing does indeed occur in clinical pain. Cause and effect 
relationships however have yet to be established.
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Psychophysical properties of superficial and deep tissue pain
Chapter 3
Introduction
Chapter three presents the methodology and results of Experiment One; a 
laboratory based investigation of the psychophysical properties of hypertonic 
saline induced pain in muscle (MS), intradermal (ID) and subcutaneous (SC) 
tissues.
The key aims of experiment one were (i) determine whether the psychophysical 
properties of deep and superficial pain differ when pain of similar intensity is 
induced using the same method of noxious stimulus and (ii) to investigate the 
applicability and reliability of the hypertonic saline model to consider its use in 
the planned fMRI studies.
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3.1 Background
Pain, in common with any form of somatic sensation, is typically described in 
terms of sensory, cognitive and affective aspects. Sensory aspects generally 
include location, magnitude and spatiotemporal properties. Affective components 
include the hedonic aspect -  i.e. the degree of unpleasantness of the sensation and 
a motivational aspect -  producing the motivation to limit the experience of the 
noxious stimulus (Sewards et al 2002). It has been argued that the hedonic and 
sensory aspects of somatic sensation are represented and processed in parallel but 
distinct pathways throughout the nervous system and may reflect differences in 
psychophysical properties of cutaneous and muscle pain.
Sensory and affective components of pain evoked by different modalities have 
been shown to differ (Rainville et al., 1992). Therefore in order to undertake a true 
comparison of pain arising from cutaneous and muscle tissues the same type of 
stimulus should be employed.
Experimental muscle pain induced by intramuscular injection of hypertonic saline, 
originally described by Kellgren (1938), and subsequently developed by others 
(Arendt Nielsen et al., 1996; Graven Nielsen et al., 1997) has become a reliable 
and valid technique for investigating both peripheral and central mechanisms of 
muscle pain (Graven-Nielsen et al., 1997). The properties of intradermal 
hypertonic saline have not been similarly investigated; Witting et al., (2001) 
suggests this may be due to the volume required intradermally.
The aim of this experiment was to undertake a direct comparison of the 
psychophysical properties of hypertonic saline induced pain in muscle (MS), 
intradermal (ID) and subcutaneous (SC) tissues. Compared to previous studies 
employing different modes of induction this study utilised identical noxious 
stimulation allowing for an accurate comparison of superficial (ID and SC) and 




Sixteen healthy volunteers (6 male, 10 female) mean age 36 (range 19 - 60) 
participated in the study. Subjects were recruited via advert to staff of The Walton 
Centre for Neurology and Neurosurgery and the clinical sciences department of 
The University of Liverpool which included visiting health care students.
Each subject underwent a semi-structured interview that consisted of past medical 
history and current symptoms. Subjects were excluded if there was (i) history of a 
cervical and /or upper limb musculoskeletal condition that had at any stage 
required investigations or treatment, (ii) history of skin disease (e.g., psoriasis, 
eczema,), (iii) history of injury of upper arm or neck, (iv) ongoing current 
musculoskeletal symptoms (e.g., pain, weakness, stiffness), (v) any persistent pain 
(including chronic daily headaches; however occasional migraine attack were 
allowed), (v) any systemic disease (except mild hypertension well controlled with 
medication), (vi) any chronic allergic conditions (e.g., urticaria; however, allergic 
rhinitis was accepted), (vi) history of a psychiatric or neurological condition, (vii) 
history or suspicion of current ongoing abuse of alcohol or drugs, (viii) current 
use of medications with analgesic properties even if used for other purposes, e.g. 
tricyclic antidepressants or non-steroidal anti-inflammatory drugs, (ix) any 
ongoing non-drug therapy with analgesic properties (e.g., acupuncture for 
smoking cessation).
The St Helens & Knowsley local research ethics and The Walton Centre for 
Neurology and Neurosurgery Research Governance committees approved the 
study protocol and written informed consent was obtained from all subjects prior 
to enrolment in the study. Documentation relating to ethics and research 
governance can be found in Appendix A.
All subjects received a written and verbal explanation of the protocol prior to 




Selection of hypertonic saline solution strength and volume of injectate was based 
both on the literature (Graven-Nielsen et al 1997) and also preliminary laboratory 
testing of five volunteers; the latter in particular guided selection of appropriate 
volumes. (These volunteers subsequently did not participate in the actual study) 
The primary considerations when selecting these were the aims to induce pain of 
(i) sufficient intensity (>4/10 on a VAS) (ii) relatively limited duration (iii) similar 
intensity in all three tissue types
Both 5% and 6% hypertonic saline solution strengths have been reported in the 
literature; however, 6% is the most consistently utilised. The 6% saline solution 
also consistently provoked pain in the 5 test subjects and was therefore selected 
for this study. Volumes injected into muscle, subcutaneous and intradermal tissues 
were 0.35ml, 0.25ml and 0.2ml respectively.
Disposable plastic catheters (Vygon, 26 g, 25mm) were inserted in to the posterior 
aspect of the non-dominant forearm, using an aseptic technique, at three separate 
sites; the extensor digitorum muscle belly, intradermal and subcutaneous tissue 
between 5-10 cm distal to the muscle catheter in the skin overlying the extensor 
digitorum muscle. All three catheters were inserted prior to the subject receiving 
the first injection and removed after the last injection.
Each site was injected twice with the 6% hypertonic saline at intervals of eight 
minutes in a single session. The order of the first injection into each site was 
randomised; however, to reduce the likelihood of accommodation the same order 
was then kept for the second injection. Subjects were blinded to the site at the 
moment of injection. As they subsequently were asked to indicate the extent of 
local and referred pain it was not possible to maintain this blinding. All subjects 
attended two sessions that were separated by a period of at least seven days.
65
3.2.3 Pain Assessment
Prior to commencing the study subjects received verbal instructions regarding the 
psychophysical data that was to be collected and familiarised with equipment and 
documentation involved.
3.2.3.1 Intensity
Intensity of pain was scored on an in-house designed electronic visual analogue 
scale (VAS) consisting of a handheld pressure sensitive device that outputs data to 
a dell laptop. A vertical scale is displayed on the computer screen with fixed end 
points representing ‘no pain’ and ‘worst possible pain’. Subjects by means of the 
pressure device move a horizontal bar displayed perpendicular to the vertical line 
to the point on the scale that represents their pain. The software samples the line 
once per second (and stores it). Calibration was checked after 3-4 subjects to 
ensure the scale continued to represent 0-100.
Pain intensity was rated continuously for sixty seconds immediately following 
each injection; from this data highest pain reported, peak VAS, was determined 
from the output of the electronic VAS. Repeat intensity scores were taken as 
single recordings at 120 s and 210s post injection.
All VAS data was plotted and area under the curve (AUC) was calculated as a 
function of VAS and time for the initial sixty second period (AUC_60s) and for 
the full three minutes of VAS data collection to give a ‘total pain’ score 
(AUC total). AUC measurements were determined using the mathematics 
software package Sigmaplot; this integrates under curves using the trapezoidal 
rule which may be used for equal or unequally spaced x values (SigmaPlot, 
V I0.0, Systat Software, Inc., 2006).
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3 .2 2 . 2  Unpleasantness
Unpleasantness of a painful stimulus has been shown to be subjectively 
distinguishable from intensity of the same stimulus (Rainville et al 1992). 
Subjects received verbal instructions based on those used by Price et al (1987):
“th ere  a re  tw o  aspects  o f  p a in  which w e  a re  in terested  in m easuring: the 
in tensity, h ow  stro n g  the p a in  fee ls , an d  the unpleasantness, h ow  unpleasan t o r  
d istu rb in g  the p a in  is f o r  you . The d istinction  betw een  these tw o asp ec ts  o f  p a in  
m ig h t b e  m ade c lea rer  i f  yo u  think o f  listen in g  to a  sound, such a s a radio. A s the  
vo lu m e o f  the sound increases, I  can a sk  yo u  h ow  lou d  it sounds o r  how  
u n p leasan t it is to hear it. The in tensity  o f  p a in  is like loudness; the 
u n pleasan tn ess o f  pa in  depends n o t on ly on in tensity  bu t a lso  on o ther fa c to r s  
w hich m ay affect you . There are  sca les  f o r  m easuring  each o f  these tw o asp ec ts  o f  
p a in . A lthough  som e p a in  sen sa tion s m ay b e  eq u a lly  in tense a n d  unpleasant, w e  
w o u ld  like  y o u  to ju d g e  the tw o asp ec ts  independen tly. ”
This has been shown to be effective in conveying the understanding necessary for 
subjects to evaluate both sensory and affective qualities of induced pain (Duncan 
et al., 1988, 1989; Miron et al., 1989).
At sixty seconds post injection subjects rated the unpleasantness of the pain on a 
visual analogue scale where ‘O’ represented ‘not at all unpleasant’ and ‘10’ 
represented ‘the most unpleasant sensation imaginable’.
3.2.2.4 Quality
The Short Form (SF) McGill pain questionnaire uses a series of words to evaluate 
the sensory and affective components of pain, is well validated and has previously 
been used to reflect these properties in both cutaneous and muscle pain conditions 
(Klepac et al 1981).
After rating unpleasantness, subjects completed the SF McGill pain questionnaire.
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3.2.2.5 Area of pain
Subjects used a fine temporary marker to outline the area of both local and 
referred pain anywhere in the injected arm. As the non-dominant arm was being 
tested, the dominant arm was free for marking.
Referred pain was defined as pain after injection in an area separate and distinct 
from the area immediately surrounding the injection site and subjects were 
instructed to differentiate between the two.
After confirming the correctness of the indicated area the outline was transferred 
to transparent acetate and the areas measured with a digital planimeter (Klonk, 
Quantify One, Denmark)
3.2.2.6 Allodynia
The presence of both punctate (static) and mechanical (dynamic) allodynia was 
tested for within the area of local pain; this area having been previously indicated 
by the subject. Where referred pain was present, allodynia was also tested for 
within that area, again as indicated by the subject.
Punctate (static) allodynia
A Von Frey filament (30g) was placed within the area of pain and held in place 
for 5 seconds whilst sufficient pressure was applied to cause the filament to bend. 
Subjects were asked whether this resulted in any increase in pain and if so to rate 
the resulting pain on a visual analogue scale. Prior to testing within the area of 
pain, the test was carried out in the mirror area on the opposite limb to confirm 
that the selected Von Frey filament caused only mechanical pressure not pain in 
the control area.
Mechanical (dynamic) allodynia
Using a 2cm wide soft brush, five strokes (3-5cm long) were applied within the 
area of pain. This was repeated 5 times at a frequency of <0.2Hz (to avoid a 
summation effect). Again, prior to testing the affected side, the test was carried 
out on the mirror site to allow for subject’s to compare the sensations evoked.
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Subjects were asked whether this resulted in any increase in pain and if so to rate 
the resulting pain on a visual analogue scale.
3.2.3 Statistical Analysis
As stated above, three types of injection (ID, MS, SC) were given each on four 
occasions (two at time one and two at time two) to all participants. In order to 
examine whether there were any significant differences between each injection 
type and also to determine any differences between the same type of injection on 
different occasions, a series of two factor within subject ANOVAs were 
conducted.
The independent variables were injection type (ID, MS, SC) and time (1, 2, 3 & 4; 
where 1&2 were the first session and 3&4 the second session). The dependent 
variables considered in separate analyses were: pain intensity, unpleasantness, 
time to peak intensity (VAS), AUC 60 and AUC total.
Mauchly's Test demonstrated that assumptions of sphericity was violated for the 
interaction term injection*time in the pain intensity analyses (X2 = 33.6, dflO , 
p=.03), therefore Greenhouse Geisser adjusted F values are reported for this 
effect.
Bonferroni pairwise comparisons were used to determine the differences for 
significant effects.
Kruskal-Wallis was used to analyse differences in SF McGill data.
SPSS vl4 (SPSS Inc., 2006) was used for all analyses.
3.3 Results
3.3.1 Pain intensity: peak visual analogue scale (VAS) score (see appendix B 
for full SPSS output)
Mean peak VAS score across all injections for ID, SC and MS were 5.5 (2.0), 
4.1(2.3) and 5.0 (2.0) respectively (see table 3.1).
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The two factor within subjects ANOVA revealed a significant difference between 
each type of injection (F (2,30) = 13.20, p<.0005. Partial eta squared = .47) and 
Bonferroni pairwise comparisons showed these differences to be between ID& SC 
and SC & MS (injection type 1 & 2, and 2 &3.)
There was no significant interaction between injection type and time (F (6, 90) = 
2.41, p>.05).
3.3.2 Area under the curve; initial 60 second period (AUC_60) (see appendix 
B for full SPSS output)
Mean area under the curve for the initial 60s period (AUC 60) across all 
injections for ID, SC and MS were 272.4 (s.d., 15.9), 178.4 (s.d., 15.6) and 182.6 
(s.d., 14.6) respectively (see table 3.1).
There was a significant difference in area under the curve between injection types. 
F (2, 28) = 23.10, p<.0005. Partial eta squared = .623. There was also a significant 
difference between injections at each time point F (3, 42) = 5.89, p=.002. Partial 
eta squared = .296. The planned Bonferroni comparisons show the significant 
difference to be between injection type ID & SC and ID & MS but not between 
SC&MS.
There was no significant interaction between area under the curve and time F (6, 
84) = 1.58, p>.05. Therefore there was no significant difference within injection 
type across the four different time points
3.3.3 Area under the curve -  total time period (AUC total) or “Total pain” 
(see appendix B for full SPSS output)
There was a significant difference in AUC_total between each injection type 
(F(2,28) = 4.27, p<.05. Partial eta squared =.234).
There was also a significant difference in AUC_total at each time for all injection 
types F (3, 42) = 11.29, p<.0005. The planned Bonferroni pairwise comparisons
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show that the difference in AUC total was between injection types ID & SC, not 
between ID &MS or SC & MS.
The interaction between injection and time was not significant F (2.13) = .58, 
p>.05. Therefore there was no significant difference within injection type across 
the four different time points
Table 3.1 Summary of psychophysics data
N
Std.
Statistic Mean Std. Error Deviation
Peak intensity
ID 64 5.5 .25 2.00
SC 64 4.1 .29 2.31
MS 64 5.0 .25 1.98
Unpleasantness
ID 64 4.6 .29 2.33
SC 64 3.5 .29 2.36
MS 64 4.1 .28 2.27
AUC_60
ID 60 272.4 15.93 122.93
SC 60 178.4 15.64 121.20
MS 60 181.6 14.61 113.15
AUC_total
ID 60 636.37 39.28 304.27
SC 60 536.060 44.14 341.94
MS 60 554.67 42.30 327.72
Time to peak VAS
ID 64 31.73 1.77 14.17
SC 64 40.14 1.75 13.96
MS 64 45.06 1.72 13.743
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There was a significant difference in AUCtotal between each injection type (F 
(2, 28) = 4.27, p<.05. Partial eta squared =.234).
There was also a significant difference in AUC_total at each time for all injection 
types F(3, 42) = 11.29, p<.0005. The planned Bonferroni pairwise comparisons 
show that the difference in AUC total was between injection types ID & SC, not 
between ID &MS or SC & MS.
The interaction between injection and time was not significant F (2.13) = .58, 
p>.05. Therefore there was no significant difference within injection type across 
the four different time points
3.3.3 Area under the curve -  total time period (AUC_total) or “Total pain”
(see appendix B for full SPSS output)
3.3.4 Time to peak VAS (see appendix B for full SPSS output)
There was a significant difference in time to peak vas for each type of injection 
(F(2,30) = 13.85, p<.0005. Partial eta squared = .48.). Here the planned 
Bonferroni pairwise comparisons show the difference to be between ID & SC and 
ID & MS (p<0.05) with no significant difference between SC and MS (p>0.05).
There was no significant effect of time, i.e. no differences between each injection 
(F (3, 45) = 2.07, p >.05)
Finally there was no significant interaction between injection and time (F (6, 90) 
.997, p>.05). Again therefore there was no significant difference within the 
injection type across the four different time points
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Figure 3.2. Time to peak VAS intensity at each injection time, arranged 
according to tissue type.
( Y axis = time to reach peak VAS score in seconds; X axis = injection number: 1 

















The two factor within subjects ANOVA revealed a significant difference between 
each type of injection for unpleasantness ratings (F (2, 30) = 5.65, p<.01. Partial 
eta squared = .27)
There was also significant differences between each time (F (3, 45) = 12.28, 
p<.0005). Bonferroni pairwise comparisons demonstrate the significant 
differences to be between injection type ID & SC.
There was no significant injection time interaction (F(6,90) = 1.76, p>.05). 
Therefore there was no significant difference within the same type of injection 
across the four different time points
Unpleasantness was found to correlate with intensity in all three conditions 
(Pearsons r = .836, p<.000 (ID), r = .820, p<.000 (SC), r = .678, p<.000 (MS) 
(see table 3.2 and figure 3.1. ).
3.3.5 Unpleasantness ratings (see appendix B for full SPSS output)





ID 64 .836(**) .000
SC 64 .820(**) .000
MS 64 .678(**) .000






















Figure 3.3 Mean intensity and unpleasantness scores at each injection time, 
arranged according to tissue type.
( Y axis = peak VAS score left column , peak unpleasantness right column; X axis 
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Figure 3.4 Scatter plots of unpleasantness and peak intensity for each tissue type. 




































Figure 3.5 Mean area under the curve* for initial 60s (AUC60) (left column) 
and total time period (AUCtotal) (right column)
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The two factor within subjects ANOVA revealed a significant difference between 
each type of injection (F(2,30) = 7.98, p<.002. Partial eta squared = .35) and 
Bonferroni pairwise comparisons showed these differences to be between 
injection type ID & MS.
There are was also significant differences between each time (F(3,45) = 3.04, 
p<.05). Bonferroni pairwise comparisons demonstrate the significant differences 
to be between times 3 & 4, i.e. within session two.
No significant interaction between injection type and time was found (F (6, 90) = 
.75, p>.05).
3.3.6 Area of local pain (see appendix B for full SPSS output)
3.3.7 Referred pain
A separate area of referred pain was reported after 1, 8 and 28 injections for ID, 
SC & MS pain respectively. In view of the infrequent findings referred pain in 
both ID and SC conditions no formal statistical analysis was undertaken. 
Measured area results however are summarised in table 3.3
3.3.8 Allodynia -  punctate and brush
Both punctate and brush allodynia, tested in the area of local pain was found 
infrequently (Punctate; N = 16, 19 & 14 and Brush; N = 14, 8 & 3 for ID, SC and 
MS respectively). Where present, VAS scores were low (Punctate; vas = 2.1 (sd 
.85), 1.8 (sd .21) & 1.9 (sd .22) and Brush; VAS = 2.2 (sd 1.2), 2.0 (sd. 1.07) &
3.3 (s.d.1.52) for ID, SC and MS respectively).
In the area of referred pain brush allodynia was found once after one MS injection 
only (VAS = 3); whilst punctuate allodynia was found three times, after MS 
injection (one each in three different subjects), (VAS = 1.7, sd 1.15).
In view of the infrequent findings of either punctuate or brush allodynia, in 
addition to the very low VAS scores reported when present, no formal statistical 
analysis was undertaken. Results however are summarised in table 3.
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Table 3.3 Summary of area of local and referred pain, frequency of referred pain 




Site N Mean Std. Error Deviation
Local pain
ID 64 31.3 3.07 24.55
SC 64 36.3 3.46 27.64
MS 64 52.2 4.24 33.91
Referred pain
ID 1 .3 .30 2.40
SC 8 1.8 .64 5.10
MS 28 13.2 3.34 26.79
VAS score
Std.
Frequencyb Mean Std. Error Deviation
B rush allodynia N
ID local 14 2.2 .32 1.20
ID referred 0
SC local 8 2.0 .38 1.07
SC referred 0
MS local 3 3.3 .88 1.52
MS referred 1 3.0
P unctate
allodyn ia N
ID local 16 2.1 .21 .85
ID referred 0
SC local 19 1.8 .21 .89
SC referred 0
MS local 14 1.9 .22 .83
MS referred 3 1.7 .67 1.15
0
Frequencya - number of times referred pain was reported 
Frequencyb - number of times where a VAS > 1 was reported.
79
3.3.9 Short form McGill Pain Questionnaire
There was a significant difference in sensory words selected in the ID and MS 
conditions when compared with the other two conditions.
During ID pain, ‘hot/buming’, ‘stabbing’ and ‘sharp’ were selected more 
frequently and scored higher (p<0.05) than both MS and SC. The word ‘shooting’ 
during ID scored higher than MS but not the SC condition.
During the MS condition ‘gnawing’, ‘aching’, ‘heavy’ and ‘cramping’ were 
selected more frequently and also rated higher (p<0.05) than both the ID and SC 
conditions.
During the SC condition no descriptor was selected more frequently or scored 
higher than either ID or MS conditions.
Overall affective descriptors were selected less frequently than sensory words, 
however when selected this was more frequent in muscle pain (ID 6, SC 9, MS 
14). Due to the infrequent selection, no formal analysis was undertaken.
Frequency of selection is summarised in table 3.4.
Table 3.4 Frequency of word selection from the SF McGill pain questionnaire
Sensory throb shoot stab sharp cramp gnaw'g
Hot/
burn’g ache heavy tender Split’g
Injection
type
ID 18 13 29 51 4 2 28 15 2 21 7
SC 19 12 17 31 12 4 18 35 9 15 6
MS 30 2 9 7 31 24 8 32 25 11 3
Affective Tiring sickening fearful cruel
ID 1 2 1 2
SC 5 1 2
MS 4 6 3 4
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3.4 Discussion of findings
3.4.1 Intensity of pain
During hypertonic saline induced experimental pain in healthy volunteers into 
both intradermal and muscle independently, peak VAS scores were of similar 
magnitude within session and between sessions. Remarkably; peak VAS scores 
were also very similar irrespective of whether the injection was ID or MS. In 
contrast, SC injections did not perform as consistently resulting in VAS scores 
that were less comparable than those reported after ID or MS injections.
Therefore it may be argued that ID and MS hypertonic saline injections can be 
incorporated into a protocol in which pain of comparable intensity is required 
between cutaneous pain and deep tissue pain; whereas SC injection would offer a 
rather less robust model.
3.4.2 Temporal characteristics
Time to peak pain was shorter in the intradermal condition compared to both the 
muscle and subcutaneous conditions which is consistent with previously reported 
findings of comparisons between cutaneous and muscle experimental pain 
(Graven-Nielsen et al., 1997; Witting et al., 2000).
Unsurprisingly therefore area under the curve for the first 60 seconds was also 
greater after intradermal injection than both subcutaneous and muscle injections 
which is also consistent with previous reports comparing intradermal and muscle 
capsaicin injection (Witting et al., 2000).
However total pain (AUC total) scores showed no significant difference between 
intradermal and muscle injections; in both conditions this measure was also 
consistent across all four injection times. In contrast subcutaneous AUC_total was 
significantly less than intradermal, although not muscle.
These results suggest that although the onset curve for ID is steeper, the offset 
curve for MS is slightly flattened, therefore ‘total pain’ reported for the duration
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of measurement showed no significant difference between intradermal and muscle 
injection.
The consistent performance of ID and MS injections in producing comparable 
amounts of pain over three minutes indicate these models may be useful in study 
protocols in which pain of moderate intensity but time limited pain is required.
Again, in contrast, SC injections provide a lesser stable model.
3.4.3 Unpleasantness
With regards to intensity of unpleasantness of induced pain, both MS and ID 
injections produced similar scores with no significant change within or between 
sessions. A strong positive correlation was found between intensity and 
unpleasantness scores in both conditions
This is somewhat in contrast to previous reports (Rainville et al., 1992; Svensson 
et al., 1997a). However, although both of these studies investigated differences 
between pain arising from deep and superficial tissue, both groups employed 
different methods of pain induction for the two tissue types.
3.4.4 Extent of pain
Referred pain was a feature of the muscle pain condition but not intradermal. 
Although a few incidences of referred pain after subcutaneous injection were 
reported; overall the results suggest that referred pain is a feature arising from 
introduction of a nociceptive stimulus to deep but not superficial tissue.
Area of local pain was greater in the muscle than the intradermal condition; again 
this is consistent with the literature with cutaneous pain being described as 
typically well defined and localised (Staahl et al., 2006) in contrast to the more 
diffuse, less defined quality of muscle pain (Graven Nielsen et al., 1997).
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It should be mentioned however; areas of local and referred pain were measured 
separately with subjects asked to delineate between the two. A judgement had to 
be made therefore regarding overlap of the two which may have falsely increased 
the local pain results and decreased the incidence of referred pain.
3.4.5 Hyperalgesia
Interestingly, incidence of allodynia was low across all three conditions although 
punctate allodynia was more frequently seen than brush allodynia; where present 
the VAS scores were also low. Presence of cutaneous allodynia was specifically 
tested for as Kupers et al., (2004) employed ‘mechanical hyperaesthesia as one of 
their comparators during a PET study investigating neural correlates of muscle 
pain. Previous studies of sensory changes associated with experimental muscle 
however are inconsistent; Hockaday and Whitty (1967) reported inconsistency in 
both the extent and appearance, often delayed, of hyperalgesia. Vecchiet et al., 
(1988) also report a gradual onset of cutaneous hyperalgesia after painful 
electrical stimulation of the muscle; conversely Graven Nielsen et al., (1997) 
observed hypoalgesia to both pain prick and light touch after intramuscular HS 
infusion. Animal studies also point to differing temporal patterns in the 
development of hyper / hypoalgesia; after electrical induced referred muscle pain 
in rats Giamberardino et al., (1988) demonstrated an initial hyperalgesia which 
changed in time to hypoalgesia.
3.4.5 Qualitative differences
The results indicate that experimental cutaneous and muscle pain, when induced 
through the same mode of stimulus, can be differentiated through subjective 
descriptors of quality by completion of the SF McGill Pain Questionnaire. 
Descriptors selected were predominantly from the sensory as opposed to the 
affective category of words which is consistent with previous reports (Graven 
Nielsen et al., 1997; Beattie et al., 2004)).
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Although it has been suggested that experimentally induced muscle pain may 
result in a relatively larger activation of affective mechanisms (Svensson et al., 
1997a); this was not reflected by selection of affective words from the SF McGill 
pain questionnaire.
However when affective words were selected there was a trend for these to be 
after muscle injection, selection of words from this category was too infrequent to 
undertake any sensible analysis. Affective word selection therefore did not 
strongly support the hypothesis that muscle pain would results in a greater 
selection of these than intradermal and subcutaneous pain.
It is likely that the results reflect both the study population of healthy volunteers 
as opposed to a patient population particularly those with chronic pain and the 
experimental situation in that participants were aware that induced pain would be 
of relatively short duration.
3.5 Summary
In studies in which perceptual differences between cutaneous and deep tissue pain 
are assessed, the similarity of peak pain and total pain between the two modes of 
injections (ID and MS) affords a unique opportunity. If the aim is to evaluate 
neural correlates of the different qualities of pain the subjects feel (as per their 
responses on SF McGill), there is a very obvious advantage in a model where the 
likelihood of maintaining pain intensity and unpleasantness levels as standard.
In contrast, reliability of the subcutaneous condition was not found which would 
suggest caution when investigating certain experimental models which may not 
stimulate specifically either cutaneous or muscle nociceptors; particularly if the 
aim of investigation is to explore differences between superficial and deep tissue 
pain specifically. Comparative studies that evaluate differences between ID and 
SC may not therefore be reliable. The significant variability seen within the SC 
pain model excludes it as a useful model to compare with a muscle pain model in 
further investigations.
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The robust ID and MS results also suggest that it may be possible to explore 
activations in relation to generic pain features, such as unpleasantness. An 
exploration of perception of unpleasantness with a hypothesis that a certain brain 
region or circuitry is responsible for generating the percept, irrespective of the 
mechanism, is much easier if the intensity and total burden of experimental pain 
can be controlled (e.g., if the hypothesis under testing is, say, that activation in 
insula co-varies with unpleasantness scores and does so after both ID and MS 
injections).
The presented results are consistent with the first hypothesis that when subjected 
to a similar peripheral stimulus, healthy subjects perceive pain arising from skin 
and muscle tissues as qualitatively different.
The results however did not support the hypothesis that when subjected to a 
noxious stimulus of the same type into cutaneous and muscle tissues; the resulting 
intensity matched muscle pain when compared to cutaneous pain will be 
perceived as more unpleasant.
This provides the foundation for the next hypothesis that neural correlates of each 
pain will de different. The differences are likely to found in the activation patterns 
of structures that have been broadly referred to as the ‘pain matrix’ and provides 
the rationale for the next investigation.
Based on these findings, ID and MS injections were chosen as the method of 




Neural correlates of superficial and deep tissue pain
The next two experiments reported in this thesis utilised functional magnetic 
resonance imaging of the brain.
This chapter therefore begins with an overview of the methodology involved in 
fMRI acquisition and the analysis principles and procedures undertaken.
Methods specific to the main experiment described in this chapter are then 
described and psychophysical and fMRI results presented.
The chapter concludes with a brief discussion of the key findings of the 
experiment presented, with further discussion to follow in chapter 6.
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4.1 Functional Magnetic Resonance Imaging
Functional Magnetic Resonance Imaging (fMRI) studies rely on what has been 
termed the Blood Oxygenation Level Dependent contrast or BOLD response.
Haemoglobin in the blood, when bound to oxygen is diamagnetic whereas 
deoxygenated haemoglobin is paramagnetic and therefore has a higher magnetic 
susceptibility (Ogawa et al 1990). In diamagnetic material the magnetic flux is 
reduced whereas in paramagnetic material the magnetic flux is enhanced or in 
other words the magnetic field is ‘attracted’ to it. Hence a change in haemoglobin 
oxygenation will bring about changes in the local distortion of any magnetic field 
that is applied to it.
Ogawa et al (1990) demonstrated this in a cat made hypoxic, gradient echo 
magnetic resonance (MR) images of the animals brain showed signal loss around 
the blood vessels; the effect being reversed when baseline levels of oxygenation 
were restored. The deoxygenated blood produced an increase in the blood vessels 
magnetic susceptibility in relation to the surrounding brain tissue, in turn 
generating local field gradients and locally decreased tissue T2* in tissue water 
surrounding the blood vessels. Ogawa further suggested the potential for this 
phenomenon to be utilised in measuring small changes in the relative blood 
oxygenation levels that occur with neural activity in the brain. When an area of 
the brain is active there is a corresponding increase in local blood flow bringing 
oxygenated blood to the area. The increase in local blood flow far outweighs that 
which is actually required for local tissue metabolism and leads to a decrease in 
magnetic susceptibility and therefore an increase in the fMRI(BOLD) signal.
The increase is relatively small (2-5%) and questions have arisen as to whether 
increase in signal actually reflects neuronal activity. However work by Logothesis 
et al (2001) has demonstrated that local field potentials (LFPs) correlate with the 
BOLD signal during a visual stimulation task providing evidence that fMRI 
(BOLD) contrast does indeed provide a measure of neuronal activity in the brain 
albeit an indirect measurement.
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4.1.1 Temporal resolution of fMRI (BOLD)
When a stimulus is presented to an individual causing a change in brain activity 
there is an initial small dip in BOLD signal intensity that occurs over the first 
second following the stimulus presentation. Following this there is a progressive 
increase in the signal intensity over the next 2-4 seconds that remains at a 
relatively constant level for the duration of stimulation (Bandettini et al 1997). It 
is suggested that the initial dip reflects initial deoxygenation of capillary blood 
due to the high oxygen requirements of local neuronal activity.
This is followed in the next 2-5s by an increase in blood flow which is far in 
excess of requirements for oxygen therefore increasing the oxyhaemoglobin / 
deoxyhaemoglobin ratio and hence the signal intensity (Malonek et al 1997). On 
removal of the stimulus the signal decreases over a few seconds reaching a level 
that is actually below the initial baseline termed the ‘undershoot’, after which it 
then recovers back to baseline over a few seconds. The undershoot is thought to 
be due to a slowly resolving increase in cerebral blood volume post stimulus 
(Mathews 2001).
Overall therefore there is an average 4-6 second time lag in the expected response 
time between the stimulus presentation and the peak of the haemodynamic 
response measured in the brain.
Variations in the time lag exist between individuals (Aguirre et al., 1998) and also 
in cortical areas and different tasks (Rajapaske et al., 1998).
4.1.2 Spatial Resolution of the BOLD response
The ability to distinguish change in an image across different spatial resolutions is 
a particular strength of fMRI; the spatial resolution being given by the voxel size 
used for functional acquisition. As voxel volume is decreased, although there is an 
increase in the functional contrast to noise ratio (CNR) there is also a decrease in 
the signal to noise ratio (SNR) (Macovski, 1996).
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The increase in CNR results from the minimisation of partial volume averaging of 
gray matter (where BOLD signal changes occur), and other tissue e.g. white 
matter and cerebrospinal fluid, where BOLD effects do not occur. Conversely a 
reduction in voxel size will also result in a reduction in the overall signal that can 
be measured from that voxel and hence the likelihood of a reduced signal to noise 
ratio (Howseman et al., 1999). Therefore it is the vascular nature of the BOLD 
response that limits the spatial resolution.
4.1.3 Analysis of fMRI data
Signal changes within fMRI data are relatively small and data gathered is 
inherently noisy therefore to enhance the signal to noise ratio i.e. extract the signal 
for statistical analysis a number of pre-processing steps are undertaken.
All fMRI analysis described in this experiment utilised tools from the FMRIB 
FSL toolbox (Smith et al., 2001).
4.1.3.1 Pre-processing; motion correction.
Subject head movement in the scanner can be reduced by fixing with head 
restraints however inevitably some degree of motion will occur. Movement can 
result in any signal that is obtained not corresponding to exactly the same voxel 
throughout the duration of the experiment. The problem can be overcome by 
aligning all volumes from an experiment with a single volume, which was 
implemented using FMRIBs linear image registration tool (MCFLIRT, Bannister 
and Jenkinson 2001, Woods et al 1999).
FLIRT uses a rigid body transformation that takes the assumption that a single 
voxel in the brain may change position and size but not shape.
4.1.3.2 Spatial Altering (‘blurring’)
Spatial filtering also known as ‘smoothing’ is applied for two reasons. Firstly 
smoothing can enhance the signal to noise ratio by reducing the noise level whilst 
retaining the underlying BOLD signal. To ensure the signal itself is not lost during
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smoothing it is essential that the extent of smoothing is not greater than the size of 
the activated area.
Secondly in order to meet the assumptions that underlie the statistical theory of 
Gaussian Random Field Theory that is later applied to the data, spatial smoothing 
must have occurred.
In the studies reported here a smoothing kemal of 5mm full width half maximum 
(FWHM) of all fMRI data was applied.
4.1.3.3 Temporal filtering
Temporal filtering is applied to fMRI data in order to remove unwanted 
components of a time series whilst retaining the signal of interest. Unwanted 
components may be of high or low frequency and therefore both high-pass and 
low-pass filtering is applied to each voxels time series.
High pass filtering removes slowly varying unwanted signals in each voxel which 
may include physiological confounds e.g. cardio- respiratory or non-physiological 
scanner drift. By removing low frequency signals that are not related to the 
stimulus and therefore signal of interest apparent noise in the data is reduced in 
statistical analysis.
During block designed experiments it is of particular importance to ensure that the 
cut-off period of the filter is not set too low (Smith 2001) otherwise the signal of 
interest may be lost.
The aim of low pass filtering is to reduce high frequency noise, again without 
affecting the signal of interest. The risk of removing the signal of interest in 
experiments that use an event related design where signal of interest may be 
rapidly changing are particularly high.
FSL implements instead ‘Prewhitening’ as it is considered more efficient to not 
carry out low pass filtering and instead ‘pre-whiten’ the data within statistical 
analysis (Woolwich et al., 2001).
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4.1.4 Statistical Analysis
FEAT implements data modelling that is based on general linear modelling 
(GLM), otherwise known as multiple regression. The experimental design is 
described from which a model of explanatory variables is created and then fit to 
the data. A good fit of the data to the model implies that the data were caused by 
the stimulus from which the model arose.
The FEAT tool implements a GLM of analysis that is univariate therefore the 
signal time course from each voxel is separately fitted to the time course of the 
model.
GLM method used on first-level (time-series) data is known as FILM (FMRIB's 
Improved Linear Model). FILM uses a robust and accurate nonparametric 
estimation of time series autocorrelation to prewhiten each voxel's time series; 
giving improved estimation efficiency compared with methods that do not pre­
whiten (Jenkinson 2001).
The GLM may be represented by a simple equation: y = p x + e
Where y is the data, x is the model factor, e  is the error in the data and p is the
parameter estimate or parameter ‘weight’ i.e. is a scaling factor.
In order to test the significance of a model factor for a given voxel, the PE is 
divided by the error in the estimate of this PE value, also known as the residual, 
resulting in a t value.
A low PE relative to estimated error is interpreted as the fit being non significant 
therefore t reports how significantly the data is related to a particular explanatory 
variable i.e. is a good measure of whether we can believe the estimate of the PE 
value.
Standard transformations to convert a t value into a P (probability) or z 
(gaussianised ‘t ’) statistic is then applied producing a statistic map of activation.
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Statistical inference or thresholding is then applied to find which parts of the brain 
were activated at a given level of significance.
In the experiments described in this thesis, statistical inference has been applied to 
images using Gaussian random field theory (GRF) or cluster detection a specific z 
values.
A cluster based approach is considered to be superior to voxel based approaches 
in that it is more physiologically sound as activation patterns within the brain 
extend over a number of voxels and therefore should not be tested as independent. 
Cluster based approaches have also been shown to be more sensitive to change 
than voxel based approaches (Smith 2001).
In order to determine whether one PE or explanatory variable is more relevant to 
the data, or, in other words, better explains the images produced one PE is 
subtracted from the other and then divided by the standard error of the subtraction.
4.1.5 Conversion of raw data
Data recorded from the scanner were processed using MRIConvert v2.0 (Smith 
2007) a freeware software package that has been extensively tested, to convert the 
DICOM images obtained from the scanner to the Nifti format recognised by FSL.
Although laterality should be preserved, issues have arisen within the imaging 
community regarding preservation of laterality during conversion (FSL discussion 
list).
The conversion pipeline used for the data described here was therefore initially 
checked on a data set gathered from a short scanning paradigm involving a 
unilateral motor task known to produce robust contralateral activation patterns. A 
MR visible oil capsule was placed on the right side of the head and the resulting 
converted images checked to ensure reported laterality within FSL matched that 
which was seen of the oil capsule on visual inspection of the images.
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4.1.6 Group analysis
The analysis techniques discussed thus far are initially applied on an individual 
subject basis. Multi subject or group analysis is then undertaken. Low-resolution 
fMRI data from individual subjects is first registered to their own high resolution 
structural scan using 7 degrees -  of - freedom (dof) linear fit then registered to the 
MNI 152 standard brain template using a 12 dof linear fit.
Registration into standard space ensures that first (individual) level statistic maps 
are all in alignment.
There are two common approaches towards group analysis; (i) fixed effect (FE) 
and (ii) mixed effects (ME)
Fixed effects analysis assumes that the experimental effect on the BOLD signal is 
constant or ‘fixed’ across all subjects except for the influence of random noise i.e. 
it ignores cross subject or cross session variance. This makes the FE approach 
sensitive to extreme results from one or two individual e.g. in a group of seven 
subjects, one or two with very strong activation will skew the results as the data is 
averaged. The main disadvantage therefore of FE is that statistical inference is 
restricted to a select study population.
Mixed-effects (ME) analysis utilises both the FE variance (within-session across- 
time variances estimated in the first-level analyses) and random effects (RE) 
variance - an estimate of the inter-session or inter-subject variance
Group analyses performed on experiments reported in this thesis use FLAME 
(FMRIB's Local Analysis of Mixed Effects) (Smith et al., 2004) which 
implements a mixed effects (ME) model in a Bayesian framework. FLAME 
models and estimates the inter-subject random effects component of the mixed- 
effect variance.
93
4.1.7 Experiment one: Paradigm design
FMRI experiments will typically follow either a block design whereby a stimulus 
is presented repeatedly over a prolonged but fixed period of time followed by a 
period of rest. Blocks are then repeated a number of times. Event related designs 
utilise discrete, short duration events or stimuli. The order and timing of which 
may be randomised and the interstimulus interval varied.
The experiment which follows utilised an atypical block design; atypical in that 
time periods of blocks were longer than that frequently reported elsewhere in the 
literature.
There exists a relationship between the intensity of pain induced by hypertonic 
saline and the time frame in which the pain subsequently abates. Although not 
strictly linear, the correlation is positive; that is in order to induce a pain of 
sufficient intensity one must accept the accompanying temporal aspects.
It was not possible to induce muscle pain via hypertonic saline injection that 
lasted for a shorted period of time than that stated whilst ensuring pain of 
sufficient intensity resulted.
The aim of this experiment was to investigate differences between brain activation 
patterns during muscle and cutaneous pain therefore the fMRI paradigm design 
implemented had to be selected based on the restrictions imposed by the 
experimental model of muscle pain.
4.2 Psychophysical data
As previously discussed a number of factors can affect the perception of pain 
either enhancing or reducing it. The scanning environment itself may contribute to 
this as demonstrated by Boyle et al., (2006) where reported VAS scores of pain
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and unpleasantness were reduced by the simple addition of the noise of the 
scanner.
Additionally although confident that the hypertonic saline would reliably induce 
pain based on the psychophysical testing detailed in chapter three there remained 
some variation between injections therefore it was deemed imperative that online 
ratings of pain were gathered.
The choice to undertake both intensity and unpleasantness ratings may be 
questioned, given that the results from chapter three indicate a strong correlation 
between these two measures for both muscle and cutaneous pain. However the 
decision to gather both unpleasantness and intensity data online was again based 
upon the theoretical possibility that the scanning environment may affect the 
perception of either or both of these qualities.
A key finding from the psychophysical data reported in chapter three was that 
cutaneous and muscle pain could clearly be differentiated through the selection of 
sensory descriptors on the Short Form (SF) McGill pain questionnaire; therefore 
to ensure that the scanning environment itself did not corrupt that aspect of the 
pain sensation online SF McGill data was also gathered.
All the psychophysical data were therefore collected simultaneously whilst 
subjects were being scanned in order to (i) ensure subjects were experiencing pain 
and (ii) enable correlation in pain and unpleasantness scores with brain activation 
patterns
The in-house designed VAS device previously described in chapter three was 
therefore utilised throughout each scan. Sensitivity of the pressure pad was 
adjusted for each subject to ensure that a maximum score could be reached with 
minimum motor effort whilst minimum scores could also be reported. The device 
was also utilised to both determine unpleasantness ratings and to score the Short 
Form McGill Pain Questionnaire.
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4.3 Methodology: Experiment one
An atypical extended block fMRI paradigm was utilised. Pain was induced in six 
blocked periods, each lasting approximately six minutes with rest periods within 
and between the blocks. During each block subjects received instructions to either 
focus on the pain, rate intensity or unpleasantness of the pain or rate words from 
the SF McGill Pain Questionnaire.
4.3.1 Subjects
Eighteen healthy volunteers (7 male, 11 female) mean age 36 (range 19 -60) 
participated in the study. All subjects were right-handed (by self-report). Subjects 
had near - normal or corrected-to-normal (with contact lenses) visual acuity. This 
was important to ensure that subjects were able to read instructions displayed to 
them during the scan.
Subjects were recruited via adverts to staff of The Walton Centre for Neurology 
and Neurosurgery and via The University of Liverpool intranet targeting both 
staff and students.
The South Sefton local research ethics committee and The Walton Centre for 
Neurology and Neurosurgery and Aintree Hospital (NHS) Trust Research 
Governance committees approved the study protocol.
Written informed consent was obtained from all subjects prior to enrolment in the 
study after provision of both written and verbal explanations of the protocol.
A semi-structured interview was undertaken in each individual; this consisted of 
past medical history and current symptoms. Subjects were excluded if there was 
(i) history of a cervical and /or upper limb musculoskeletal condition that had at 
any stage required investigations or treatment, (ii) history of skin disease (e.g. 
psoriasis, eczema), (iii) history of injury of upper arm or neck, (iv) ongoing 
current musculoskeletal symptoms (e.g., pain, weakness, stiffness), (v) any
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persistent pain (including chronic daily headaches; however occasional migraine 
attack were allowed), (v) any systemic disease (except mild hypertension well 
controlled with medication), (vi) any chronic allergic conditions (e.g., urticaria; 
however, allergic rhinitis was accepted), (vi) history of a psychiatric or 
neurological condition, (vii) history or suspicion of current ongoing abuse of 
alcohol or drugs, (viii) current use of medications with analgesic properties even 
if used for other purposes, e.g. tricyclic antidepressants or anti-inflammatories), 
(ix) any ongoing non-drug therapy with analgesic properties (e.g., acupuncture for 
smoking cessation, aromatherapy for allergy).
Subjects were also screened for safety reasons by a radiographer to ensure there 
were no contraindications to undergoing MR scanning.
4.3.2 Pain induction and psychophysics evaluation
A total of four disposable plastic catheters (Vygon, 26 g, 25mm) were inserted in 
to the posterior aspect of the non-dominant forearm at two separate sites; extensor 
digitorum muscle belly and 1cm distal to this into intradermal tissue. These were 
inserted utilising an aseptic technique in a treatment room adjacent to the scan 
room.
Here the subjects were also familiarised with the online electronic VAS and the 
SF McGill pain questionnaire and informed that ratings of both intensity and 
unpleasantness would be requested. The difference between intensity and 
unpleasantness was explained by again using the verbal description of Price et al 
(1987) detailed previously in chapter three.
The fixed VAS end points representing ‘no pain’ and ‘worst possible pain’ during 
intensity rating, ‘not at all unpleasant’ and ‘the most unpleasant sensation 
imaginable’ during pain unpleasantness rating and ‘none’ and ‘severe’ during the 
SF McGill.
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Subjects were asked to recount back to the investigator their own interpretation of 
the difference between intensity and unpleasantness to ensure the concept was 
understood. They were asked to utilise the full length of the scale as it reflected 
the sensation they were experiencing.
4.3.3 Scanning procedures
Once in the scan room the subjects were again familiarised with the electronic 
VAS and sensitivity was adjusted to ensure each subject could utilise the full 
extent of the scale with minimal motor effort.
In order to control for attention effects, instructions were displayed throughout the 
whole scanning duration on a screen visible to the subject via a mirror placed 
above the head coil. Instructions were to either ‘focus on your pain’, ‘rate pain 
intensity’, ‘rate pain unpleasantness’, ‘rate pain words’ -  followed by each word 
displayed for 9s, or ‘rest’.
‘Focus on your pain’ was displayed in 4 x 30 seconds blocks from moment of 
injection with 9 second breaks for intensity ratings, followed by an unpleasantness 
rating.
A rest period of 18 seconds both preceded and followed the pain word ratings; 
immediately prior to the second rest period a final intensity rating was also 
obtained to ensure pain levels had reduced to a negligible level prior to 
proceeding to the next injection. Total scan time was approximately 36 minutes. 
Figure 4.1 below outlines the timings of one ‘block’ of the paradigm.
Each subject received a total of six injections of 6% hypertonic saline, via 
extension leads connected to the cannulae, at intervals of six minutes in one 
scanning run.
Injections alternated between muscle and cutaneous sites; subjects were blinded to 
both the order and to which site was being injected. As the injections were given 
via extension tubing, the subjects also had no awareness of when a new injection 
was given or about to be given. Volume of injection required to produce a
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moderate short lasting pain was previously determined in the laboratory setting;
these were 0.35ml for muscle and 0.2ml for cutaneous.
Figure 4.1 Scanning paradigm timings of one block
30s 9s 30s 9s 30s 9s 30s 9s 9s 9s 15 x9s 9s 18s
focus on pain
rate intensity o f pain
rest
rate unpleasantness of pain
rate pain words (Short Form McGill Pain Questionnaire)
rate int
* 9 second fixation between ratings of intensity 
and unpleasantness
4.3.4 MR1 procedure and image acquisition
MR images were acquired using a 3T Trio MR Scanner (Siemens, Erlangen, 
Germany) using a BOLD (blood oxygen level dependent) sensitive T2 * -weighted 
multislice gradient echo-planar imaging (EPI) sequence (echo time, 35 ms; 
repetition time, 3 s; flip angle, 80°; field of view, 224mm; slice thickness, 3.5 
mm). Thirty contiguous axial slices were prescribed covering the whole brain. A 
total of 730 EPI volumes were collected.
Anatomical scans for co-registration of functional data and visualisation purposes 
were also obtained; a high resolution Ti-weighted 3D inversion recovery prepared
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gradient echo sequence was acquired (TE = 5.4ms, TR = 12.3 ms, TI = 450ms, 
1mm slice thickness, FOV = 20 cm, 256 x 192 matrix), with 192 axial slices.
4.3.5 Analysis of Imaging Data
4.3.5.1 Initial procedures
After converting scanner data from Dicom utilising MRIConvert v 2.0 (Smith
2002) the resulting FSL compatible Nifti 4d images were loaded into FSLview 
and observed in movie mode to look for any obvious artefacts or excess motion, 
the latter particularly in view of the length of the scan.
Whilst some head motion was observed in a number of subjects this was not 
excessive except in one subject in whom it was noted in particular excess head 
motion throughout most of the scanning period. Although initial analysis on an 
individual basis on this subject was undertaken the McFLIRT motion correction 
analysis confirmed excessive head motion throughout the scan therefore this 
subject was excluded from further analysis.
4.3.5.2 Brain extraction
Brain extraction was carried out on the subjects’ structural images using FMRIBs 
brain extraction tool (BET2) (Smith 2002); deleting non-brain tissue from the 
image using a surface model approach. The structural images are implemented in 
the later stages of FEAT for registration purposes of functional data and then for 
co-registration with the MNI standard template brain. Successful registration is 
enhanced by improved BET outputs (Smith 2002).
4.3.5.3 Initial modelling of data
Although BET has been shown to be a reliable and valid too for brain 
segmentation (Smith 2002), a visual inspection was carried out by loading the 
BET output images into fslview. Two subjects were deemed to have less than 
ideal outputs with excess skull tissue remaining and were therefore re-processed 
implementing a vertical gradient of the fractional intensity threshold of 0.6 (from
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the default of 0.5) which resulted in structural brain images with minimal skull 
tissue remaining.
Pre-processing steps were applied to each functional dataset: spatial smoothing 
(Gaussian kernel, full width at half-maximum: 5 mm), motion correction and non­
linear high-pass temporal filtering (sigma: 15 s).
A general linear model (GLM) was applied on a voxel by voxel basis to these data 
(Worsley and Friston, 1995) using FILM (FMRIB's improved linear model) 
(Woolrich et al., 2001) to model blood-oxygen-level-dependent (BOLD) signal 
intensity changes in response to painful stimuli. This first level analysis was 
undertaken on an individual basis of all subjects, including all data points, without 
reference to any psychophysical data.
The subject level statistical images were registered into MNI (Montreal 
Neurological Institute) standard space using FLIRT (Jenkinson and Smith, 2001). 
Separate explanatory variables (EVs) for inclusion were modelled for five 
conditions; muscle pain, cutaneous pain, attention to pain and attention to 
unpleasantness; the later two each having two separate EVs, one for muscle and 
one for cutaneous pain. Each regressor was constructed by convolving a boxcar 
function with a gamma haemodynamic response function. Voxel-wise parameter 
estimates (PEs) were derived for each regressor and for each subject a statistical 
image was calculated for each EV. The FSL model is shown in figure 4.2 below.
The same analyses were carried out using negative contrasts which tests for 
decreases in the BOLD signal. To explore further potential differences between 
intensity and unpleasantness, additional regressors were added to the model 
consisting of the de-meaned intensity and unpleasantness scores.
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Figure 4.2 FSL design matrix used to model the individual first level analysis.
ns ns ak ak mp_va»p_wanr_va»r_vasp_vaap_vaar_vaar_vans_unpa_unpk_unpk_unj
Cl muscle 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C2 skin 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
C3 mp_vas 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
C4 mr_vas 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
CS sp_vas 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
C6 sr_vas 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
C7 msjunp 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
C8 sk_unp 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
Cl muscle; C2 cutaneous; C3 muscle intensity during pain; C4 -  muscle intensity 
during no pain; C5 cutaneous intensity during pain; C6 -  cutaneous intensity 
during no pain; C7 muscle unpleasantness; C8 cutaneous unpleasantness;
For second level analysis, muscle and cutaneous events where VAS was < 3 were 
included in the model as EV’s of no interest.
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4.3.5.4 Second analysis
One of the advantages of obtaining online psychophysical data was the ability to 
obtain real time information regarding actual pain scores instead of relying upon 
off line pre-testing or post scan questionnaires.
On scrutinising the pain intensity data it was apparent that not all subjects 
experienced at least ‘moderate’ pain scores during all injections.
As a main objective of this study was to compare cutaneous and muscle pain 
when induced by the same method and of similar intensities only those events 
where intensity and unpleasantness of pain was rated as > 3 during both muscle 
and cutaneous pain were included in the analysis; for this reason two subjects 
were excluded. SF McGill data was also scrutinised to ensure that word selection 
reflected the results obtained during non-scanning conditions for muscle and 
cutaneous pain. One further subject was excluded from the final analysis due to 
excessive head motion throughout the scanning period. A total of 15 subjects 
therefore contributed to the group analysis.
The subject level statistical images were registered into MNI (Montreal 
Neurological Institute) standard space using FLIRT (Jenkinson and Smith, 2001). 
For each subject, one statistical image was calculated each for muscle and for 
cutaneous pain conditions which met the inclusion criteria.
Group analyses were performed using FLAME (FMRIB's Local Analysis of 
Mixed Effects) (Smith et ah, 2004) which implements a mixed effects model in a 
Bayesian framework. FLAME models and estimates the inter-subject random 
effects component of the mixed-effect variance. Group statistical maps were 
thresholded at Z = 2.3 with significant clusters defined according to spatial extent 
at P  < 0.01 (corrected for multiple spatial comparisons according to Gaussian 
random field theory (Worsley et al., 1992).
Group statistical maps were calculated using one regressor constant across 
subjects for each condition to determine a group activation map for each
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condition. Two-sample paired T-Tests were then implemented within FLAME to 
determine muscle -  cutaneous differences; the FSL design matrix for this is 
shown below in figure 4.3.
Figure 4.3 FSL design matrix used to model the group contrasts muscle > 
cutaneous and cutaneous > muscle.
Condition A = muscle; condition B = cutaneous.
EVs si-si 5 model each subject's mean effect and are added as EV of no interest to 
the model to ensure that the individual mean effects do not interfere with the 
estimation of the A-B paired differences (Smith 2001)
4.3.5.5 Region of interest analysis
In order to test further the hypothesis that muscle pain, having a greater affective 
component, would demonstrate activation in more rostral areas of the anterior 
insula a region of interest analysis (ROI) was carried out to determine co­
ordinates of peak activation on an individual basis.
Featquery is a tool within FSL that allows further interrogation of FEAT results in 
a user defined mask or set of co-ordinates to determine mean stats values (Smith 
2001). Two ROIs were drawn onto the MNI template brain; the anterior insula 
(insula anterior to the central sulcus) was subdivided into a caudal and a rostral 
part. The middle and posterior short gyrus was defined as caudal anterior insula 
(cAI) and the anterior short gyrus as rostral anterior insula (rAI) following the
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subdivision previously published by Schweinhardt et al (2006). The anterior limit 
of the short anterior gyrus is the anterior limiting sulcus; the posterior short gyrus 
is limited posteriorly by the central sulcus of the insula. Anterior and middle short 
gyri are separated by the short insular sulcus.
Featquery was then run on each subject’s first level analysis results; only those 
events where pain was >3 were included.
4.4 Results
4.4.1 Psychophysical data
The results presented include only those taken during injections which were 
included in the fMRI analysis as discussed above.
Peak VAS score during muscle pain ranged from 3 - 9.8 (mean 4.4, sd 2.5) and 
from 3 - 9  (mean 4.9, sd 2.1) during cutaneous pain. There was no significant 
difference between the peak VAS scores of the two pain conditions (p>0.05). The 
course of pain onset and offset is shown in fig. 4.1 below.
Unpleasantness scores during muscle pain ranged from 3 - 1 0  (mean 3.9, sd 2.7) 
and from 3 — 9.7 (mean 4.3, sd 2.5) during muscle and cutaneous pain 
respectively. No difference in unpleasantness rating (p>0.05) was found between 
ID and MS across all six injections
Unpleasantness was found to correlate with intensity (Pearsons r = .83, r = .88, 
p < 0.01) for muscle and cutaneous pain respectively.
The words hot burning / stabbing / sharp / shooting were selected more frequently 
and scored higher in the ID condition (p<0.05). During MS condition throbbing / 
gnawing / aching / heavy and cramping were selected more frequently and scored 
higher (p<0.05).
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ID 33 4.9 2.1
MS 33 4.4 2.5
Unpleasantness
ID 33 4.3 2.5
MS 33 3.9 2.7
Figure 4.4 Mean VAS scores of muscle pain (A) and cutaneous pain (B)
A. Time (s) B. Time (s)
4.4.2 fMRI results
4.4.2.1 Similarities
Both cutaneous and muscle pain was associated with an increase in BOLD signal 
in bilateral primary sensory and motor cortices (SI and MI) and anterior and 
posterior insula cortices. Bilateral anterior cingulate signal increase was also 
present with both conditions demonstrating separate peaks of activation in the 
pMCC and aMCC.
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In a number of brain regions bilateral signal increase was observed during muscle 
whilst during cutaneous pain this was only contralateral (secondary sensory cortex 
(SII), the cingulate motor area (CMA), orbito-frontal cortex and the putamen) or 
ipsilateral (DLPFC, VLPFC, PCC).
4 .4 .2 .2  Differences: laterality
4.4.2.3 Differences: muscle versus cutaneous pain
Areas where signal increase occurred only in muscle pain were bilateral thalamus 
and MPFC, and contralateral perigenual ACC, caudate nucleus and cerebellum. 
Peak activations are reported in Table 4.2 and areas of activation figures 4.5 and 
4.6.
The contrast of muscle>cutaneous showed ipsilateral pACC and contralateral 
pACC and caudate nucleus activation. Cerebellum and MPFC did not survive 
thresholding at z > 2.3 however both showed sub threshold differences at z = 2.03 
and z = 1.9 respectively. These results are also shown in table 4.2 and figure 4.7.
No activation survived the cutaneous > muscle contrast.
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Table 4.2 Areas of activation during muscle pain, cutaneous pain and the 
muscle -  cutaneous contrast.























ACC -  aMCC I -0, 26, 28 3.5 I -6 ,1 8 , 36 2.88 I -2, 28, 28 2.3
C 2 ,2 4 ,2 4 3.4 C 4, 18, 26 2.69 C 2 ,4 0 , 16 2.42
ACC -  pMCC I -12, 8, 40 3.2 I -4, 4, 44 2.41 I
C 12, 6 34 2.83 C 2 ,4 ,4 4 3.05 C
ACC- CMA I -2, 4, 36 3.5 I I -2, 8 ,4 0 2.3
c 2 ,4 ,  38 3.3 c 4 ,-1 0 , 40 2.64 c
ACC perigenual I I I -8, 40, 6
c 6, 34, -2 2.7 c c
PCC I -2, -19, 36 2.7 I -2 ,-1 6 , 42 2.35 I
c 2 ,-1 8 ,3 8 2.69 c 4 ,-1 6 ,4 4 2.71 c
Anterior insula I -36, 18, -4 3.56 I -44, 4, -8 3.32 I -28, 18 ,6 3.2
c 36, 20, -6 3.56 c 32, 14, 0 2.41 c
Posterior insula I -34, -8, 4 3.5 I -40, -6, -4 3.56 I
c 36,-10,2 4.94 c 40, -4, 12 4.4 c
Thalamus I -8 ,-1 6 , 6 I I
c 8, -8 ,6 2.42 c c 8, -22, 12 2.4
MI I -4,-28,58 3.22 I -2, -26, 54 2.69 I
c 10,-26,64 4.54 c 10, -26, 64 4.64 c
SI I -8,-42,54 2.67 I -54, -20, 4.25 I
c 10, -36, 60 3.26 c 5 4 ,-1 0 ,3 2 4.02 c
SII I -54, -4, 12 3.8 I I -56, -4, 10 3.3
c 50, -20, 16 3.2 c 5 4 ,-1 0 , 10 4.02 c
Cerebellum I I I
c 24, -76, -26 3.25 c c 22,-76, -24 *2.03
Putamen I -28, 8, 0 2.77 I I -24, 12, 6 2.5
c 26, 8, 0 3.92 c 26, 14, 4 4.64 c
Caudate nucleus I I I
c 16, 16 ,2 3.25 c c 14, 20, 0 3.5
DLPFC I -36, 36, 18 3.78 I -36, 32, 22 3.49 I -32, 3 8 ,4 0 3.6
c 3 4 ,3 6 , 16 3.96 c c 36, 38, 18 2.35
VLPFC I -4 0 ,4 2 , -4 3.36 I -4 6 ,4 0 ,4 3.48 I -3 6 ,4 2 , 16 2.36
c 4 0 ,4 2 , -4 3.6 c c 42, 40, 2 3.8
MPFC I -10, 38, -8 2.55 I I -12, 46, -2 1.9*
c 10, 36, -6 2.95 c c
Orbitofrontal I -38, 38, -8 3.28 I I
c 36, 34, -6 3.4 c 34, 26, -4 c
MPFC and cerebellum activation in contrast muscle > cutaneous just below 


































































































4.4.2.4 Attention to intensity
During attention to / rating of intensity increases in BOLD signal were seen 
bilaterally in ACC and SMA and ipsilateral in MI and SI in both conditions. 
Bilateral putamen activation was also observed during attention to intensity of 
muscle but not cutaneous pain. This putamen activation however did not survive a 
muscle - cutaneous contrast. Bilateral ACC and SMA and ipsilateral MI and SI 
activation showed a positive linear variation with intensity ratings; no differences 
were seen between the two conditions in terms of intensity co-variance. 
Co-ordinates of peak activations are reported in Table 4.3; those areas where 
activation co-varied with intensity score are shown in table 4.5. *
Table 4.3 Activation during attention to intensity rating








aMCC I -4, 18, 34 3.25 I -2, 28, 30 2.72
C 6, 16, 34 3.13 C 8,2,38 3.1
Anterior insula I -32, 22, -4 3.71 I
C 30, 20, 6 3.88 C
MI I -30,-18, 58 4.85 lr~ -30,-18,58 4.12
C 30, -6, 50 2.87 c
SMA I -6, -2, 58 3.98 I -4, -2, 56 3.48
C 6, -2, 54 3.31 c 4, 4, 52 2.83
SI I -44, -30, 48 4.28 I -46, -28, 48
c c
Putamen I -22, 6, -2 3.15 I
c 24, 6, 2 3.51 c
* No activation survived the muscle > cutaneous or cutaneous > muscle 
contrast
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4.4.2.5 Attention to unpleasantness
During attention to unpleasantness an increased number of brain regions were 
activated including bilateral putamen, pallidum and prefrontal cortex. Those areas 
showing a positive linear relationship with unpleasantness ratings included 
bilateral ACC and MI, ipsilateral anterior insula, OFC and cerebellum and 
contralateral DLPFC during both conditions. Additional areas showing a positive 
linear relationship during muscle pain only included ipsilateral caudate nucleus 
and putamen and bilateral VLPFC.
A decrease in BOLD signal that co-varied linearly with unpleasantness scores 
during attention to unpleasantness in the muscle but not cutaneous condition was 
also seen in bilateral amygdala and contralateral cerebellum and posterior insula. 
Co-ordinates of peak activations are reported in Table 4.4; those areas where 
activation co-varied with unpleasantness score are shown in table 4.6. See also 
figures 4.8, 4.9, 4.10)
Figure 4.8 Decrease in activation in the amygdala bilaterally during attention to 
unpleasantness during muscle pain which correlated with unpleasantness score
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Table 4.4 Activation during attention to unpleasantness rating








ACC - aMCC I -4, 24, 32 3.13 I -6, 20, 34 2.56
C 2, 18, 36 3.9 C 2, 18, 36 3.57
ACC-pMCC I -4, 4, 40 3.33 I -2, 0, 44 3.32
C 2, 6, 44 3.6 C 2, 6, 42 3.51
PCC I I
C 2, -38, 30 2.56 C
Anterior insula I -32, 22, -6 3.67 I -32, 22, -2 3.56
C 34, 22, -6 3.7 C 32, 22, -6 3.69
Thalamus I -10,-18,8 3.38 I -18, -2, 8 3.89
C 10,-14,2 3.01 C 12, 0, 10 3.47
MI I -42, -4, 42 5.02 I -40, -2,42 4.63
C 42, 0, 46 3.9 c 38, -8, 54 3.94
SI I -44, -30, 50 3.84
C
SII I -54, -22, 26 2.96
C
Cerebellum I -30, -60, -26 2.82 I -36, -64, -30 2.56
c 34, -60, -36 3.05 c
Putamen I -16, 8, -2 3.91 I -26,4, 12 3.13
c 18, 10, -2 3.86 c 16, 10,2 3.68
Pallidum I -18,4,0 3.58 I -12, 4,2 3.21
c 16, 6,0 3.42 c 22, -4, 0 2.78
DLPFC I I
c 34, 42, 18 3.39 c 44,32,12 3.35
VLPFC I -40, 42, 4 3.23 I
c
Orbitofrontal I -48, 22, -2 2.88
c






















































































































Table 4.5 Areas of brain activation during attention to intensity showing linear
correlation with intensity vas








aMCC I -4, 20, 34 2.93 I -6, 24, 34 3.14
C C
pMCC I -2, 8, 38 3.5 I -2, 6, 40 2.8
C 4, 10, 38 3.51 c 2, 12, 40 3.1
SI I -34, -28, 54 4.22 I -46, -36, 50 4.2
MI I -38, -18, 56 3.74 I -32, -26, 50 4.29
SMA I -2, 0, 46 2.97 I -2, -4, 52 2.82
C 4, 2, 46 3.54 c 2, -10, 56 3.01
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Table 4.6 Areas of brain activation during attention to unpleasantness showing
linear correlation with unpleasantness vas








aMCC I -4, 24, 34 3.2 I -2, 18, 36 2.8
C 8, 26, 24 2.41 C 2, 16, 36 3.36
pMCC I -2, 8, 42 3.6
C 8, 10,38 3.1
PCC I -6, -38, 36 2.47
c 6, -38, 34 3.2
Anterior insula I -30, 24, -8 3.25 I -38, 16, -4
MI I -38, 0, 42 4.33 I -40,-10, 54 3.74
c 44, -2, 42 3.41 c 38,-12, 54 3.71
SI I -36, -26, 54 2.53 I -34, -28, 62 3.2
Cerebellum I -30, -60, -26 2.82 I -38, -64, -30 2.98
Caudate nucleus I -12, 10,2 3.02 I
Putamen I -20, 10, -2 2.61 I
DLPFC I -50, 18, 20 3.16 I
c 52, 24, 20 3.41 c 44, 34, 10 3.48
VLPFC I -52, 22, 6 3.36 I
c 50, 30, 8 3.18 c
Orbitofrontal I -50, 26, -6 2.67 I -44, 22, -8 2.52
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4.4.3 Region of interest analysis
Activation was observed in the anterior insula during both muscle and cutaneous 
pain conditions Results from group analysis show that the co-ordinate of peak 
activation in the anterior insula during muscle pain was more rostral than it was 
during cutaneous pain (muscle; -36, 18, -4; 36, 20, -6., cutaneous: -44, 4, -8; 32, 
14,0). See Figure 4.11.
A paired t-test was carried out on the ‘y’ co-ordinates, comparing muscle and 
cutaneous pain and was found to be not significant (p>0.05).
Figure 4.11 Anterior insula activation during cutaneous and muscle pain
A: Anterior insula activation -  group activation appears more rostral (rAI) during 
muscle than during cutaneous pain. (A)
B : Anatomical details o f  delineation o f  the rostral anterior insula (rAI, green) and caudal anterior insula (cAI, 
blue). rAI was defined to consist o f  the anterior short gyrus o f  the insula and cAI o f  the middle and posterior 
short gyrus. The short anterior gyrus is limited anteriorly by the anterior limiting sulcus; the posterior short 
gyrus is delimited posteriorly by the central sulcus o f  the insula. Anterior and middle short gyri are separated 
by the short insular sulcus, ant lim sul, anterior limiting sulcus; CS, central sulcus (o f  the insula); short ins 
sul, short insular sulcus. [Reproduced from Schweinhardt et al., 2006. Copyright (2006), with permission 
from Elsevier, see Appendix C]
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4.5 Summary of fMRI results
4.5.1 Similarities
Both cutaneous and muscle pain were associated with an increase in BOLD signal 
in bilateral primary sensory and motor cortices (SI and MI) and anterior and 
posterior insula cortices. Bilateral anterior cingulate signal increase was also 
present with both conditions demonstrating separate peaks of activation in the 
pMCC and aMCC.
Activation in these areas of the brain has previously reported in a number of 
experimental pain studies (Derbyshire et al., 1997; Davis et al., 1998, Apkarian et 
al., 1999, Becerra et al., 1999, Gelnar et al., 1999).
This finding therefore provides support for the validity of the HS model as a 
method of pain induction within a scanning environment and also the paradigm 
employed.
4.5.2 Differences
In a number of brain regions bilateral signal increase was observed during muscle 
pain whilst during cutaneous pain this was only contralateral (secondary sensory 
cortex (SII), the cingulate motor area (CMA), orbito-ffontal cortex and the 
putamen) or ipsilateral (DLPFC, VLPFC, PCC).
Previous reports in the literature suggest that an increasing number of brain areas 
in addition to increased bilateral activation occur as pain intensity increases 
(Peyron et al., 2000; Apkarian et al., 2005).
Similar levels of pain intensity were induced in both the muscle and cutaneous 
conditions in this study therefore greater intensity would not appear to explain the 
increase in bilateral activation in muscle compared to cutaneous pain observed 
here.
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Areas where signal increase occurred only in muscle pain were bilateral thalamus 
and MPFC, and contralateral perigenual ACC, caudate nucleus and cerebellum. 
These brain regions have all been reported in previous brain imaging studies; the 
frequency of report however is rather less than it is for ‘pain matrix’ areas.
In the case of MPFC and perigenual cingulate, activation has been more 
frequently reported in clinical pain studies or experimental studies pain studies 
involving manipulation of attentional aspects; increased activity being associated 
with arousal related to emotional / motivational processing (Critchley et al., 
2004).
4.5.3 Attention to intensity
During attention to / rating of intensity, increases in BOLD signal were seen 
bilaterally in ACC and SMA and ipsilateral in MI and SI in both conditions. 
Bilateral putamen activation was also observed during attention to intensity of 
muscle but not cutaneous pain.
Bilateral ACC and SMA and ipsilateral MI and SI activation showed a positive 
linear variation with intensity ratings; no differences were seen between the two 
conditions in terms of intensity co-variance.
Again these regions have all been implicated in pain intensity coding in previous 
studies (Peyron et al., 2000, Apkarian et al., 2005); providing further validation of 
the model chosen.
4.5.4 Attention to unpleasantness
During attention to unpleasantness an increased number of brain regions were 
activated including bilateral putamen, pallidum and prefrontal cortex. Those areas 
showing a positive linear relationship with unpleasantness ratings included 
bilateral ACC and MI, ipsilateral anterior insula, OFC and cerebellum and 
contralateral DLPFC during both conditions.
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A decrease in BOLD signal that co-varied linearly with unpleasantness scores 
during attention to unpleasantness in the muscle but not cutaneous condition was 
also seen in bilateral amygdala and contralateral cerebellum and posterior insula.
4.5.5 Region of interest analysis
The anterior insula was a specific a priori area of interest in this study; it was 
hypothesised that HS induced muscle pain, having a greater affective component 
(Rainville et al., 1992) and showing behavioural characteristics of clinical 
musculoskeletal pain syndromes (Curatolo et al., 2000) would more closely 
resemble brain activation patterns observed in clinical pain condition.
However, despite the group activation maps indicating that the anterior insula 
activation was more rostral during muscle compared to cutaneous pain; 
subsequent ROI analysis revealed no significant difference between the two 
conditions in terms of co-ordinates of peak activation.
ROI analysis on an individual subject basis revealed distinct areas of activation 
during both conditions, in both rostral and caudal Al bilaterally. A possible 
explanation for this finding may be the tonic nature of stimulation employed in 
this study in comparison to the brief phasic pain typically employed in other 
experimental studies included in the review by Schweinhardt et al (2006).
Rostral anterior insula activation observed here, during both conditions may well 
be related to the inescapable / aversive nature of prolonged pain (Lumb et al., 
2001) .
It should also be noted that the ROIs drawn in this study are somewhat more 
conservative than those employed by Schweinhardt and colleagues (2006). 
Although based on the anatomical landmarks reported by those investigators; 
ROI’s in this study were also guided by reference to MNI probalistic maps. It has 
been argued that this method is more accurate. On reproduction and visualisation
Additional areas showing a positive linear relationship during muscle pain only
included ipsilateral caudate nucleus and putamen and bilateral VLPFC.
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of Schweinhardt’s (2006) previously published maps on the standard MNI brain 
in FSL view, the rostral map was observed to encroach onto the orbitofrontal 
cortex where activation was also seen. ROI analysis, as implemented by 
Featquery, searches for the peak of activation therefore the accuracy of the results 
are dependant on the accuracy of the map selected.
Therefore to avoid the confound of activation in the orbitofrontal cortex during 
ROI analysis where the primary question was regarding rostral anterior insula 
activation the more conservative route was employed
4.6 Key fMRI findings
Activation of areas of the ‘pain matrix’ was observed during both conditions 
providing support for the validity of the model employed.
FMRI results suggest patterns of brain activity associated with muscle and 
cutaneous pain induced by the same method, whilst sharing commonalities do also 
demonstrate differences which may warrant further investigation.
Changes in signal observed during muscle pain is consistent with the hypothesis 
that muscle pain engages more affective and emotional processing when 
compared to cutaneous pain.
Furthermore differences observed also provide support for the proposal that the 
experimental muscle pain model more closely reflects clinical pain than does the 
experimental cutaneous pain model.
Further interpretation, particularly in relation to the literature, and the implications 
of these results are discussed in chapter six.
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Chapter 5
Neural correlates of superficial and deep tissue pain
Chapter five presents the results of two small fMRI experiments carried out with 
three patients with a diagnosis of unilateral epicondylitis (tennis elbow).
The first experiment implements the same methodology used in the previous 
chapter.
As small numbers do not allow for sensible statistical analysis the results are 
presented predominantly as a narrative with images for illustration purposes.
Despite the limited numbers, some interesting observations are made.
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5.1 Background
The studies described thus far in this thesis have focussed on experimentally 
induced pain, addressing differences in the psychophysical properties and neural 
correlates between cutaneous and muscle pain. The relative strengths of 
experimental pain in terms of controllability, repeatability and reliability however 
also contribute to the weakness of experimental pain in relation to clinical pain.
As reported in Chapter 2, clinical pain conditions are inherently variable in nature 
due to both intrinsic and extrinsic factors. However increasingly investigators 
have realised that brain activation patterns observed during acute, physiological 
pain processing may not reflect that which happens in chronic pain conditions. Of 
late therefore researchers’ have turned their attention to these patient populations 
although the overriding problem is the difficulty in assembling a homogenous 
patient cohort, particularly in respect to matching symptom profile, duration of 
disease, medication history and age distribution (May 2007).
This chapter describes two experiments carried out on three patients with a 
diagnosis of unilateral lateral epicondylitis (tennis elbow). This clinical condition 
was specifically chosen for a number of reasons including (i) it is a well defined 
clinical condition with known local tissue pathology involving deep tissue, (ii) it 
is typically unilateral, thereby allowing for the patient to serve as their own 
control (iii) it is frequently a self limiting condition that spontaneous resolves, or 
resolves with simple therapeutic interventions (Calfee et al., 2008).
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5.2 Methods: Experiment one
5.2.1 Subjects
Three subjects (male, average age 40 (32- 47) took part in experiment one, which 
replicated the experiment described in chapter four in 18 healthy volunteers. 
Injections of hypertonic saline were administered as per the protocol outlined in 
Chapter four; the arm not affected by lateral epicondylitis was in this case 
injected.
In subjects A and B this was the left arm; in subject C this was the right arm.
5.2.2 Clinical examination
A semi-structured interview was undertaken in each individual; this consisted of 
past medical history and history of current symptoms; including any ongoing 
therapies.
Subjects were excluded if there was (i) history of a cervical and /or upper limb 
musculoskeletal condition that had at any stage required investigations or 
treatment other than their present condition, (ii) history of skin disease (e.g. 
psoriasis, eczema), (iii) history of injury of upper arm or neck, (iv) ongoing 
current musculoskeletal symptoms (e.g., pain, weakness, stiffness), (v) any 
persistent pain (including chronic daily headaches; however occasional migraine 
attack were allowed), (v) any systemic disease (except mild hypertension well 
controlled with medication), (vi) any chronic allergic conditions (e.g., urticaria; 
however, allergic rhinitis was accepted), (vi) history of a psychiatric or 
neurological condition, (vii) history or suspicion of current ongoing abuse of 
alcohol or drugs, (viii) (ix) any ongoing non-drug therapy with analgesic 
properties (e.g., acupuncture for smoking cessation, aromatherapy for allergy). 
Subjects were also screened for safety reasons by a radiographer to ensure there 
were no contraindications to undergoing MR scanning.
This was followed by a physical examination to confirm diagnosis of lateral 
epicondylitis. Diagnosis was confirmed by the history and examination findings
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A neurological cervical spine examination was also carried out to rule out co­
existing pathology.
Although a decision was made not to exclude patients who were currently using 
medications with analgesic properties, including non steroidal anti­
inflammatories, subjects were asked to refrain from taking these on the day of 
scanning. However none of the patients recruited reported the use of any analgesic 
medication on a regular basis.
o f (i) local pain (ii) increased pain on palpation over the lateral epicondyle /
musculotendinous junction o f the common extensor muscle group, (iii) increased
pain on resisted extension o f the radiocarpal joint.
Table 5.1 Patient demographics
Patient A Patient B Patient C
Age / Sex 32 /M 41 /M 47 /M
Affected arm Left Right Right
Duration of symptoms (months) 7 4 6
5.2.3 Statistical Analysis
Whilst single subject data can yield interesting findings, extrapolation of findings 
to the wider population is limited. SPM software package (Wellcome Department 
of Cognitive Neurology, London, UK) allows for conjunction analysis (Price and 
Fnston, 1999). A Conjunction model is less stringent than a Random Effects 
model and essentially seeks consistent activations (not necessarily to the same 
magnitude as random effects) in small samples.
Data collected in this experiment were therefore analysed using the SPM software 
package, implementing the same design and parameters employed in the previous 
study; the intention being to undertake a conjunction analysis of the three 
subjects.
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UNIX workstations processed and analysed the data using SPM (Wellcome 
Department of Cognitive Neurology, London, UK) implemented in Matlab 
environment (Mathsworks, Sherbom, MA) (Friston et al, 1995). The scans from 
each subject were realigned using the first image as a reference. Following 
realignment, all images were transformed into a standard stereotaxic space (MNI).
The data were then smoothed using a 6 mm isotropic FWHM gaussian kernel. 
Statistical comparisons between the conditions were performed on a voxel-by- 
voxel basis using t statistics, generating SPM(t) maps subsequently transformed to 
the unit distribution SPM(Z) maps. Each regressor used in the GLM was obtained 
by convolution of an ideal box-car response with a canonical haemodynamic 
response function (Friston et al., 1995). Statistical significance was estimated 
voxel-by-voxel with probability criterion of P<0.05 corrected for multiple 
comparisons. Within each region of statistical significance, local maxima of signal 
increase were determined (the voxel of maximum significance). The anatomical 
localisation of the local maxima was determined in MNI space.
5.3 Psychophysics Results
Pain intensity -  peak visual analogue scale (VAS) score
Mean peak VAS scores for patients A, B & C respectively were ID: 7.1 (.7), 5.2 
(1.3) and 3.9 (.48) and for MS: 6.9 (.89), 6.7 (1.1) and 3.1 (.10)
Mean peak unpleasantness scores for patients A, B & C respectively were ID: 6.2 
(.73), 5.1 (1.5) and 3.4(.34) and MS; 5.8 (.63), 6.7 (1.1) and 3.0 (.05).
Table 5.2 Summary of psychophysics data
Patient A Patient B Patient C
Mean Std. Error Mean Std. Error Mean
Peak intensity
ID 7.1 .70 5.2 1.3 3.9 .48
MS 6.9 .89 6.7 1.1 3.1 .10
Unpleasantness
ID 6.2 .73 5.1 1.5 3.4 .34
MS 5.8 .63 6.7 1.1 3.0 .05
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5.4 FMRI results
Although the analysis intention was to undertake a conjunction analysis on the 
three subjects; as can be seen from the psychophysical data, Subject C reported 
very low pain VAS scores therefore the individual analysis reports are reported 
here.
5.4.1 Subject A (see table 5.4)
Similarities
Ipsilateral activation was observed during both muscle and cutaneous conditions 
in contralateral thalamus and cerebellum.




Activation observed during muscle but not cutaneous pain included contralateral 
anterior and posterior insular cortices and ventrolateral prefrontal cortex; 
ipsilateral SII; bilateral activation was also observed in the putamen.
Cutaneous
Activation observed during cutaneous but not muscle pain included bilateral 
pMCC and MPFC.
5.4.2 Patient B (see table 5.5)
Similarities
Bilateral activation was observed during both conditions in anterior insular cortex, 
cerebellum and MPFC. Contralateral thalamus and SII activation was also 
observed in both.
Hippocampus activation was observed in both conditions; this was ipsilateral 




Bilateral posterior insula activation was seen during muscle but not cutaneous 
pain; as was ipsilateral MI, SI, putamen and caudate nucleus and contralateral 
amygdala and PCC activation.
Cutaneous
No differences observed
5.4.3 Patient C (see table 5.6)
Similarities
Ipsilateral SII, hippocampus, posterior insula and bilateral cerebellum activation 
was present during both pain conditions.
Differences
Muscle
Bilateral perigenual ACC and ipsilateral SI activation was seen during muscle but 
not cutaneous pain;
Posterior insula and hippocampus activation was also bilateral compared to 
ipsilateral in cutaneous
Cutaneous
Ipsilateral thalamus, MI and VLPFC activation was observed in cutaneous but not 
muscle pain condition.
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Table 5.4 Areas of activation during muscle and cutaneous pain conditions
Patient A








ACC-pMCC I I 5, -6, 44 5.55
C C -4, -12, 40 4.38
Anterior insula C -39, 22, 0 6.42 C
Posterior insula C -43, -8, 8 5.89 C
Thalamus C -4,-10,4 5.23 C -10,-16, 16 6.48
I I
SII I 54, -38, 32 5.32 I
C C
Cerebellum I 13, -43,-18 5.04 I
C -24, -43, -24 6.62 C -13, -43, -22 6.72
putamen I 30, 4, 0 4.92 n r
C -31,4,2 5.12 c
Hippocampus I 27, -10. -20 6.02 I 27,-15,-16 5.44
C -26, -36, -10 5.38 c
Amygdala I 26, -6, -20 5.74 I 27, 0, -23 4.19
C -26, 2, -17 5.43 c -26, -12, -14 5.27
VLPFC C -40, 42, -4 6.59 c
MPFC I 2, 50, 0 4.44
c -3,42,-13 4.91
Figure 5.0 Example of hippocampus activation observed during both muscle and 
cutaneous pain in patient A.
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Table 5.6 Areas of activation during muscle and cutaneous pain conditions
Patient B




Z score Side MNI
co-ordinates x,y,z
Z score
ACC -  pMCC I -4, 10, 43 4.67 I
C 5, 23, 24 5.43 C
PCC I 3, -32, 50 6.01 I
C C
Anterior insula I -33, 16, -1 4.89 I -38, 1 ,-4 5.35
C 44, 9, -5 5.11 C 44, 13, -3 5.84
Posterior insula I -47, -7, 3 5.26 I
C 42, -8, -2 4.98 C
Thalamus I I -3 ,-1 3 , 4 4.72
C 4, -8, 6 5.33 C 5 ,-1 5 , 4 4.34
MI I -5, -12, 68 6.27 I
SI I -45, -26, 59 5.42 I
SII I -45, -35, 24 5.43 I 5 8 ,-2 1 ,3 1 6.23
r c ~ 54, -35, 24 4.88 c
Pallidum c hc ~
Cerebellum i -20, -53 ,-17 6.04 I -27, -73,-23 5.21
c 26, -54, -47 6.14 c 2 1 ,-8 6 ,-2 3 4.34
Putamen I -25, 10, -2 4.32 I
Caudate nucleus I -20, 16, 14 5.37 I
Hippocampus I -29, -22, -27 5.41 I 5.51
c c 24, -26, -8
Amygdala I I
c 29, 0, -30 4.33 c
MPFC I 4, 4 3 ,-1 0 4.08 I -1 ,4 2 ,-1 2 5.47
c -6, 52, -13 5.11 c 5, 42, -12 4.88
Figure 5.0.1 Example of hippocampus activation observed during both 
muscle and cutaneous pain in patient C.
Note activation is ipsilateral in muscle condition and contralateral in cutaneous 
condition
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Table 5.7 Areas of activation during muscle and cutaneous pain conditions
Patient C














I 5, 39, -3 5.44 I
C -3, 40, -3 5.67 C
Anterior insula I -39, 7, 11 6.55 I
C C
Posterior insula I -41,-14,8 5.98 I -44, 0, 0 6.22
c 38,-11,8 6.35 C
Thalamus I I -5,-19, 8 5.27
MI I I -6,-15, 77 5.76
SI T~ -19,-41,73 6.28 I
SII i -49, -29, 29 5.44 I -49, -29, 29 6.5
Cerebellum i 28, -78, -37 5.70 I 29, -72, -35 6.78c -48, -54, -37 5.31 c -47, -52, -34 6.48
Hippocampus I 34,-18,-15 6.41 I -26, -17, -13 6.56c -25,-21,-12 7.44 c
VLPFC I I -44, 34, 0 5.49
Figure 5.0.2 Example of hippocampus activation observed during both 
muscle and cutaneous pain in patient C.
Note activation is bilateral in muscle condition and ipsilateral in cutaneous 
condition
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5.5 Summary of findings after hypertonic saline injection.
Taken together the three patients appear to show many similarities to those 
observed in the healthy volunteer group. Additional activation however was also 
observed in the individual analysis of the patients which was not seen in the 
healthy volunteer group analysis.
In summary, during the first experiment (injection of HS), areas of the pain matrix 
were activated including ACC, MI, SI, SII, anterior and posterior insular cortices 
and cerebellum, suggesting similarity to the healthy volunteer population.
The findings of preponderance towards bilateral activation of so called ‘pain 
matrix areas during muscle pain as opposed to an ipsilateral or contralateral 
tendency in cutaneous pain in the healthy volunteers also appears to be mirrored 
in the patient sample. Basal ganglia activation was also observed in two of three 
patients during muscle but not cutaneous pain. Again this appears to reflect the 
findings of the healthy volunteer group, however as the small numbers do not 
allow for a direct comparison caution must be taken in drawing comparisons.
The co-ordinates of peak activation in SII also appear to be more posterior in the 
three patients which may suggest a somatotopic shift within the parietal 
operculum in these particular patients.
The observation of activation in the hippocampus and amygdala in all three 
patients during both muscle and cutaneous pain (which was not apparent in either 
condition with the healthy volunteer group) may suggest greater engagement of 
the hippocampal / amygdala complex in patients, irrespective of whether the pain 
originates in cutaneous or muscle tissue.
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5.6 Methods: Experiment Two
5.6.1 Subjects
Two of the patient subjects from study one also took part in study two (Patients A 
and C); this was undertaken on a separate occasion from the first scan.
5.6.2 Experimental procedures
A simple pressure algometer was constructed as described by Johnson and 
Watson (1997), who have shown reliability of this method for repeated pain 
pressure thresholds. The device consists of a closed low friction syringe with a 
rubber-tipped probe at the end, the area of which was ~ 1cm2; allowing consistent 
application of predetermined pressure thresholds.
The scale on the syringe may be tested with a pressure algometer to determine 
actual pressures involved.
Three pressure thresholds were determined; PI = mild pain, P3 = touch, no pain, 
P3 = moderate pain
Testing was carried out pre scan to determine the pressures required to produce 
mild pain (PI, VAS = 3 - 4 )  and touch (P2, VAS = 0) on both the affected and 
unaffected arms
Pressure required PI for the unaffected arm was then tested on the affected arm; if 
resulting pain was (i) greater than 7 on a VAS and (ii) acceptable to patient then 
this was deemed P3 for the affected side. P3 on the unaffected arm was then 
determined by determining pressure required to produce the same VAS as P3 on 
the affected arm.
Pressure thresholds were retested immediately post scan to ensure background 
clinical pain had not been exacerbated by the procedures.
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5.6.3 fMRI design
Stimuli were delivered manually in blocks of 12 seconds at one of the pre­
determined pressures as above in response to a visual cue to the investigator. 
Subjects were informed that they would be receiving pressure stimuli of a variety 
of magnitudes throughout the scanning period which may or may not be painful; 
they were not informed how many variations there were in pressure and were 
blinded to the order of pressure. Subjects also wore a black-out eye shield to 
ensure they received no visual cues from the colour cues that were displayed to 
the investigator to indicate level of pressure application.
5.6.4 Data acquisition
MR images were acquired using a 3T Trio MR Scanner (Siemens, Erlangen, 
Germany) using a BOLD (blood oxygen level dependent) sensitive T2 * -weighted 
multislice gradient echo-planar imaging (EPI) sequence (echo time, 35 ms; 
repetition time, 3 s; flip angle, 80°; field of view, 224mm; slice thickness, 3.5 
mm). Thirty contiguous axial slices were prescribed covering the whole brain. A 
total of 240 EPI volumes were collected.
5.6.5 Analysis of Imaging Data
After converting scanner data from Dicom utilising MRIConvert v 2.0 (Smith 
2006) the resulting FSL compatible Nifti 4d images were loaded into FSLview 
and observed in movie mode to look for any obvious artefacts or excess motion. 
Pre-processing steps were applied to each functional dataset: spatial smoothing 
(Gaussian kernel, full width at half-maximum: 5 mm), motion correction and non­
linear high-pass temporal filtering (sigma: 15 s).
A general linear model (GLM) was applied on a voxel by voxel basis to these data 
(Worsley and Friston, 1995) using FILM (FMRIB's improved linear model) 
(Woolrich et al., 2001) to model blood-oxygen-level-dependent (BOLD) signal
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intensity changes in response to painful stimuli. The subject level statistical 
images were registered into MNI (Montreal Neurological Institute) standard space 
using FLIRT (Jenkinson and Smith, 2001).
A single regressor for each level of pressure was modelled; each regressor 
constructed by convolving a boxcar function with a gamma haemodynamic 
response function. Voxel-wise parameter estimates (PEs) were derived for each 
regressor and for each subject a statistical image was calculated for each EV. 
Appropriate contrasts were modelled to enable comparisons in activation between 
the different pressure thresholds.
5.7 Psychophysics results
Application of PI (mild pain) determined in the unaffected arm, to the affected 
arm in both subjects resulted in a moderate to high pain (>7) on a VAS score. This 
was therefore implemented as P3 in the affected arm. Pressure required to produce 
a moderate to high VAS on the unaffected arm was considerably higher.
5.8 fMRI results
5.8.1 Pressure pain
Both patients were interviewed immediately after the end of scanning to assess 
whether a summation effect occurred during the pressure pain paradigm in either 
the affected or unaffected side; both denied any significant increase in background 
pain.
Both subjects demonstrated activation distributed throughout various regions of 
the brain during pressure pain on both affected and unaffected areas. Areas of 
increased signal included bilateral ACC, posterior and anterior insular cortices, 
MI, SI, thalamus, putamen and cerebellum.
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5.8.2 Matched pressure
A contrast was carried out between PI on the unaffected arm and P3 on the 
affected arm i.e. amount of pressure delivered was similar but pain scores were 
greater on the affected side. No activation survived the PI > P3 contrast (Z> 2.3, 
cluster size minimum 10).
Widespread activation was apparent in the P3 > PI contrast; some co-ordinates 
are presented in table 5.8 to indicate areas of activity.
Figures 5.1 and 5.2 demonstrate the widely distributed activation patterns and are 
included for illustrative purposes.
Table 5.8
Areas of brain activation during pressure matching affected (P3) > unaffected (PI)







ACC I I 6, 34, 10
C 2, 22, 28 C
Anterior insula I -22,32, 4 I 34, 24, 0
Thalamus I -12,-14,6 I
C C -18, -26,2
MI I -20, -26, 60 I
c c
Putamen I -20, 6, -2 I 16, 14, -6
c 28,-2,-2 c
caudate I -16, 16,2 I
Precuneus I I
c c -4, -68. 44
Amygdala c c -18,-14,-18
Hippocampus/
parahippocampus
I I 20, -28, -8
c 22, -8, -26 c
DLPFC I -36, 32, 32 I 36, 30, 24
c c
MPFC / orbitoffontal I l © 4̂ K> i 00 I 14, 20, -8
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Fig 5.1 Patient A -  activation observed during matched pressure (affected >
unaffected)
* ~ *  *» O  i*
4 %




Marked widespread activation was observed during innocuous pressure to the 
affected arm. A further contrast was therefore investigated; innocuous pressure in 
affected arm > innocuous pressure in the unaffected arm.
Results of this contrast are presented in table 5.9 and figure 5.3 and 5.4 
No activation survived threshold (Z> 2.3, cluster size minimum 10) in the 
opposite contrast.
Table 5.9 Brain regions showing increases in BOLD signal during innocuous 
pressure on the affected side compared to the unaffected side






ACC I -8,-2,40 I 14, 0, 40
C 12, 22, 32 C 10,2,42
PCC I -8, -32, 44 I
Anterior insula I -44, 14, -6 I
Posterior insula I -8,-18,-4 I
c C -16, -28,6
MI I -18, -24, 60 I 34, -20, 66
SI I -36, 42, 60 I 32. -40, 68
c 36, -40, 64 c
Amygdala I I 20, -6,-16
c 22,-2,-6 c -22,-12,-16
Hippocampus / 
parahippocampus
I I 22,-18, -6
c c -16,-12, -22
DLPFC I -34, 34, 24 I
c c -38, 24, 38
VLPFC c c -42, 56, 2
MPFC / orbitofrontal c -16, 62,6
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Figure 5.3 Patient A Areas of activation during innocuous touch (affected >
unaffected)
Figure 5.4 Patient C Areas of activation during innocuous touch (affected > 
unaffected)
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5.9 Summary of pressure pain findings
During pressure pain on both the affected and unaffected arms in two patients 
with tennis elbow, widespread brain activation was observed in areas consistent 
with previous reports of pressure pain.
When stimulus intensity but not pain intensity was matched, greater activation 
was observed when the stimulus was applied to the affected arm than when 
applied to the unaffected arm.
Finally during innocuous (i.e. non pain provoking) stimulus application to the 
affected arm, widely distributed activation was again observed in a number of 
brain regions known to be active during a noxious stimulus.
5.10 Chapter summary
The over-riding caveat when interpreting the results of the patient data is of 
course that any interpretation or attempts at extrapolation are limited due to the 
small number of subjects. Nevertheless the activation patterns observed in the 
patients make for interesting discussion.
Taken together the three patients appear to show many similarities but also some 
key differences in brain activation patterns than those observed in the healthy 
volunteers.
In summary, during the first experiment (injection of HS), areas of the pain matrix 
were activated including ACC, MI, SI, anterior and posterior insular cortices and 
cerebellum, demonstrating similarity to the healthy volunteer population.
Preponderance towards bilateral activation of so called ‘pain matrix’ areas during 
muscle pain compared to an ipsilateral or contralateral tendency in cutaneous pain 
was observed in the healthy volunteer group described in the previous chapter. 
This finding does also appear to be mirrored in the small patient sample reported 
here although a direct comparison was not carried out therefore again caution 
must be applied in drawing direct comparisons.
Basal ganglia activation was also observed in two of three patients during muscle 
but not cutaneous pain which again would appear to reflect the findings of the 
healthy volunteer group.
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Activation in the hippocampus and amygdala in all three patients during both 
muscle and cutaneous pain was present when compared to rest on an individual 
analysis basis. This may suggest greater engagement of the hippocampal complex 
in patients as this finding was not observed in the healthy volunteer group analysis 
during either cutaneous or muscle pain. Further investigation of a larger number 
of patients would allow a direct comparison to be undertaken and therefore further 




This thesis describes four experiments; one each in chapter three and four and two 
in chapter five; the first two carried out with separate groups of healthy 
volunteers, the latter two with two / three patients who had a diagnosis of 
unilateral lateral epicondylitis (tennis elbow).
This final discussion chapter begins with a summary of the findings, followed by 
a review of associated methodological issues and then further discussion of each 
experiment in turn.
The chapter concludes with a discussion regarding the implications of the findings 
of all three experiments and makes recommendation for future investigations.
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6.1 Psychophysical properties of deep and superficial pain
The first experiment described in this thesis was an investigation of the 
psychophysical properties of pain arising from superficial and deep tissue, 
induced by the same method; in this case hypertonic saline. Two locations of 
superficial tissue were investigated -  intradermal and subcutaneous, whilst one 
deep tissue was investigated; extensor digitorum muscle of the forearm.
Summary of results from this study
Peak intensity, as measured by visual analogue scale, of hypertonic saline induced 
pain in intradermal or muscle tissue in healthy volunteers was of similar 
magnitude within and between sessions. The selected injection volumes reported 
produced peak intensity scores that were very similar within subjects, irrespective 
of whether the injection was ID or MS. In contrast, SC injections gave VAS 
scores that were less comparable than those reported after ID or MS injections.
It is likely that during ID and MS injections the nociceptors (i.e., free nerve 
endings) that abound in the skin and muscle are directly stimulated by the 
injectate. By contrast, the SC injectate can only reach the dermal and intradermal 
nociceptors by diffusion. The subcutis itself is almost devoid of free somatic 
nerve endings although autonomic fibres and mechanoreceptors (e.g., Pacinian 
corpuscles) are found. The present results reflect those reported in a rat study 
investigating the hyperalgesic effects of prostaglandin E2 and bradykinin (Khasar 
et al., (1993); After intradermal and subcutaneous injection of these inflammatory 
mediators, the investigators observed dose dependent lowering of paw withdrawal 
thresholds after ID but not SC injection. The authors suggest the lack of effect of 
the SC injection may reflect the inability of the injectate to reach its receptor sites 
in the terminals of the primary afferent nociceptors.
The findings reported here indicate that subcutaneous injection of an algesic 
substance is less reliable that intradermal injection.
The time to reach peak intensity after intradermal injection was less than it was 
for subcutaneous and muscle and therefore predictably area under the curve for 
the initial 60s VAS data was also greater after intradermal injection. However, no 
difference was reported between ‘total pain’ intensity, as measured over the
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ensuing 210 seconds, between intradermal and muscle pain, although a significant 
difference between intradermal and subcutaneous conditions was found.
Unpleasantness scores were also similar between muscle and intradermal pain and 
showed a strong positive linear relationship with peak intensity scores.
Pain arising from muscle and intradermal tissue could be reliably differentiated 
through selection of sensory descriptors from the SF McGill Pain Questionnaire. 
During muscle pain words most frequently selected and rated higher were 
‘gnawing’, ‘aching’ ‘heavy’ and ‘cramping’ whilst during intradermal pain 
‘hot/buming’, ‘stabbing’ and ‘sharp’ were selected more frequently and scored 
higher than both subcutaneous and muscle. Subcutaneous pain resulted in no 
descriptor being selected either frequently or scoring higher than either 
intradermal or muscle pain.
Methodological issues
The use of hypertonic saline injections over other methodologies was based on 
practicalities dictated by the need for suitability in MRI environment, consistency 
in evoked pain, controllability, repeatability, a relatively short duration of pain 
elicited, and acceptability in a patient population. The key benefits in using 
hypertonic saline were considered to be (i) the same stimulus was used for both 
cutaneous and muscle pain ensuring, at least in theory, a similar mode of 
activation of peripheral nociceptors, (ii) localisation of needles was the same, 
and the subject was not distracted or confused by two different pain eliciting 
modes (e.g., laser or contact heat in the skin and injections to the muscle as 
employed in a number of previously reported studies) (iii) the injections could be 
carried out in the same setting, (iv) the magnitude of provoked pain could be 
easily adjusted by the volume of the injectate. The author also predicted that the 
time course following each injection would be comparable, and that the subjects 
were able to rate the intensity and unpleasantness of provoked pain separately. As 
discussed above, the key similarities between ID and IM injections were evident, 
providing support for the chosen method and allowing it to be implemented in the 
next stage of the study.
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Some limitations of the method however should be considered. Referred pain was 
commonly seen during muscle pain but not in either of the cutaneous pain 
conditions. This may be seen as a weakness in terms of comparison as extent of 
referred pain may contribute to the intensity or affective quality of a painful 
stimulus. The findings however are in agreement with the literature in that 
referred pain is a phenomenon associated with pain arising from muscle but not 
cutaneous tissue (Graven-Nielsen et al., 1997; Arendt-Nielsen., 1996). 
Mechanisms underlying referred pain are not fully understood but are suggested 
to involve convergence of inputs into the spinal cord by separate sets of afferents, 
as well as aspects of central hyperexcitability (Hoheisel et al., 1993). Referred 
pain from a muscle or cutaneous injection has recently been shown to be reflected 
in an increased activation in somatosensory cortex (which is somatotopically 
oriented), cerebellum and mid cingulate regions of the brain (Macefield et al.,
2007).
A further potential confounding factor in investigating repeated pain within the 
same session is that of habituation. Attention was paid to the time intervals 
between injections which were selected to ensure that temporal summation did not 
occur (Graven-Nielsen et al., 1997) but it was impossible to predict from the small 
pilot study whether or not habituation would occur. Although intensity data 
showed no statistically significant difference within session for muscle and 
intradermal pain, visual inspection of the plotted data suggests a trend for a 
decrease in peak VAS in all conditions during the second injection within both 
sessions. These findings however provided further guidance with regards to 
timings and number of needles required for the fMRI experiment.
A further criticism that may be levelled is that despite a great deal of attention to 
methodology in the attempt to control as many confounding variables as possible, 
actual pain values reported by individuals showed a wide range suggesting that 
the study design may be less than optimal. Furthermore, inspection of individual 
VAS scores suggested that failure of the technique with regards to muscle pain 
may have occurred in up to four injections, although not in the same subject. The 
latter issue in particular provided further insight into the need to perform the fMRI 
experiment with meticulous attention to the details of pain provocation.
147
The present results add to the limited literature that exists of direct comparisons of 
pain induced in the two tissue types employing the same method of induction 
(Witting et al., 2001).
It is worth mentioning again at this point, that in addition to the investigation of 
the similarities / differences between pain induced in two tissues types using the 
same method of induction, the experiment was predicted to produce a reliable 
model to take into a scanning environment. Indeed, the results helped to guide the 
technique of injection, selection of injectate volume for each tissue type, and 
providing a predictable time course for scanning; adding to the intention of the 
investigator to have a methodologically sound way of invoking pain of sufficient 
intensity but limited duration
Further discussion
Unpleasantness of a painful stimulus has been shown to be dependant on stimulus 
modality (Price et al., 1983; Rainville et al., 1992; Svensson et al., 1997) and 
temporal aspects (Chen and Treede, 1985; Miron et al., 1989). Although the 
temporal aspects between muscle and intradermal pain showed some variation in 
the present study; both gave rise to a tonic rather than phasic pain and therefore 
may be considered comparable.
Experiment one produced pain of comparable intensity, duration and 
unpleasantness in two distinct tissue types; differences reported in sensory 
descriptors therefore may reasonably be attributed to differences in the perceived 
quality of pain arising from either cutaneous or muscle pain independent of time 
and type of stimulus.
It was hypothesised that subjects would select affective words more frequently to 
describe the pain induced in the muscle compared to that induced in the 
subcutaneous or cutaneous tissue. Previous reports have suggested that 
experimentally induced muscle pain may result in a relatively larger activation of 
affective mechanisms (Svensson et al 1997) and more closely mimic chronic pain 
(Rainville et al., 1992; Arendt-Nielsen et al., 1997). The findings here of lack of 
selection of affective words from the SF McGill pain questionnaire however do 
not lend support for the hypothesis.
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The lack of selection of affective words may reflect the study population of 
healthy volunteers as opposed to a patient population particularly those with 
chronic pain; participants were aware that induced pain, even if intense and 
unpleasant, would be of relatively short duration. A further consideration is 
whether the SF McGill is sensitive enough to detect any difference in the affective 
response to muscle and cutaneous pain. Although previous studies have shown 
this to be the case (Svensson et al., 1997a; Rainville et al., 1992), again these 
studies did not compare the same method of induction therefore differences may 
have been related to type or temporal aspect of stimulus rather than tissue type. 
The only study to date which has used the same stimulus compared intradermal 
and intramuscular capsaicin injection (Witting et al., 2001). Whilst that group did 
use the McGill Pain Questionnaire, it was the long form version therefore direct 
comparisons would be difficult to make. In addition the authors provided only a 
brief description of the words selected and did not separate these into sensory and 
affective.
Previous reports also suggest pain arising from deep tissue is found to be more 
unpleasant than that from superficial tissue. Relative unpleasantness of contact 
heat and cutaneous electrical pain was found to be less than both ischaemic 
exercise and cold-pressor induced pain (Rainville et al., 1992) whilst Svensson et 
al (1997) reported greater relative unpleasantness during experimentally induced 
muscle compared to cutaneous pain. Results of the experiment presented here are 
again contrary to both of these previous findings in that no difference was found 
in unpleasantness ratings between cutaneous and muscle pain. Possible reasons 
for the differences are (i) differences in the temporal aspects of the stimulus 
presentation and pain induced; in Rainville and colleagues’ study (1992) the two 
stimuli shown to be relatively more unpleasant (ischaemic exercise and ‘cold- 
pressor’ were of a tonic, that is longer duration, whilst the less unpleasant stimuli 
(contact heat and cutaneous electrical stimulation) consisted of short lasting 
phasic pain. A number of studies report on both intensity and relative 
unpleasantness of a painful stimulus without systematically evaluating the 
temporal relationship. However those investigating short duration (typically < 5s) 
have tended to report unpleasantness ratings that are lower than intensity (Price et 
al 1983, Harkins et al., 1986; Duncan et al., 1989).
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It should also be noted that both studies employed different modalities of pain 
induction and differences observed in unpleasantness ratings may reflect the 
relative affective response to different types of stimulus rather than tissue 
involved. As previously stated, cutaneous and muscle pain in the experiment 
described here was induced by the same modality (hypertonic saline) and resulted 
in pain of similar duration, albeit the onset slope was greater in intradermal whilst 
the offset was slower in muscle. One of the aims of the first experiment was to 
investigate the psychophysical properties of muscle and cutaneous pain when the 
temporal aspects and induction methods were closely matched which did not 
allow for further exploration of relative unpleasantness / intensity differences at 
varying stimulus intensities. Although unpleasantness was found to correlate with 
peak intensity, as only one unpleasantness rating was taken it was also not 
possible to determine if the relative unpleasantness varied over time. It was not 
feasible to obtain simultaneous ratings of intensity and unpleasantness; however, 
it would have been possible to obtain more frequent unpleasantness ratings which 
would allow changes in unpleasantness to be evaluated as a function of time.
The presented results however are consistent with the hypothesis that when 
subjected to a similar peripheral stimulus, healthy subjects perceive pain arising 
from skin and muscle tissues as qualitatively different in that SF McGill sensory 
descriptors vary significantly.
These results provided the foundation for the next hypothesis; that neural 
correlates of each pain are likely to show differences and also the methodology for 
the next investigation. It was hypothesised that such differences are likely to be 
found in the activation patterns of structures that are generically referred to as the 
pain matrix.
Conversely those investigating more tonic pain appear to suggest that affective or
unpleasantness ratings are equal or greater than perceived intensity (Maixner et
al., 1990; Chen et al., 1989).
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6.3 Neural correlates of deep and superficial pain
Chapter four describes the main fMRI experiment in which eighteen healthy 
volunteers were exposed to both cutaneous and muscle pain of similar intensity, 
duration and unpleasantness and arising from the same type of stimulus. The 
author will discuss here in what way the differences observed in brain activation 
patterns may be attributed to differences in the sensory, affective, cognitive and 
motivational qualities that are generated by noxious stimulation of the two 
separate tissue types.
Summary of fMRI results in healthy volunteers
Both cutaneous and muscle pain were associated with an increase in BOLD signal 
in bilateral primary sensory and motor cortices (SI and MI) and anterior and 
posterior insula cortices. Bilateral anterior cingulate signal increase was also 
present with both conditions demonstrating separate peaks of activation in the 
pMCC and aMCC. In a number of brain regions bilateral signal increase was 
observed during muscle whilst during cutaneous pain this was only contaralateral 
(secondary sensory cortex (SII), the cingulate motor area (CMA), orbito-frontal 
cortex and the putamen) or ipsilateral (DLPFC, VLPFC, PCC). Areas where 
signal increase occurred only in muscle pain were bilateral thalamus and MPFC, 
and contralateral perigenual ACC, caudate nucleus and cerebellum.
During attention to / rating of intensity increases in BOLD signal were seen 
bilaterally in ACC and SMA and ipsilateral in MI and SI in both conditions. 
Bilateral putamen activation was also observed during attention to intensity of 
muscle but not cutaneous pain. Bilateral ACC and SMA and ipsilateral MI and SI 
activation showed a positive linear variation with intensity ratings; no differences 
were seen between the two conditions in terms of intensity co-variance.
During attention to unpleasantness an increased number of brain regions were 
activated including bilateral putamen, pallidum and prefrontal cortex. Those areas 
showing a positive linear relationship with unpleasantness ratings included
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bilateral ACC and MI, ipsilateral anterior insula, OFC and cerebellum and 
contralateral DLPFC during both conditions. Additional areas showing a positive 
linear relationship during muscle pain only included ipsilateral caudate nucleus 
and putamen and bilateral VLPFC.
A decrease in BOLD signal that co-varied linearly with unpleasantness scores 
during attention to unpleasantness in the muscle but not cutaneous condition was 
also seen in bilateral amygdala and contralateral cerebellum and posterior insula.
Methodological issues
Due to the nature of the pain induced the duration of scanning paradigm was long; 
approximately 36 minutes. Potential problems associated with longer paradigms 
include increased tendency for motion artefacts, scanner drift, changes in level of 
attention / concentration from the subjects, lack of acceptability of procedure for 
subjects.
However initial scanning was undertaken, incorporating a number of paradigms, 
on five subjects to assess the affect of and to minimise these issues. These initial 
results and subjects were evaluated for reproducibility, technical variations, 
tolerability in terms of time, levels of pain induced, and compliance with the task. 
Motion artefacts were of particular interest given the duration of the scans.
Post scan interviews revealed that the time period was completely acceptable; 
indeed, most subjects expressed surprise when informed of the total time in the 
scanner, reporting that ‘it felt considerably less’. These interviews also revealed 
that instructions projected were clear and understandable and that the levels of 
pain produced, although unpleasant were acceptable in the time frame that they 
were presented.
Importance of not moving was stressed to subjects and a significant period of time 
was spent ensuring maximum level of comfort was met, through use of 
appropriate padding on the scanner bed, prior to commencement of the scan. Each 
subject’s head was restrained by padded side bars on the head coil but due to the 
length of scan the decision was made not to employ the use of a bite bar. Pre-
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processing of the acquired data indicates that these measures were successful with 
only one subject having to be excluded due to excess motion.
Attentional aspects were managed by frequent changes in projected instructions. 
Specifically during the SF McGill pain questionnaire words subjects were 
instructed to touch the VAS button once to acknowledge that the word had been 
read therefore ensuring attention to each word individually.
Post-scan interviews also revealed that subjects felt that the presence of the 
investigator in the scan room throughout the period of acquisition of the 
functional images provided a reassuring presence which reduced anxiety due to 
the noise and enclosed nature of an MRI scanner. Levels of anxiety however were 
not formally measured which may be seen as a weakness in the methodology as 
this could effect the results. Although such data would have been interesting it 
was not felt necessary as it was considered that any situational anxiety caused by 
the scanning environment would be similar during both muscle and cutaneous 
pain.
All subjects were screened by and provided verbal instructions from a single 
investigator (the author) to ensure consistency of information. The same 
investigator also inserted the cannulae and subsequently administered the 
injections thereby also ensuring consistency of technique.
All data reported in experiment two was analysed by the author using the FSL 
analysis software suite, having undertaken training in the use of FSL. However to 
ensure no systematic error occurred during data analysis, three subjects’ data sets 
were selected at random and analysed using SPM 2 (Friston 2002) by a senior 
research fellow with extensive experience of fMRI analysis. The results were then 
visually inspected to check that results were comparable.
Another limitation perhaps is that data regarding individual psychometrics, for 
example levels of fear avoidance, catastrophizing were not gathered. The 
justification for this being that it was expected that if an individual had had high 
levels of catastrophizing that they would have a heightened response equally to 
both cutaneous and muscle pain. In retrospect of course one could argue that
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Although this question was not a specific aim of the experiment, in view of the 
findings, this may lead to a future line of investigation. It is also worth noting that 
subjects were self -  selecting, that is they answered an advertisement and were 
aware that they would be undergoing an experiment whereby pain of moderate to 
high levels would be induced. It is possible therefore that this self selection would 
have filtered out extremes with regards to psychometric profile.
It is argued that a particular methodological strength of this experiment was that it 
sought to undertake a direct comparison between superficial and deep pain 
induced by the same method and therefore differences observed can not be 
explained by differences in stimulus type. As previously discussed experimental 
pain induced by different methods result in different levels of reported 
unpleasantness (Rainville et al., 2002, Svensson et al., 1997a).
Typically, pain studies also threshold pain at the beginning of a scan and make the 
assumption that pain levels are consistent throughout. Although extensive 
laboratory testing of the model indicated a high level of consistency both within 
and between sessions, a number of trials did not result in pain rated at least three 
on the visual analogue scale. Whilst this may be seen as a methodological 
weakness, through gathering psychophysics data in real time, events where pain 
did not reach 3 on the VAS scale were modelled as events of no interest in the 
final analysis. Therefore it can be stated with confidence that events included in 
the ‘muscle’ and ‘cutaneous’ conditions were all pain events. The selection of 3 as 
the inclusion criteria was based on that previously reported (Henderson et al., 
2006, 2007; Kupers et al., 2004). Furthermore additional ratings of unpleasantness 
and SF McGill were also able to be taken into account before pain epochs were 
included in the final analysis model.
given the elements observed in brain activation a stronger level o f catastrophizing
may have been associated with a stronger response in the muscle pain condition.
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Discussion
A review of the literature undertaken at the beginning of this course of study 
failed to reveal any brain imaging studies that had adequately undertaken a direct 
comparison between cutaneous and muscle pain employing the same method of 
induction. However Henderson and colleagues published in 2006 the results of a 
study utilising fMRI to investigate 15 healthy volunteers during both HS induced 
muscle and cutaneous pain; the first group to undertake this direct comparison; the 
results of which were reviewed in chapter two. Subsequently this group of 
investigators have also published further studies employing the HS model 
reporting on gender differences between muscle and cutaneous pain (Henderson et 
al., 2008), somatotopy for muscle and cutaneous pain in the insula (Henderson et 
al., 2007) and associated referred pain (Macefield et al., 2007).
Results from the study presented here provide some support for but also asks 
questions of the findings of Henderson and colleagues in relation to brain 
processing of muscle and cutaneous pain in healthy volunteers. There were 
commonalities in findings between those published and the results of the study 
presented here but crucially also differences, particularly in relation to subcortical 
structures and perienual ACC. Potential explanations for the differences will be 
explored below.
The results reported here also add a new dimension by application of the 
experimental model in admittedly small clinical pain condition; the findings of 
which again make for interesting discussion, addressed later in this chapter.
Anterior Insula
The finding of Henderson et al., (2006) of ipsilateral anterior insula activation 
only during the deep pain condition is somewhat surprising and in contrast to the 
majority of the literature with Al being the most consistently reported region of 
activation in both experimental (Coghill et al., 1999, Craig et al., 2000, 
Derbyshire et al., 1997, Porro, 1998 and Tolle et al., 1999) and clinical pain 
studies (Maihofner et al., 2003, Peyron et al., 2004 and Petrovic et al., 1999 and
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Schweinhardt et al 2006). The authors suggest their results may be due to the 
tonic nature of the stimulus or the type of stimulus. However this would not 
explain the difference seen in their results compared to those reported here. The 
reliance of Henderson’s group on only a single injection may have given 
insufficient power to detect signal changes and is an alternative explanation.
Methodological issues or insufficient power may well explain Henderson and 
colleagues (2006) initial findings as the same group of investigators in two later 
studies involving a larger group of subjects did this time demonstrate ipsilateral 
AI activation during both cutaneous and muscle pain. Furthermore reported co­
ordinates show that not only is the peak of activation in rostral AI but it is also 
somatotopically organised (Macefield et al., 2007) in both cutaneous and muscle 
pain conditions.
The results observed in the healthy volunteer study therefore is in agreement with 
the majority of the literature in that strong bilateral anterior insula activation was 
observed during both superficial and deep pain conditions; the peak of activation 
in the group analysis was more rostral during deep pain. Ipsilateral rostral anterior 
insula activation also survived the muscle > cutaneous contrast suggesting greater 
activation during muscle pain compared to cutaneous pain.
The insula receives input from spinothalamically activated posterior thalamic 
nuclei, has projections to the amygdala (Burton and Jones, 1976, Friedman and 
Murray, 1986) and is considered part of circuitry related to fear avoidance (Morris 
et al., 1999). Engagement of the anterior insula has also been reported during 
other aversive challenges including aversive gustatory stimulation (Zald et al., 
1998), fearful vocalizations (Morris et al., 1999), heartbeat detection (Critchley et 
al., 2004) hunger (Tataranni et al., 1999) and air hunger (Evans et al., 2002).
Encoding of perceived intensity of experimental pain in healthy volunteers is also 
consistently found in anterior insula (Coghill et al., 1999; Craig et al., 2000; 
Derbyshire et al., 1997 and Peyron et al., 1999). It has been suggested that as 
interoception moves from sensation to cognition, initial sensory recognition 
occurs in the posterior insula then remapped to the right anterior insula via
156
corticocortical and/or callosal pathways (Kong et al 2006). The second-order 
representation in the right AI is proposed to subserve subjective feelings (Craig et 
al., 2000; Craig, 2002); suggesting AI has an important role in cognitive 
modulation of pain perception (Kong et al., 2006).
In the present study, it was hypothesised therefore that muscle pain, being less 
familiar and having greater emotional salience than cutaneous pain would provoke 
a greater response in the rostral anterior insula when compared to cutaneous pain. 
The finding of ipsilateral rostral anterior insula activation that survived the muscle 
> cutaneous contrast should be interpreted with caution given the bilateral 
activation seen during both conditions compared to rest. It is not uncommon 
within the literature for researchers to present only the results of a contrast when 
undertaking comparisons of two or more conditions; the anterior insula findings 
discussed here perhaps highlight the importance, in this type of study, of reporting 
group activation maps as well as contrasts to facilitate discussion and 
interpretation of results.
As this study was only undertaken on one arm (left) it is not possible to infer 
anything from the results regarding laterality of insula activation which may be 
seen as a weakness in the methodology. However the use of the non dominant arm 
in the healthy volunteer group was specifically chosen to enable comparison with 
the planned patient group.
Although the results do indicate that the peak of anterior insula activation during 
muscle pain is more rostral than that observed during cutaneous pain, when 
compared to the meta-analysis undertaken by Schweinhardt et al (2006), 
experimental pain studies. Indeed, although in the group analysis the co-ordinates 
of peak ipsilateral activation during cutaneous pain fell within the caudal part of 
the AI (as defined by Schweinhardt et al, 2006), ROI analysis on an individual 
subject basis revealed distinct areas of activation during both conditions, in both 
rostral and caudal AI bilaterally.
A possible explanation for this finding may be the tonic nature of stimulation 
employed in this study in comparison to the brief phasic pain typically employed
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in other experimental studies. Pain that is prolonged or inescapable is more 
aversive (Lumb et al., 2002) therefore it is not entirely surprising that both 
conditions resulted in strong rostral anterior insula activation. Indeed a positive 
linear relationship with unpleasantness ratings during both conditions was evident 
during attention to unpleasantness.
The results therefore suggest that encoding of pain in the rostral AI may be related 
to the inescapable / aversive nature of prolonged pain rather than supporting the 
argument that it reflects the difference in nature between the tissues from which 
the noxious input is arising. A study investigating differences between short 
lasting muscle and cutaneous pain induced by the same method would facilitate 
further exploration of the question of whether rostral AI does also encode for pain 
of tissue type.
Posterior Insula
It has been suggested that posterior insula activation during experimental pain 
reflects basic sensory aspects of nociceptive input itself as opposed to the 
subjective experience of the pain (Apkarian et al., 2005, Brooks et al., 2005, 
Ostrowsky et al., 2002); opinion which is supported by the findings of 
somatotopic organisation in posterior insula (Brooks et al., 2005 and Craig 1995, 
Henderson et al., 2007; Macefield et al., 2007, Craig et al, 2000) suggests 
posterior insula may encode intensity of the nociceptive stimulus rather than the 
actual perceived pain intensity.
A significant increase in signal was observed bilaterally during both muscle and 
cutaneous pain in this study with no differences between the two conditions. This 
result is consistent with opinion from published literature that the posterior insula 
encodes for pain intensity; as intensity ratings were similar between muscle and 




Frontal lobe activity during pain in general is considered to be related to cognitive 
and attentional processes (Coghill et al 1999, Casey 1999, Peyron et al 1999). 
MPFC has also been shown to be involved in negative emotions, response 
conflict, and detection of unfavourable outcomes, especially in relation to the self 
(Baliki et al., 2006).
Previous studies suggest that dorsolateral prefrontal cortex (DLPFC), is important 
for continuous monitoring of the external environment, information processing of 
short-term memory and directing appropriate and efficient performance in the 
presence of aversive or distractive stimuli (MacDonald et al., 2000, Bunge et al., 
2001; Miller et al., 2001; Fuster, 2001).
Wager et al (2004) suggests that DLPFC has a role in the placebo response, 
demonstrating increased signal change DLPFC during anticipation of pain relief 
that correlated with increases in midbrain signal anticipation, which the authors 
suggest is consistent with their hypothesis that opioid release in the midbrain is 
triggered by prefrontal mechanisms. Although acknowledging the alternative 
interpretation; that DLPFC redirects attention away from pain, having been 
implicated in studies investigating general attentional processes (Peyron et al., 
1999) they cite their midbrain findings as further evidence that placebo is opioid 
mediated and is reflected in DLPFC activity.
Lorenz et al (2003) report that during capsaicin induced heat hyperalgesia, 
unpleasantness ratings were significantly higher during low compared with high 
DLPFC activity; the authors suggesting that the DLPFC modulates the 
unpleasantness of the pain. An inverse relationship was also demonstrated in the 
correlation of midbrain and medial thalamus activity during left DLPFC activation 
-  the correlation being less strong during left DLPFC activity suggesting the 
DLPFC has a ‘top-down’ modulation of midbrain / medial thalamus circuitry.
It is interesting therefore to consider the finding of increased DLPFC activation 
during muscle pain compared to cutaneous pain in the results reported here. 
When one also considers the lack of perceived difference in unpleasantness 
between the two conditions, a possible interpretation is that muscle pain is
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initially more unpleasant but DLPFC subsequently mediates the degree of 
unpleasantness. Unpleasantness ratings were recorded approximately two minutes 
after onset of pain therefore it is not possible to confirm this although it does 
make an interesting hypothesis. Future studies collecting serial unpleasantness 
ratings would be useful to investigate this further.
Lorenz et al., (2003) also report that the relationship of the perigenual ACC 
activity with unpleasantness was left DLPFC dependent; a positive correlation 
was present during low left DLPFC activity, whilst a negative correlation was 
observed during strong left DLPFC activity. The authors suggesting this may 
explain why they did not observe a correlation of perigenual ACC with 
unpleasantness independent of left DLPFC activity.
A recent meta-analysis (Apkarian et al., 2005) indicates that studies investigating 
either clinical pain or experimental models that attempt to replicate clinical 
models for example capsaicin induced allodynia (Baron et al., 1999, Lorenz et ah, 
2002 Maihofner and Handwerker, 2005, and Zambreanu et ah, 2005), have a 
greater likelihood of reporting PFC signal change. However approximately 55% 
of experimental pain studies in healthy subjects also report PFC activation 
(Apkarian et ah, 2005). Hence, PFC activation is not uniquely associated with 
clinical pain. Rather, PFC activation is likely to depend on the degree to which a 
certain type of pain engages higher order cognitive, emotional and attentional 
processes (Schweinhardt et ah, 2006).
Medial prefrontal areas and the perigenual cingulate are both activated by 
expectancy of pain (Ploghaus et al 1999, Sawamoto et ah, 2000), interaction of 
pain with anxiety (Petrovic et al 2002) and cognitively demanding tasks (Bantick 
et ah, 2002). Simpson et al (2001) however demonstrated a decrease in rCBF in 
two regions of the MPFC (Brodmann Areas 10/32 and 24/25) during anticipation 
related anxiety. Interestingly the changes were inversely correlated with anxiety 
scores so that subjects who were less anxious exhibited large rCBF reductions, 
whilst those with high anxiety levels showed no or minimal reduction.
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Patients with bilateral lesions of the OFC, (Homak et al 2003) demonstrate 
impairment in all those aspects of emotion relative to patients with lesions in the 
dorsolateral prefrontal cortex that did not have problems with these measures of 
emotion suggesting the OFC is important for aspects of emotion. The study 
included three patients with bilateral OFC lesions and very little medial prefrontal 
cortex damage that displayed deficits of voice expression identification and 
subjective emotional state providing evidence that damage to the OFC is sufficient 
to produce these changes if the lesions are bilateral.
The greater signal change observed during the muscle pain compared to cutaneous 
pain in the study reported here therefore lends support for the hypothesis that a 
nociceptive stimulus arising from muscle tissue may engage higher order 
cognitive, emotional and attentional processes more strongly than a nociceptive 
stimulus to cutaneous tissue does. Indeed this engagement may explain the 
absence of expected difference in the perceived affective qualities, as measured 
thorough the SF McGill, and unpleasantness.
Anterior Cingulate Cortex (ACC)
The ACC receives nociceptive inputs via medial thalamic nuclei (Vogt and 
Pandya, 1987, Vogt et al., 1987) and has extensive connections with the prefrontal 
cortex and parietal cortex as well as the motor system (Bush et al., 2000). Hence it 
has been suggested it may have a central role in processing top-down and bottom- 
up stimuli and assigning appropriate control to other areas in the brain.
It has been shown to code affective components of painful stimuli (Craig et al., 
1996; Rainville et al., 1997; Sawamoto et al., 2000) in addition to being involved 
in attentional processing (Gitelman et al., 1999; Peyron et al., 1999). Furthermore 
it has been shown to have a role in learning associations between aversive and 
neutral stimuli (Ploghaus et al., 1999, Buchel et al., 2002).
Although the ACC is considered to code for unpleasantness rather than intensity 
of a painful stimulus, discrete intensity associated areas have been identified 
within the mid cingulate cortex (Coghill et al 1999, Derbyshire et al 1997).
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Buchel et al’s (2002) study of both innocuous and noxious laser stimulation 
suggest dorsal pMCC codes stimulus intensity whilst ventral pMCC (and 
perigenual ACC) was related to pain intensity. They report that aACC signal 
changes were not stimulus specific therefore suggest activation here is related to 
working memory and attentional processes.
Activation of both these areas, observed in the present study during both muscle 
and cutaneous pain conditions, with no difference in extent is therefore 
unsurprising given that intensity of pain was in the main, matched for the two 
conditions.
The perigenual anterior cingulate cortex (pACC) contains a high level of opioid 
receptors (Vogt et al., 1995); is located in the affective subdivision of the ACC 
(Bush et al., 2000) and has been linked to arousal associated with 
emotional/motivational processing (Critchley et al., 2004). Kalisch et al. (2005) 
suggest activation in medial prefrontal / pACC and anterolateral prefrontal cortex 
modulates anticipatory anxiety evoked by pain.
Studies of clinical pain states including angina (Rosen et al., 1994) and migraine 
(Weiller et al., 1995) have also reported activity in perigenual cingulate; Rosen et 
al. (1994) suggest the inescapable, frightening or worrying aspect of angina pain 
may explain the activation of perigenual cingulate.
Activation of the ventral anterior cingulate cortex, including the subgenual / 
perigenual areas has also been demonstrated in response to emotionally salient 
words (Elliott et al., 2000). Drevets (2000) suggests that the subgenual cingulate 
cortex has a role in the regulation of mood states, and that hypofunction of this 
region may confer vulnerability to mood disorders in some patients. Indeed 
significant changes in the subjective emotional state of patients with surgical 
lesions involving the pACC has also been reported (Homak et al. (2003).
The finding in the present study of perigenual ACC signal increase during muscle 
pain combined with the medial PFC signal change provides support for the 
hypothesis that muscle pain engenders a greater affective salience than cutaneous
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pain resulting in greater activation in brain regions associated with fear and 
anxiety.
There is however some inconsistency in the literature with regards to the pACC; 
increased signal has been reported during cold pain (Kwan et al., 2000) and 
during anticipation of a noxious stimulus (Porro et al., 2002) whilst a decrease in 
signal has been reported following subcutaneous ascorbic acid injections (Porro et 
al., 1998), during rectal distension (Dunckley et al., 2005) and hypertonic saline 
induced muscle pain (Henderson et al., 2006, 2007). The subgenual cingulate 
cortex, located more ventral to the perigenual cingulate (Vogt et al., 2003) has 
many interconnections with the caudal posterior cingulate cortex (Van Hoesen 
1993) and signal decrease in subgenual has been reported during anticipation 
(Porro et al., 2002) and anxiety (Simpson et al., 2001).
A possible explanation for the reported inconsistencies may lie in semantics; 
within the literature there appears to be some degree of inter-changeability 
between perigenual and subgenual cingulate cortices when reported co-ordinates 
of activation are compared. Although the work of Vogt et al., (2003) clearly 
differentiates the two, this differentiation is not always consistently applied within 
the literature.
The finding of pACC activation in the present study contradicts that of Henderson 
and colleagues (2006 and 2007) who report a d ecrea se  in signal during muscle 
pain with no discernible change in signal during cutaneous pain. Again given that 
both studies employed HS as the method of pain induction, this result is somewhat 
surprising.
Methodological differences however between the two studies may point to 
reasons why the findings are different. In Henderson’s study the subjects had a 
single injection into each tissue, separated by some 20 minutes whereas in the 
study reported here subjects were aware that they would receive a total of six 
injections and were unaware of the timing of these. It may be argued therefore that 
here, there was a greater degree of uncertainty, particularly during muscle pain 
with regards to duration and intensity of pain.
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A possible explanation for the increase observed in this study therefore may well 
lie with expectancy. Subjects received no visual clues as to when pain was about 
to be induced therefore expectancy was not controlled for; this lack of control for 
expectancy may of course be criticised and possibly seen as a weakness in the 
methodology. The decision was made specifically not to manipulate expectancy 
with the expectation that this would be similar in both conditions.
There exists however the possibility that expectancy / anticipation in terms of 
degree of intensity and hence unpleasantness may have been greater during the 
muscle pain condition; the faster onset of cutaneous pain means that it peaked 
more quickly and therefore would also start to subside more quickly. The 
relatively slower onset of the muscle pain, it may be argued, could lead to an 
increased uncertainty and this may explain the difference seen in the results 
reported in chapter four. However, when subjects were specifically asked to attend 
to and rate the unpleasantness of the pain, thereby negating any expectancy effect, 
a sub significant increase (Z = 2.1) in peri genual signal was also observed during 
muscle but not cutaneous pain; this also showed a positive linear relationship with 
unpleasantness but not intensity ratings.
Whilst it is possible to control for, and / or manipulate expectancy, as others have 
demonstrated (Porro et al., 2002), such control relies on the ability to both predict 
and match the onset of a noxious stimulus. With the hypertonic saline model 
employed in the fMRI study reported here it was not possible to exactly match the 
onset curves of the muscle and cutaneous conditions and is acknowledged as a 
limitation of the study.
Posterior Cingulate cortex
Maddock et al (1999), in a meta-analysis of functional imaging studies 
demonstrated that the caudal part of the posterior cingulate cortex was 
consistently activated by emotional stimuli compared to matched, emotionally 
neutral stimuli. A confound of these studies however, is the finding that the PCC
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also has a function related to episodic memory (Andreasen et al., 1995; Henson et 
al., 1999; Maddock et al., 2001). The authors of the meta-analysis suggest that 
the contrast in observations may be reconciled by the hypothesis that the posterior 
cingulate cortex has a role in the modulation of memory by emotionally arousing 
stimuli. This group later demonstrated PCC activation during both pleasant and 
unpleasant words; activation which was not present during recall of neutral words 
(Maddock et al 2003).
A recent literature review suggests PCC activation is frequently reported as being 
activated during pain studies of heat and mechanical stimulation of the skin, 
following hypnosis and suggestion and painful distension of the rectum. (Nielsen 
et al., 1999). Activation has also been demonstrated during distraction from pain 
(Valet et al 2004).
The exact role of the PCC in relation to pain processing however remains unclear. 
The findings of studies showing increased activation during both positive and 
negative affect suggest that PCC rather than reflecting the emotional valence of a 
stimulus it may reflect its emotional salience.
Although bilateral PCC increased signal was observed during both muscle and 
cutaneous pain, the activation showed a positive linear relationship with 
unpleasantness rating during only the muscle and not the cutaneous pain 
condition.
Lack of co-variance during cutaneous pain militates against a pure distraction 
effect; therefore it is possible the PCC signal change reflects a stronger emotional 
response to the muscle compared to cutaneous pain. That is the muscle condition 
is more salient to the individual than cutaneous pain; the later being of equal 
intensity but of less interest / relevance to the individual. A further possible 
explanation, in view of the evidence presented above regarding episodic memory 
is the possibility that the experimental pain evoked a memory of a previous pain 
experience that was emotionally salient to the individual.
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Amygdala
The amygdala monitors external and internal stimuli and mediates behaviours that 
facilitate survival (Tillfors 2004). It is also now considered an important part of 
the pain system (Neugebauer et al 2004), receiving pain related information from 
thalamus, anterior and posterior insula, medial prefrontal cortex, anterior cingulate 
cortex, perigenual ACC orbitofrontal cortex and prefrontal cortex. (Millan 1999; 
LeDoux 2000; Price 2000; Maren and Quirck 2004; Vogt 2003).
The amygdala is heavily influenced by orbital and medial PFC; both exerting a 
predominantly inhibitory influence. Viewing of emotionally arousing pictures is 
associated with increases in activation of ventral PFC and decreased activation of 
the amygdala (Hari et al., 2003). Conversely, direct thalamo-amygdalar 
connections provide a pathway whereby rapid activation of the amygdala follows 
sensory stimulation, both noxious and threatening (Bemtson et al., 2003)
The amygdala is also considered to be involved when orientating to 
motivationally salient stimuli, integrating prior experience and decision making 
(Rolls 2000, Baxter and Murray 2002), participating in the enhancement of both 
perception of, and memory for, emotionally arousing stimuli (Adolphs et al., 
1997; Anderson and Phelps, 2001; Cahill et al., 1995). Rats with amygdala lesions 
fail to respond to either contextual or explicit cues indicative of danger such as an 
impending painful shock (Selden et al., 1991; Kim et al., 1993).
Animal studies suggest amygdala involvement in processing both negative and 
positive stimuli; however human studies provide greater evidence for amygdala 
involvement in negative or aversive stimuli as opposed to positive stimuli 
(Maddock et al., 2003).
Pain related signal changes in the amygdala have been demonstrated in a number 
of imaging studies in healthy human volunteers during experimental pain. 
However signal changes have been reported by some as showing an increase 
during heat pain (Bingel et al., 2002) and vascular pain (Schneider et al., 2001)
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whilst others have reported a decrease in signal during heat pain (Derbyshire et 
al., 1997; Becerra et al., 1999).
Clinical studies present a similar story; whilst increased amygdala activation was 
seen in patients with irritable bowel syndrome (Naliboff et al., 2003), in 
neuropathic pain patients, during mechanical allodynia stimulation, bilateral 
amygdala de-activation was reported (Petrovic et al., 2004).
Conversely many experimental pain studies have failed to report any signal 
change in the amygdala. However it is worth remembering that both the fMRI 
BOLD signal and the rCBF changes measured in PET studies are indirect 
measures of brain activity i.e. they measure only the net change of associated 
neuronal activity to a stimulus and cannot make inferences regarding 
differentiation of inhibition from excitation. There has therefore been a reluctance 
to report a reduction in signal as ‘de-activation’ which may account for the lack of 
amygdala activation seen in much of the pain literature.
Determining the exact role of the amygdala in relation to pain processing 
therefore presents a challenge. Aversive conditioning studies suggest that the 
amygdala is only activated during the initial stages of acquisition (Quirk et al, 
1997, Biichel et al, 2002) or extinction (LaBar et al., 1998) -  where there is a 
degree of uncertainty about whether a stimulus will be aversive or neutral.
Bomhovd et al. (2002), in a study investigating response to five levels of laser 
stimuli ranging from non-perceived to mild warmth and strong heat pain report 
interesting patterns of amygdala activation. The response pattern in both the 
amygdala and the perigenual ACC was different from that in SII and insula 
cortices in that sub-threshold stimuli evoked BOLD responses almost as high as 
those evoked during the moderate pain stimuli. In contrast warmth and mild pain 
evoked minimal changes in amygdala signal.
Petrovic et al (2004) suggests that the deactivations may represent a coping 
strategy in dealing with acute aversive situations; reflecting a ‘meaningful
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suppression’ of the brain systems that subserve both short-term memory and 
emotional response to aversive, in this case painful stimuli.
The finding in the present study of a reduction in BOLD signal in amygdala which 
co-varied in a linear fashion with unpleasantness ratings observed with attention 
to unpleasantness during the muscle but not cutaneous pain condition is of 
particular interest. This provides further support for the hypothesis that muscle 
pain may initially be more unpleasant than cutaneous pain but that the coping 
mechanism in healthy volunteers is such that the relative unpleasantness is 
relatively quickly reduced.
The decrease in amygdala signal observed may represent an inhibitory effect 
following increased activation in medial prefrontal cortex, MPFC, which is also 
more prominent during the muscle pain. MPFC in turn has been associated with 
monitoring one’s own emotional state and anticipation of salient emotions 
(Ochsner et al., 2004; Erk et al., 2006), also in association with pain (Poro et al., 
2002; Wiech et al., 2005)
Basal Ganglia
The basal ganglia appear to be an area of the brain where clear differences exist 
between muscle and cutaneous pain. During muscle pain, bilateral putamen 
activation was observed which was only contralateral during cutaneous pain. 
Contralateral caudate activation was also observed during muscle pain with no 
significant change in signal during cutaneous pain.
Although bilateral putamen during attention to unpleasantness was observed 
during both conditions, changes in signal showed a positive correlation with 
unpleasantness scores in ipsilateral putamen and caudate only in the muscle pain 
condition.
In early brain imaging studies investigating pain, basal ganglia activation 
observed was frequently either not reported or attributed to either a suppression of 
motor response or a ‘planned’ motor response to the painful stimulus. However, 
increasingly, investigators have shown interest in the role of the basal ganglia in 
pain and at least one component of the basal ganglia complex feature in more
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recent pain studies or indeed have been the primary focus of study (Scott et al., 
2006, Wood et al., 2007).
A number of lines of evidence point to potential roles of the basal ganglia in pain 
processing. Putamen has been shown to encode for stimulus laterality during pain 
(Bingel et al 2002) and there is evidence of somatotopy in the contralateral 
putamen to a painful laser stimulus (Bingel et al 2004); suggesting the putamen 
processes behaviourally relevant nociceptive information without input from non 
-  nociceptive receptors.
High concentrations of opiate receptors have been demonstrated in various basal 
ganglia nuclei in animal studies (Pasternak et al., 1975; Simantov et al., 1976; 
Atweh and Kuhar 1977). Furthermore in humans high levels of opiate receptor 
binding within the caudate nucleus and putamen have also been demonstrated 
(Jones et al., 1991b).
Lee and Wang (1991) report loss of pain withdrawal responses in patients who 
had sustained a post-traumatic basal ganglia haemorrhage in the putamen or 
caudate nucleus, whilst striatum infarction resulted in patients failing to respond 
to any sensory stimulation (Healton et al. 1982; House and Hodges 1988). 
Furthermore surgical lesions in the putamen alleviated phantom limb pain 
(Yamitsky et al., 1988) and reduced sensation to pin-prick, light-touch and 
temperature (Yang, 1991).
This concomitant sensory neglect and inattention that can follow basal ganglia 
damage may confound studies investigating the effects of striatal or nigral lesions 
on pain behaviour (Chudler and Dong (1993). However Ljungberg and Ungerstedt 
(1976) found in rats with chemically induced substantia nigra lesions that the 
ability to orient to visual, olfactory and auditory stimuli are regained at different 
rates compared to that for somatosensory stimuli. This would suggest that the 
observed sensory neglect or inattention is not therefore due to a motor 
phenomenon. In other words, the lack of response to a stimulus may not simply be 
attributed to an inability, through lack of motor control, to orient to a stimulus..
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Lineberry and Vierck (1975) demonstrated in monkeys that electrical stimulation 
of the caudate nucleus reduces pain reactivity without any accompanying changes 
in escape latencies i.e. without alterations in arousal or motor ability suggesting 
caudate nucleus stimulation may reduce pain reactivity directly rather than 
reducing the ability to react. The authors attribute their results to a reduction in 
affective components of pain by caudate stimulation
A single case study also reports alleviation of chronic facial pain in a human by 
electrical stimulation of the caudate nucleus (Ervin et al. 1966), providing further 
evidence for a role in pain attenuation for the basal ganglia.
Motor aspects of the basal ganglia
Peyron et al (2007) in a study designed to investigate the motor component of 
pain reports on the central representation of the RIII reflex -  a nociceptive 
withdrawal reflex. High intensity electrical stimulation was associated with a 
high-amplitude RIII reflex and bilateral brain activation in cerebellar vermis, MI, 
SI, and paracentral cortices and contralateral activation in premotor, SII and 
posterior cingulate cortices. No activation in any of the basal ganglia structures 
was reported.
Withdrawal assessed by the RIII nociceptive reflex, is known to be generated at 
the spinal-cord level and does not imply a voluntary or a conscious process 
(Peyron et al., 2007) therefore is an involuntary or passive response. Whilst in 
Peyron and colleagues’ study subjects were explicitly instructed not to try and 
suppress any motor response, this is in contrast to most imaging studies of pain 
where the importance of avoiding movement during the scanning period is 
typically reinforced to subjects prior to entering the scanner. Basal ganglia 
activation observed during pain studies may still therefore represent a suppression 
of motor response.
Mink (1996), based on anatomical, physiological and lesion studies in both animal 
and humans hypothesised that ‘tonically active inhibitory output of the basal 
ganglia acts as a “brake” on motor pattern generators (MPGs) in the cerebral
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cortex (via thalamus) and brainstem’. When a movement is initiated by a 
particular MPG, basal ganglia output neurons projecting to competing MPGs 
increase their firing rate, thereby increasing inhibition and applying a “brake” on 
those generators. At the same time basal ganglia output neurons projecting to the 
areas involved with the desired movement will decrease their discharge which 
removes inhibition and in doing so releases the “brake” from the desired 
movement patterns. Selected movements are therefore enabled whilst competing 
movements are inhibited therefore do not interfere with that selected.
If the bilateral activation of the basal ganglia observed during muscle but not 
cutaneous pain represents a motor response the question is why should this be so? 
Pain arising in muscle tissue, as discussed previously, may from an evolutionary 
perspective produce a different behavioural response -  that of a ‘STOP’ sign. If 
pain arising from deep tissue results in a stronger inhibitory signal, the bilateral 
basal ganglia activation may indicate this. However the counter argument is that 
cutaneous pain produces a ‘flight’ response i.e. removal of the painful part from 
danger. This response of course may be overridden by the controlled environment 
in which the stimulus is given.
Assessment of threat by the basal ganglia
Research in primates indicate that the basal ganglia are involved in threat 
assessment (Baxter, 2003; MacLean, 1972, 1990); such responses are thought to 
be relatively automatic, but take past experience into account, and consider 
appropriate behavioural responses for example ‘fight or flight’.
Maclean (1990) therefore suggested that the basal ganglia represent an early threat 
assessment system, which still operates in primates and presumably humans. In 
monkeys, neuronal discharge in both caudate and anterior putamen has been 
shown in anticipation of predictable events (Apicella et al., 1992).
The basal ganglia are considered to function at a preconscious and pre-emotional 
level (Flannelly et al 2007) and assessment of threat by the basal ganglia and the
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limbic system said to operate on the principle of “better to be safe than sorry” 
(Gilbert 2001); or put another way a false-positive with regards to whether a 
situation (or painful stimulus) is harmful or unsafe is better than a false-negative 
i.e. that a painful stimulation predicted not to be a threat actually is. The 
unfamiliarity of muscle pain and its association with internal, inescapable damage 
may reflect this.
The basal ganglia however are also a critical emotion / motor interface that allow 
one to translate emotional information into behavioural responses (Ring and 
Serra-Mestres 2002 and Grillner et al 2005). Loewenstein et al. (2001) reviewed 
cognitive and emotional models of information processing about potential risks or 
threats and concluded that “responses to risky situations (including decision 
making) result in part from direct (i.e., not cortically mediated) emotional 
influences, including feelings such as worry, fear, dread, or anxiety”.
Increased threat-related basal ganglia activity may be understood as representing a 
state of motor readiness in response to danger. Basal ganglia activation has been 
reported in functional imaging studies of normal (Phelps et al., 2001) and 
pathological (Lorerbaum et al., 2004) fear in humans.
Butler et al (2007) also report increased activation in bilateral putamen and right 
caudate as well as bilateral insula and thalamus during an experimentally-induced 
state of conscious fear in humans which they suggest indicates involvement of 
both executive and motor circuits. It is tempting therefore to draw comparison’s 
with Butler’s results -  the basal ganglia pattern of activation reported by this 
group during fear matches that observed during the muscle pain but not cutaneous 
pain reported here.
Limitations with regards to the motor interpretation of the results however do 
apply. Whilst all subjects were observed during the whole scanning period and no 
overt movement was observed during any pain condition, methods for assessing 
motor changes peripherally, for example electromyography, were not undertaken. 
It should also be acknowledged that whilst limiting movement (through subject 
instruction), improves the imaging signal to noise, it may also introduce a
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potential confound. Subjects were instructed on the importance of not moving and 
as such, in the main, complied; this very instruction however may introduce a 
conscious over-riding of a desire to move in response to induced pain. It may be 
difficult to resolve this within a scanning environment however a well designed 
motor paradigm may be able to address the problem. Indeed the approach taken 
by Peyron et al (2007), whereby the subjects were explicitly told not to suppress 
any movement of their limb may be one solution.
Martin et al., (2008) recently demonstrated facilitation of motoneurones at a 
spinal level with the opposite effect on motor cortex outputs by group III and IV 
muscle afferents activated by hypertonic saline. Arguably this would allow / 
facilitate rest for a potentially injured muscle from which the nociceptive stimulus 
is arising. This would suggest an excitatory effect at the spinal level but an 
inhibitory effect at cortical level and perhaps questions whether the basal ganglia 
activation observed in the results reported here was in fact an inhibitory 
activation. Although it is not possible to determine whether the increase in the 
fMRI BOLD response is excitatory or inhibitory there is some merit in this 
consideration.
A body of evidence also exists for a role of forebrain dopaminergic systems in 
pain and analgesia (Millan 2002). Electrophysiological studies in animals have 
revealed dopamine-mediated inhibition of nociceptive activity in the thalamus 
(Shyu et al., 1992) and the spinal cord dorsal horn. Fleetwood-Walker et al., 1988; 
Garraway 2001). In a PET study, Jaaskelainen et al., (2001) report a significant 
decrease in binding of fluorodopa in the right putamen of patients with burning- 
mouth syndrome, suggesting decreased dopaminergic inhibition may be a feature 
of this chronic pain syndrome.
In a recent PET study Scott et al., (2006) investigated basal ganglia dopamine 
(DA) neurotransmission during a prolonged pain induced stress response, 
reporting significant activation of DA release in dorsal and ventral regions of the 
basal ganglia. Furthermore they demonstrated positive association of activation of 
caudate nucleus and putamen DA neurotransmission with sensory and affective 
ratings of induced pain; whilst nucleus accumbens DA activation was associated
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with increased negative affect and fear ratings. The results suggest that basal 
ganglia dopamine D2 receptor-mediated neurotransmission is involved in 
responses to pain and may therefore contribute to variations between individuals 
with regards to the pain experienced.
Of note is that the experimental model of pain induction chosen in that particular 
study was infusion of hypertonic saline into the masseter muscle. It is possible 
that should the study be repeated utilising the intradermal model described in this 
thesis the results would be different. Such an approach may address some of the 
unanswered regarding the interpretation of the differences observed between 
cutaneous and muscle pain. Scott et al (2006) attribute the basal ganglia activation 
observed in the study reported above to a prolonged pain induced stress response 
however it is possible that this was in fact a specific response to prolonged muscle 
pain and the same may not be seen in cutaneous pain.
In summary it is clear that the basal ganglia have a role in pain perception, 
modulation and response. Whether the observed differences in basal ganglia 
activation described here between muscle and cutaneous pain it related to 
perceptual, modulatory or motor responses however remains unclear.
Cerebellum
The classical view that the cerebellum is only concerned with movement has been 
challenged and emerging evidence strongly suggests a role in pain. There however 
remains the challenge of separating the motor aspects from sensory and / or 
emotional response.
The output of the cerebellum originates primarily from the cerebellar nuclei (Saab 
and Willis 2003). Cerebellar regions involved in motor coordination receive 
information from the vestibular system, from the spinal cord, and from the 
sensorimotor cortex. Whilst other cerebellar regions receive information from 
frontal, parietal and occipital association areas and project back to them via the 
thalamus (Thach 1998). Projections from the ventral dentate nucleus of the 
cerebellum to the dorsal prefrontal cortex in primates has been demonstrated 
(Middleton and Strick 2001) providing evidence for the potential role of the 
cerebellum in cognitive function.
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Animal studies indicate a role in pain processing; microinjection of morphine into 
the cerebellum in rats produces profound analgesia; reversible with administration 
of naloxone (Dey and Ray 1982). Whilst in monkeys, elevation of nociceptive 
thresholds occurs following direct stimulation of the cerebellum (Siegel and 
Wepsic, 1974)
Brain imaging studies have reported activation in the vermis and ipsilateral 
cerebellar cortex during heat pain (Casey et al., 1996, Becerra et al., 1999 and 
Bingel et al., 2002). Functional interconnection of the vermis with hypothalamus, 
amygdala, and hippocampus suggests a more complex role of the cerebellum as 
part of an integrated network regulating emotional behaviour (Sacchetti et al
2005).
In addition to coordinating movement, the cerebellum participates in motor 
learning, emotional behaviour, and fear memory. The neural correlate of 
cerebellar involvement in fear learning and therefore memory consolidation is 
provided by a behaviourally induced long-term increase of synaptic efficacy 
between parallel fibers and a Purkinje cell (Sacchetti et al, 2005).
Jueptner (2001) proposes, from movement studies that the cerebellum with 
regards to motor control is specifically concerned with feedback and monitoring 
of any actual movement taking place compared to the basal ganglia which have a 
greater role in actual or planned movement.
One possible explanation for the observation of cerebellum activation during 
muscle but not cutaneous pain in the present study may lie with the referred pain 
phenomenon associated with muscle pain. Macefield et al., (2007) recently 
reported cerebellum activation during HS induced muscle pain that was associated 
with presence of referred pain; reduced or no activation was observed in the 
absence of referred pain.
In the fMRI experiment reported here no data were collected regarding pain 
referral therefore it is not possible to determine whether the cerebellar activation 
observed during muscle pain was associated with referred pain. Despite results for 
the psychophysical experiment described in chapter three indicating that referred
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pain only occurred in approximately 40% of muscle injections, it cannot be 
assumed to be the same during scanning.
Nevertheless, irrespective of referred pain, cerebellum activation observed during 
a noxious stimulus and its particular role in pain processing remains a challenge. 
Macefield and colleagues (2007) findings of cerebellum activation associated with 
referred pain is certainly interesting. The question remains as whether the 
cerebellum has a specific role in referred pain or whether the activation observed 
is related to motor intent.
6.4 Neural correlates of experimental pain in patients with lateral 
epicondylitis
Chapter five describes two fMRI experiments; the first involved three patients 
with a clinical diagnosis of lateral epicondylitis; patients were exposed, in their 
unaffected arm, to cutaneous and muscle noxious stimuli in the same manner as 
the healthy volunteers described in chapter four. The second experiment involved 
two of the three patients from the first experiment; these two patients were 
exposed to both innocuous and noxious pressure stimuli on both the affected and 
unaffected arms.
The author will discuss here the apparent differences observed in brain activation 
patterns; between healthy volunteers and patients; during presentation of an 
innocuous stimulus to the affected compared to the unaffected arm; and when 
pressure stimuli of similar intensity is presented to the affected compared to the 
unaffected arm. The discussion will consider how these apparent differences may 
be attributed to the presence in patients of an ongoing pain condition, with the 
caveat that small numbers allows for limited applicability and that a direct 
statistical comparison was not taken between health volunteer and patient data..
Methodological issues
As acknowledged previously, the main limitation with regards to the two patient 
experiments presented is in respect to the limited number of subjects tested.
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Aside from this point; issues regarding the first experiment have already been 
discussed earlier in this chapter in reference to the healthy volunteer results.
An additional potential confounding factor in both of the patient experiments is 
the presence of background pain. All three subjects however reported their clinical 
pain to be predominantly a movement evoked condition; their pain being 
relatively quiescent at rest.
Summary of findings in patient group after hypertonic saline injection
Areas of the pain matrix were activated including ACC, MI, SI, anterior and 
posterior insular cortices and cerebellum during both cutaneous and muscle pain, 
demonstrating similarity to the healthy volunteer population.
The findings of preponderance towards bilateral activation of so called ‘pain 
matrix’ areas during muscle pain compared to an ipsilateral or contralateral 
tendency in cutaneous pain in the healthy volunteers also appears to be mirrored 
in the patient sample. Basal ganglia activation was also observed in two of the 
three patients during muscle but not cutaneous pain. Again this appears to reflect 
the findings of the healthy volunteer group. Apparent differences appear to lie 
with SII and the hippocampus / amygdala complex.
The extent and peak of activation of SII during the muscle pain condition in 
patients appeared to extend more posterior to the posterior parietal cortex in 
relation to the co-ordinates of peak activation in the healthy volunteer group.
Activation in the hippocampus and amygdala in all three patients during both 
muscle and cutaneous pain was present when compared to rest on an individual 
analysis basis. This may suggest greater engagement of the hippocampal complex 
in patients as this finding was not observed in the healthy volunteer group analysis 
during either cutaneous or muscle pain. Further investigation of a larger number 
of patients would allow a direct comparison to be undertaken and therefore further 
exploration of this interesting finding.
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SII
SII is consistently activated in pain studies (Peyron 2000); its role suggested to 
relate to attention, learning and integration of nociceptive and non-nociceptive 
stimuli (Ploner et al., 1999).
A study by Ferretti et al., (2003) indicates that SII may be characterised by at least 
two neuronal populations diversely sensitive to pain; the authors demonstrating 
increasing activation in posterior but not anterior SII that showed a positive 
relationship with increasing intensity of pain. Based on their own findings and 
those from a previously published fMRI study investigating muscle pain induced 
by electrical stimulation (Niddam et al., 2002), the authors suggest parallel 
processing of distinct pain features in SII with respect to SI.
It is possible therefore that the observation of SII activation, apparently more 
posterior and more extensive in the patients, is indicative of a somatotopic shift 
within the parietal operculum. Cortical reorganisation of the motor and sensory 
homunculi in patients with Complex Regional Pain Syndrome (CRPS) (Maihofner 
et al 2004), phantom limb pain (Lotze et al. 1999) and chronic low back pain (Flor 
et al 1997) has been demonstrated. These changes have been shown not only to 
correlate with severity and chronicity of pain (Flor et al., 2001) but also to be 
reversible when pain and function improve (Maihofner et al., 2004) particularly 
after therapeutic interventions addressing sensory - motor incongruence (Flor 
2002); the mechanism of this effect however is as yet unclear. Research in this 
area has tended to focus on chronic conditions, refractory to medical intervention. 
The finding here however in the three patients, none of whom had particularly 
long standing symptoms ( 4 - 7  months), of a possible somatotopic shift would 
suggest further investigation in a larger clinical population is warranted.
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Hippocampus
The hippocampal formation does not have a single role (Schmajuk, 1984); it 
would appear to integrate a number of functions that may enable it to play a 
central role in the organisation of behaviour (Bast and Feldon, 2003), having been 
shown to be involved in episodic, declarative, spatial, and contextual learning and 
memory. Hippocampal mechanisms have also been related to the modulation of 
sensorimotor processes (Gray and McNaughton, 1983, Bland and Oddie, 2001 
and Vinogradova, 2001). It has been described as a ‘particularly vulnerable and 
sensitive region’ of the brain; expressing high levels of receptors for 
glucocorticoids or "stress" hormones (De Kloet et al., 1998). It is perhaps 
therefore unsurprising that the hippocampal complex has been reported as being 
the main area of the brain to exhibit change after repeated exposure to stressful 
stimuli which elevate glucocorticoid levels. (De Kloet et al., 1998; McEwen, 
2005).
The hippocampus has also been associated with the protective and defensive 
reactions to threatening and aversive stimuli, and hyperfunction of some 
hippocampal processes has been proposed as contributing to anxiety disorders.
It has been hypothesised that anxiety may be linked to a decrease in GABAa 
receptor-mediated inhibition in the hippocampus (Low et al., 2000); some support 
for this hypothesis comes from a rat study in which a chemically induced 
reduction in local GABAa receptor-mediated inhibition through hippocampal 
MK-801 infusion resulted in a significant increase in the animals’ startle reactivity 
(Zhang et al., 2005).
Bast and Feldon (2003) suggest that although the hippocampus processes sensory 
input in order to create memory, through contributions to spatial memory it may 
directly modulate the translation of sensory input into motor responses; the 
integration of mnemonic and sensorimotor functions perhaps serving to turn 
memory or experience into action. Indeed the anatomical substrate exists for 
integration of sensory motor function; highly processed input is received in 
projections from the sensory association cortices predominantly to the dorsal 
hippocampus (Moser and Moser, 1998).
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Early animal studies also revealed a role for the hippocampus in nociception; 
lesions in rats increase the vocalisation threshold to painful stimuli (Blanchard 
and Fial, 1968) whilst electrical stimulation of the hippocampus increases tail- 
flick latency (Prado, 1985) and lidocaine injections into the dentate gyrus produce 
analgesia (Yeung et al., 1977, McKenna and Melzack, 1992). Hyperfunction of 
some hippocampal processes, possibly due to reduced inhibitory GABA 
transmission within the hippocampus, has also been suggested to contribute 
significantly to clinical symptoms of anxiety disorders (Low et al., 2000).
The hippocampus and amygdala in addition to prefrontal cortex all show 
morphological changes as a result of stress-related disorders such as depression 
and PTSD. Animal models of repeated psychosocial and restraint stress suggests 
there are multiple mechanisms for changes in volume of brain structures; these 
include neuronal damage, glial cell loss, dendritic remodelling and reduced 
dentate gyrus granule cell number (McEwen 2005). Homyak et al., (2007) report 
slightly increased gray matter density in the ventral hippocampus in patients with 
restless leg syndrome.
Kuchinad et al., (2007), in turn report reduced gray matter density in fibromyalgia 
patients compared to healthy controls in a number of brain regions including 
cingulate, insular and medial frontal cortices and parahippocampal gyri; the 
reduction correlating with duration of symptoms.
The hippocampal complex therefore has been implicated in both stress and 
nociception. Activation during experimental pain studies however is rarely 
reported. The observation therefore of increased signal in the hippocampal 
complex in all three patients presented here during both cutaneous and muscle 
pain is of interest. Whether this represents an increase in stress experienced by 
the patients in relation to that experienced by the healthy volunteers is a question 
that cannot be answered from the results here but perhaps sets a challenge for 
future research.
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That an increase in amygdala activation was observed in the patients as opposed 
to the decrease see in the healthy volunteer group is also particularly interesting.
If, as suggested by Petrovic et al (2004), that deactivation (as seen in the healthy 
volunteers) represent a coping strategy in dealing with acute aversive situations 
the question must be asked whether the three patients has poorer coping 
strategies?
Conversely it could be argued that the presence of an ongoing pain condition 
negates the need for acute coping strategies in the presence of a pain that is less 
emotionally salient in comparison to an ongoing pain condition. Further studies to 
investigate this area would be wise to gather a wider psychometric profile of 
subjects, whether they be patients or healthy volunteers.
Brain activation patterns observed in subject C are of particular interest. Despite 
reporting low pain scores (mean peak of 3.9 and 3.1 for ID and MS respectively) 
activation was still observed in amongst others pACC, insula, SI, PFC and 
hippocampus. The findings lend further weight to the hypothesis that the presence 
of an ongoing pain syndrome enhances brain activation processing of a new 
noxious stimulus; even when that stimulus induces subjectively relatively mild 
levels of pain.
Typically, clinical imaging studies have utilised a noxious stimulus very distinct 
from the ongoing pain condition, for example heat, as the acute pain stimulus. 
Hypertonic saline was chosen here as previous reports suggest the properties of 
the resulting pain reflect those of clinical musculoskeletal pain (Arendt Nielsen et 
al., 1996). Lateral epicondylitis was also specifically chosen as the clinical 
condition of interest for this study as it was felt to represent a clinical condition of 
musculoskeletal pain that is focal and well defined; it also allowed for induction 
of pain in similar tissues on the contralateral, unaffected arm.
It is tempting to hypothesise that by selecting the mirrored site for pain induction, 
in addition to the HS model producing a more tonic pain, that brain activation 
patterns observed in the patients; in particular the hippocampal activation reflects 
an increase stress response or perhaps even evoked a memory of their own pain.
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Again both the low numbers and study design of course do not allow that 
interpretation to be made; however future studies may wish to consider this.
Summary of findings associated with noxious and innocuous pressure
During noxious pressure on both the affected and unaffected arms in two patients 
with tennis elbow, widespread brain activation was observed in areas consistent 
with previous reports of pressure pain. When stimulus intensity but not pain 
intensity was matched, greater activation was observed during stimulus 
application to the affected arm than the unaffected arm. Areas of activation 
included; SI, SII, MI, ACC, anterior and posterior insular cortices, hippocampus 
and cerebellum.
The observation of greater activation on pressure application to the affected arm 
during the intensity matched contrast is consistent with the findings of previous 
studies employing a similar technique in fibromyalgia patients (Gracely et al., 
2002) and low back pain patients (Giesecke et ah, 2004).
The findings provide further evidence that brain activation patterns observed 
during pain studies reflect the intensity of the pain experienced by the individual 
rather than the intensity of the stimulus.
The final observations relate to the widespread activation seen during application 
of innocuous pressure to the affected arm; areas which again included the 
prefrontal cortex and amygdala / hippocampal complex are of particular interest.
Medial prefrontal areas and the perigenual cingulate are both activated by 
expectancy of pain (Ploghaus et al 1999, Sawamoto et ah, 2000), whilst aversive 
conditioning studies report amygdala activation during phases where there is a 
degree of uncertainty about whether an impending stimulus will be aversive or 
neutral (Quirk et al, 1997, Buchel et al, 1998b, 1999).
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The paradigm was such that subjects were aware that they would be receiving 
various stimuli throughout the scanning period; some of which would be painful 
and some non-painfiil. Therefore a degree of expectancy / anticipation and or 
anxiety could be expected, but should in theory be no different between sides.
The results however suggest an increased fear / anxiety response during 
anticipation of an actual or potential pain is greater when the stimulus is 
anatomically located in close proximity to their ‘own’ pain.
Both patients were interviewed immediately after the end of scanning to assess 
whether a summation effect occurred during the pressure pain paradigm in either 
the affected or unaffected side; both denied any significant increase in background 
pain.
6.6 What this thesis has contributed to the body of knowledge
The work described within this thesis contributes to the body of knowledge in 
three key areas:
i. Experimental pain models -  psychophysical properties and influence of 
tissue type.
Despite frequent references in the literature to perceptual differences in pain 
arising from muscle and cutaneous tissue, direct comparisons of pain arising from 
these two tissue types have been limited and flawed.
The results of the experiment investigating psychophysical properties of deep and 
superficial pain (chapter three) have demonstrated that intradermal hypertonic 
saline is a reliable and valid method of acute pain induction. Although common in 
animal studies, there are no previous reports in the literature of a systematic 
investigation utilising hypertonic saline intradermally (as opposed to 
subcutaneously) in humans.
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It supports previous reports in the literature of perceptual differences between 
these two tissue types but adds further weight by removing the confounding effect 
of different types of stimuli.
Conversely it has also highlighted the unpredictability of a subcutaneous model; 
future studies maybe wise to target intradermal rather than subcutaneous tissue
Despite published accounts in the literature (Svensson et al., 1997a, Rainville et 
al., 1992), of muscle pain being perceived as more unpleasant than cutaneous 
pain, the results here question these previous reports. A possible explanation for 
the finding here may be that the tool used to investigate unpleasantness may not 
be sensitive enough to reveal subtle differences. Alternatively in a controlled 
environment, when the subject is aware that the pain induced is of limited 
duration, any difference in relative unpleasantness between the two tissue types is 
in fact insignificant. It is acknowledged however that as only one measure of 
unpleasantness per injection was taken, differences related to the temporal pattern 
may not have been detected.
ii. Experimental pain models -  neural correlates and influence of tissue type.
When the author embarked on this course of study, a review of the literature 
revealed few studies investigating brain activation patterns associated with muscle 
pain; even less that compared muscle and cutaneous pain.
Henderson et ah, (2006) highlighted this issue and undertook a comparison of 
hypertonic saline in muscle and cutaneous tissue; the first to do so. Whilst 
acknowledging the contribution by this group it should be noted that subcutaneous 
hypertonic saline was utilised as the cutaneous pain model. In view of the results 
reported here in chapter 3, their findings should be interpreted with caution.
The study reported in chapter four therefore is the first to undertake a direct 
comparison of brain activation patterns in superficial and deep tissue pain using 
intradermal hypertonic saline as the experimental model for superficial tissue 
pain.
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The results suggest that muscle would appear to engage more affective and 
cognitive processing than cutaneous pain; specifically in prefrontal regions and 
the basal ganglia. The finding of no difference in perceived relative 
unpleasantness however perhaps makes the interpretation of the fMRI results 
more challenging.
The findings presented reflect some but not all of the findings of Henderson and 
colleagues (2006) in relation to brain processing of muscle and cutaneous pain in 
healthy volunteers. Again, whilst acknowledging the work of Henderson’s group, 
it may be argued that the experiments here provide a greater insight into the 
differences between deep and superficial pain by (i) utilising an intradermal model 
and (ii) implementing a repeated injection model, undertaken in one scanning run, 
as opposed to single muscle and cutaneous injections.
Schweinhardt et al’s (2006) suggestion, from their review of the literature, that 
rostral anterior insula may be a key area where differences are observed between 
clinical and experimental pain are questionable based on the findings of chapter 
four. Here, rostral anterior insula activation was observed during both cutaneous 
and muscle pain. Although the activation appeared more rostral during muscle 
pain there was no difference when the co-ordinates of peak activation were 
compared. These results therefore have also served to highlight that caution 
should be observed when making comparisons between experimental and clinical 
pain; consideration must be given to the experimental model -  both in relation to 
tissue involved and the temporal characteristics of the induced pain. The over 
reliance of researchers on brief, experimental models of pain may have over sold 
differences between experimental and clinical pain.
Whilst extremely unlikely that any experimental model can completely encapture 
the nature, behaviour, or psychophysical impact of a clinical pain condition, the 
author believes that the results presented in this thesis lend support for the 
suggestion that experimental muscle pain more closely reflects a number of the 
processes involved in clinical pain processing than does experimental cutaneous 
pain.
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iii. Experimental pain models in the presence of lateral epicondylitis.
Finally, albeit in a limited number of patients, the findings of augmented 
processing in patients with a seemingly relatively benign pain condition to 
experimental pain, stimulation of clinical pain and in particular anticipation of 
clinical pain raises a number of interesting questions and directions for future 
research.
The literature review served to highlight the lack of studies that have investigated 
clinical pain populations. Those involving patient populations have focussed on 
conditions where the underlying pathophysiology is elusive or indeed where 
‘psychological factors’ are suggested to have a greater role in both severity of 
symptoms and response to therapeutic intervention. Interestingly this is also a 
point raised in a recent review (Schweinhardt and Tracey (2007); the authors 
highlighting the focus of clinical pain imaging studies on chronic pain conditions 
which are relatively ill-defined at least in terms of pathophysiology, citing 
fibromyalgia, chronic low back pain and irritable bowel syndrome as examples.
The findings presented here in this small group of patients with a relatively well 
defined clinical pain syndrome highlight the need for further investigation.
Clinical studies have tended to either investigate experimental pain distinct and 
distal from the area of clinical pain, making comparisons with the same 
experimental pain in healthy volunteers, or attempted to replicate clinical pain. 
The latter can be particularly difficult in the scanning environment. The unilateral 
nature of lateral epicondylitis allows the patient to serve as their own control and 
so comparisons between brain processing of experimental and clinical pain may 
be made. Future investigations in a larger population of patients with lateral 
epicondylitis would expand on the findings reported here.
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Implications for future research and clinical practice
Patrick Wall (2000) proposed that pain is not simply a sensation but a need state 
like hunger or thirst; as such the processing and response involves cognitive, 
affective, and sensory components. If indeed one considers pain as a need like 
state; the next question may be are the ‘needs’ of muscle and cutaneous pain 
different? The findings reported in this thesis would suggest that the brain 
certainly interprets and responds to noxious stimuli arising from these two tissues 
in a different manner.
An organism when subjected to an external stimulus is required to analyse the 
stimulus, determine and then execute an appropriate response. When considered 
from a behavioural perspective the differences observed between muscle and 
cutaneous pain reported in this thesis may well reflect the differences between 
interoceptive and exteroceptive processing, that is the consequences and response 
to an external versus an internal threat. Taken from a motor control perspective 
the difference may lie in facilitating escape from further damage / danger or 
conversely in inhibiting motor output and therefore reduce further damage and or 
promoted healing and recovery.
The work presented in this thesis has demonstrated that there are differences in 
both the psychophysical properties and brain activation patterns associated with 
muscle and cutaneous pain. Studies that investigate further the psychophysical 
properties including the temporal aspects of relative unpleasantness and other 
psychometric properties including kinesiophobia and catastrophizing would add to 
the discussion and interpretation of these results. Well thought out motor control 
studies, again utilising the two tissues would also add significantly to the debate 
about the key differences between cutaneous and muscle pain.
Significant impact on clinical care of patients with chronic pain is unlikely to be 
an immediate outcome of this research. Nevertheless, there is certainly clinical 
applicability; perhaps more so in questions that it asks rather than answers it 
provides.
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Despite there being a greater acknowledgement amongst health care professionals 
regarding psychosocial factors impacting on the symptoms and quality of life 
inpatients with pain, the management, particularly in the acute stages still tends to 
be focussed on peripheral tissues. This is especially true when considering this 
from a diagnostic point of view. Clinical diagnostics relies heavily on findings 
from physical examination - and the patient’s response to the same.
The finding therefore of widespread activation during innocuous pressure to the 
affected side in the two patients reported here would sound a note of caution. 
Furthermore, many physiotherapists regularly practice manual therapy techniques 
that involve the repeated application of light pressure -  typically non pain 
provoking. Again here the question would be asked what is the brain’s response to 
such techniques? Furthermore, despite the patient not reporting an immediate 
increase in symptoms, is there a risk that therapy maybe augmenting widespread 
brain activation and so hindering rather than helping recovery?
These are certainly questions of interest to clinicians, patients and researchers 
alike and the author would suggest valuable questions to pursue.
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Appendix A
Volunteer and Patient information sheets
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Pain Research Institute 
Dept of Neurological Science 
Clinical Sciences Centre for
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Research Fellow
Research and Education 






Title of Study: P s y c h o p h y s ic a l  p ro p e r t ie s  o f  e x p e r im e n ta l  c u ta n e o u s  a n d  m u s c le  
p a in
Researchers: M s  C a m e ro n , D r  H a rm o n , D r  T r ip a th i ,  P ro f . N u rm ik k o
You are being invited to participate in a research study. Before you decide it is important for you 
to understand why the research is being done and what it will involve. Please take time to read 
the following information carefully and discuss it with others if you wish. Take time to decide 
whether or not you wish to take part.
Consumers in Ethics in Research (CERES) publish a leaflet entitled "Medical Research and 
You". This leaflet gives you more information about medical research and addresses some 
questions you may want to ask. The leaflet may be obtained from CERES, PO BOX 1365, 
London N 16 OBW.
Thank you for reading this information sheet.
What is the purpose of this study?
This study has been designed to evaluate the differences between superficial (skin) pain and deep 
(muscle) pain. Chronic pain is a common condition which is often difficult to treat effectively.
By studying experimental pain in healthy volunteers we can learn more about the underlying 
mechanisms of pain and therefore design better treatments. You are being invited to take part in 
this project as a healthy volunteer.
Previous studies in healthy volunteers have typically used experimentally induced pain in the 
skin. Whilst these studies have helped our understanding of pain mechanisms they may not give 
a true picture when we compare it to patients with chronic pain.
We would like to compare skin pain with muscle pain as we believe muscle pain will tell us 
more about the underlying mechanisms.
How do I know if I am eligible?
We expect you to answer NO to a simple question: "Do you suffer from neck or arm pain or any 
other chronic or recurrent pain?"
If you have occasional headaches, or have suffered in the past an acute episode of neck or arm 
pain lasting less than 7 days in the past (but not in the last 6 months) you are eligible.
What will happen to me if I take part?
If you agree we will ask you to come to the Pain Research Institute, Clinical Sciences Centre, 
University Hospital Aintree on two occasions at weekly intervals. We will first ask you some 
general questions about your health and well-being. After that we will ask you to complete the 
following:
1. Three small needles will be inserted into your forearm - one into a muscle and two just in the 
skin. Before inserting the needle into your muscle you will first have a local anaesthetic cream 
placed on your skin for 30 minutes to numb the area.
2. You will then receive two infusions of a small amount (0.2 ml) of saline through each needle. 
Hypertonic saline although not harmful causes a short lasting pain when injected into muscle or 
skin. Each injection produces a moderate degree of pain which lasts 3 -4  minutes.
3. Whilst the pain is present we will
i. ask you to tell us about the pain in terms of intensity and unpleasantness and 
where you feel the sensation. We will also ask you to fill in a brief questionnaire 
to describe the quality of the pain.
ii. test the sensitivity of your skin in the area surrounding the needle by lightly 
brushing across it a few times.
Hi. Assess the affect of the pain on the blood flow around your needle using a 
machine called a laser Doppler. This in itself is not painful.
What do I have to do next?
If you are interested in taking part you should contact Heather Cameron (details on back page) 
who will answer any questions you may have. If you then decide to take part an appointment will 
be made for you to come to the Pain Research Institute.
What are the possible disadvantages and risks of taking part?
We do not expect any major side effects. However whenever a needle is inserted into muscle or 
skin there is a small risk of bleeding which may cause some discomfort / bruising that can persist 
for a few days. There is also a very small risk that you could develop an infection where the 
needle was inserted. Using a small disposable needle, inserted using an aseptic technique reduces 
this risk.
What are the possible benefits of taking part?
There is no direct benefit to you. By carrying out this type of research we hope to find new ways 
of treating patients with chronic pain.
What if something goes wrong?
This study is being undertaken by staff of The University of Liverpool. In the unlikely event that 
your participation will result in disease, illness or bodily injury, you may be entitled to 
compensation, under the indemnity arrangements that have been agreed between the University 
of Liverpool and Royal & SunAlliance Insurance Company. The copy of these arrangements will 
be provided on request
If you are during the course of this study harmed due to someone's negligence, then you may 
have grounds for legal action but you may have to pay for it.
Will my taking part in this study be kept confidential?
All information that is collected about you during the course of the research will be kept strictly 
confidential. Any information about you which leaves the university will have your name and 
address removed so that you cannot be recognised from it. We will not routinely inform you GP 
of your participation, but will be happy to do so if you so wish.
What will happen to the results of the study?
We will test several healthy volunteers. All the results will be compiled and evaluated on a group 
rather than individual basis. We expect to publish these results in international scientific journals 
that focus on pain.
Contact for Further Information
Heather Cameron, Research Fellow, Pain Research Institute, University of Liverpool, Clinical 
Sciences Centre, Lower Lane, Liverpool L9 7AL tel 0151 529 5822
Prof. T J Nurmikko, Honorary Consultant in Pain Relief, Pain Research Institute, University of 
Liverpool Clinical Sciences Centre, Lower Lane, Liverpool L9 7AL, tel 0151 529 5820
Thank you for your time
T H E  U N I V E R S I T Y  
o f  L I V E R P O O L
The Walton Centre
for Neurology and Neurosurgery
NHS Trust
Pain Research Institute 
Dept of Neurological Science 
Clinical Sciences Centre for 
Research and Education 
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Title of Study: F u n c tio n a l M R I  o f  th e  b ra in  in  c h ro n ic  te n n is  e lb o w  p a in  
Researchers: M s  C a m e ro n , P ro f . R o b e r ts ,  D r  Z a m a n , P ro f . N u rm ik k o
You are being invited to participate in a research study. Before you decide it is important for you 
to understand why the research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with others if you wish. Take time to decide whether 
or not you wish to take part.
Consumers in Ethics in Research (CERES) publish a leaflet entitled "Medical Research and You". 
This leaflet gives you more information about medical research and addresses some questions you 
may want to ask. The leaflet may be obtained from CERES, PO BOX 1365, London N16 OBW.
Thank you for reading this information sheet.
What is the purpose of this study?
This study has been designed to evaluate how the human brain handles painful information. We 
plan to carry out brain imaging in patients with chronic elbow pain. We use functional MRI, which 
is capable of detecting the shape and size of active brain structures. You are being invited to this 
project as a healthy volunteer.
Previous scans of healthy volunteers have found that some areas of the brain light up when a 
painful stimulus is applied however this brain activity changes a little depending upon the type of 
painful stimulus. We would like to compare these phenomena in patients with clinical pain and in 
healthy volunteers with experimentally induced pain.
How do I know if I am eligible?
We expect you to answer NO to a simple question: "Do you suffer from neck or arm pain or any 
other chronic or recurrent pain?" If you have occasional headaches, or have suffered in the past an 
acute episode of neck or arm pain lasting less than 7 days in the past (but not in the last 6 months) 
you are eligible.
What will happen to me if I take part?
If you agree we will ask you to come to the Magnetic Resonance Imaging and Analysis Centre 
(MARIARC). We will first ask you some general questions about your health and well-being.
After that we will ask you to complete a set of tasks. These will be similar to the ones you will be 
subjected to later, while you are being scanned. The tasks include the following:
1. First having four plastic cannulae inserted via a needle into your forearm -  two into a muscle 
and two into your skin. You will then receive an infusion of hypertonic saline.
Hypertonic saline although not harmful can cause a short lasting pain when injected into a muscle 
or skin. The aim is to produce moderate rather than intense pain. The pain is expected to last less 
than two minutes but will be repeated up to two times in each cannula. During the scan we will ask 
you to rate your pain on an electronic scale.
2. Lifting your hand against a resistance. You will be asked to do this task with both hands but one 
at a time. The aim again is to rekindle a moderate pain in the arm we previously injected lasting 
only 15 seconds. It is unlikely that this task will produce any pain in the arm that was not injected.
3. Having your hands moved passively by one of the investigators. This may cause mild 
discomfort.
You will be wearing earplugs while in the scanner to protect your hearing - the MRI scanner 
makes quite a bit of noise!
These tasks will be repeated while you are in the scanner. Each stimulus will be given to you at set 
intervals.
What do I have to do?
We will inform you when to come for the scan. You will first have to be checked by one of our 
nurses that you have no contra-indications to having the scan.
What are the possible disadvantages and risks of taking part?
We do not expect any major side effects. However whenever a needle is inserted into a muscle or 
skin there is a small risk of bleeding which may cause some discomfort / bruising that can persist 
for a few days. There is also a very small risk that you could develop an infection where the needle 
was inserted. Using a small disposable needle, inserted using an aseptic technique reduces this 
risk.
We are not aware of any real risks associated with scanning. There is a very remote possibility that 
the scan will reveal an abnormality of the brain, which has not given any symptoms. In such an 
unlikely event, we feel it is our obligation to inform you. If you cannot agree to this before the 
scan, we will not enter you into the study. (As already mentioned, your treatment will remain the 
same irrespective of whether or not you participate in this study).
We ask you to wear earplugs in order to protect you ears from the noise of the scanner. Whilst 
there is no real risk of hearing loss, you may experience temporary impairment of hearing after the 
scan.
What are the possible benefits of taking part?
There is no direct benefit to you. By carrying out this type of research we hope to find new ways 
of treating patients with chronic pain.
What if something goes wrong?
This study is a joint project of The University of Liverpool and The Walton Centre for Neurology 
and Neurosurgery NHS Trust. In the unlikely event that your participation will result in disease, 
illness or bodily injury, you may be entitled to compensation, under the indemnity arrangements 
that have been agreed between the University of Liverpool and Royal & SunAlliance Insurance 
Company. The copy of these arrangements will be provided on request.
The NHS does not have similar compensation arrangements. However, if you are during the 
course of this study harmed due to someone's negligence, then you may have grounds for legal 
action but you may have to pay for it. Regardless of this, if you wish to complain about any aspect 
of the way you have been approached or treated during the course of this research, the National 
Health Service complaints mechanism may be available to you.
Will my taking part in this study be kept confidential?
All information that is collected about you during the course of the research will be kept strictly 
confidential. Any information about you which leaves the hospital will have your name and 
address removed so that you cannot be recognised from it. We will not routinely inform you GP of 
your participation, but will be happy to do so if you so wish.
What will happen to the results of the study?
We will scan several people with elbow pain, as well as some healthy volunteers. All the results 
will be compiled and evaluated on a group rather than individual basis. We expect to publish these 
results in international scientific journals that focus on pain and brain imaging.
Contact for Further Information
Heather Cameron, Research Fellow, Pain Research Institute, Clinical Sciences Centre, Lower Lane, 
Liverpool L9 7AL. Tel 0151 529 5822
Prof. T J Nurmikko, Honorary Consultant in Pain Relief, Pain Research Institute, Clinical Sciences 
Centre, Lower Lane, Liverpool L9 7AL, tel 0151 529 5820
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PATIENT INFORMATION SHEET
Title of Study: F u n c t io n a l  M R I  o f  th e  b r a in  in  c h r o n ic  te n n is  e lb o w  p a in  
Researchers: M s  C a m e r o n ,  P ro f . R o b e r ts ,  D r . Z a m a n ,  P ro f .  N u r m ik k o .
You are being invited to participate in a research study. Before you decide it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the following 
information carefully and discuss it with your friends, relatives and your GP if you wish. Take time to decide 
whether or not you wish to take part.
Consumers in Ethics in Research (CERES) publish a leaflet entitled "Medical Research and You". This 
leaflet gives you more information about medical research and addresses some questions you may want to 
ask. The leaflet may be obtained from CERES, PO BOX 1365, London N16 OBW.
Thank you for reading this information sheet.
What is the purpose of this study?
This study has been designed to evaluate how the human brain handles painful information. We plan to carry 
out brain imaging in patients with chronic tennis elbow pain. We use functional MRI, which is capable of 
detecting the shape and size of active brain structures. We hope to perform this scan in two groups of people: 
healthy volunteers and those like yourself suffering from pain due to tennis elbow.
Why have I been chosen?
You have chronic elbow pain which is one of our clinical and research interests. We wish to explore the 
reactions of the brain in this condition in the hope that it would yield new insight into this very common 
problem.
Do I have to take part?
It is up to you whether or not to take part. If you do decide to take part you will be asked to sign a consent 
form. If you decide to take part you are still free to withdraw at any time and without giving a reason. This 
will not affect the standard of care you receive.
What will happen to me if I take part?
If you agree we will ask you to come to the Magnetic Resonance Imaging and Analysis Centre (MARIARC) 
on two separate days approximately one week apart. We will first ask you some general questions about 
your health and well-being. After that we will ask you to complete a set of tasks. These will be similar to the 
ones you will be subjected to later, while you are being scanned. On the first visit you will:
Have four plastic cannulae inserted via a needle into your forearm (the arm which does not have tennis 
elbow) -  two into a muscle and two into your skin. You will then receive an injection of hypertonic saline. 
Hypertonic saline although not harmful can cause a short lasting pain when injected into a muscle or skin. 
The aim is to produce moderate rather than intense pain. The pain is expected to last less than two minutes 
but will be repeated up to two times in each cannula whilst you are scanned. During the scan we will ask you 
to rate your pain on an electronic scale.
On you second visit we will repeat the procedure carried out on your first visit and also ask you to carry out 
the following task during scanning:
1. Lifting your hand against a resistance. You will be asked to do this task with both hands but one at a time. 
The aim again is to rekindle a moderate pain in the arm we previously injected lasting only 30 seconds. It is 
unlikely that this task will produce any pain in the arm that was not injected.
2. Having your hands moved passively by one of the investigators. This may cause mild discomfort.
3. Receiving a painful pressure stimulus applied to your forearm muscle of both your left and right arm.
Each stimulus will last 15 seconds, and will be repeated 10 times. The aim is to produce moderate rather 
than intense pain.
You will be wearing earplugs while in the scanner to protect your hearing - the MRI scanner makes quite a 
bit of noise!
These tasks will be repeated while you are in the scanner. Each stimulus will be given to you at set intervals. 
Prior to each set you will be told which stimulus to expect.
What do I have to do now?
You will have to do nothing. We will inform you when to come to the Pain Research Institute. After you 
have completed the first set of tasks we will take you to the Scanner Room and carry out the brain scan.
What are the possible disadvantages and risks of taking part?
There is a potential risk, whenever a needle is inserted into a muscle or skin of bleeding which may lead to 
some discomfort / bruising that can persist for a few days. There is also a very small risk that you could 
develop an infection where the needle was inserted. Using a small disposable needle, inserted using an 
aseptic technique reduces this risk.
We are not aware of any real risks associated with scanning. There is a very remote possibility that the scan 
will reveal an abnormality of the brain, which has not given any symptoms. In such an unlikely event, we
feel it is our obligation to inform you. If you cannot agree to this before the scan, we will not enter you into 
the study. (As already mentioned, your treatment will remain the same irrespective of whether or not you 
participate in this study).
We ask you to wear earplugs in order to protect you ears from the noise of the scanner. Whilst there is no 
real risk of hearing loss, you may experience temporary impairment of hearing after the scan.
What are the possible benefits of taking part?
There is no direct benefit to you. By carrying out this type of research we hope to find new ways of treating 
patients with chronic tennis elbow pain and similar conditions.
What if something goes wrong?
This study is a joint project of The University of Liverpool and The Walton Centre for Neurology and 
Neurosurgery NHS Trust. In the unlikely event that your participation will result in disease, illness or bodily 
injury, you may be entitled to compensation, under the indemnity arrangements that have been agreed 
between the University of Liverpool and Royal & SunAlliance Insurance Company. The copy of these 
arrangements will be provided at request.
The NHS does not have similar compensation arrangements. However, if you are during the course of this 
study harmed due to someone's negligence, then you may have grounds for legal action but you may have to 
pay for it. Regardless of this, if you wish to complain about any aspect of the way you have been approached 
or treated during the course of this research, the National Health Service complaints mechanism may be 
available to you.
Will my taking part in this study be kept confidential?
All information that is collected about you during the course of the research will be kept strictly confidential. 
Any information about you which leaves the hospital will have your name and address removed so that you 
cannot be recognised from it. Unless you disagree, your GP will be informed of your participation and will 
receive information about the nature and purpose of the study.
What will happen to the results of the study?
We will scan several people with similar types of elbow pain, as well as some healthy volunteers. All the 
results will be compiled and evaluated on a group basis rather than individually. We expect to publish these 
results in international scientific journals that focus on pain and brain imaging.
Contact for Further Information
Heather Cameron, Research Fellow, Pain Research Institute, Clinical Sciences Centre, Lower Lane, 
Liverpool L9 7AL, tel 0151 529 5822
Prof. T J Nurmikko, Honorary Consultant in Pain Relief, Pain Research Institute, Clinical Sciences Centre, 
Lower Lane, Liverpool L9 7AL,
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Appendix B
SPSS output from chapter 3
General Linear Model






Mean Std. Deviation N1 1 int_1 int_1 5.5938 2.09936 16
2 int_2 int_2 5.0563 2.37458 16
3 int_3 int_3 5.6375 1.83589 16
4 int_4 int_4 5.7000 1.78885 16
2 1 sub_1 sub_1 4.6563 2.27302 16
2 sub_2 sub_2 2.3875 1.74198 16
3 sub_3 sub_3 5.2938 1.80683 16
4 sub_4 sub_4 4.1688 2.46271 16
3 1 mus_1 mus_1 5.2500 1.83303 16
2 mus_2 mus_2 4.5563 1.87402 16
3 mus_3 mus_3 5.5625 2.15310 16
4 mus_4 mus_4 4.5938 2.04335 16
Multivariate Test#
Effect Value F Hypothesis df Error df Sia.
Partial Eta
injection Pillai's Trace .687 15.391a 2.000 14.000 .000 .687
Wilks' Lambda .313 15.391® 2.000 14.000 .000 .687
Hotelling's Trace 2.199 15.391® 2.000 14.000 .000 .687
Roy's Largest Root 2.199 15.391® 2.000 14.000 .000 .687
time Pillai's Trace .628 7.322® 3.000 13.000 .004 .628
Wilks' Lambda .372 7.322® 3.000 13.000 .004 .628
Hotelling's Trace 1.690 7.322® 3.000 13.000 .004 .628
Roy's Largest Root 1.690 7.322® 3.000 13.000 .004 .628injection * time Pillai’s Trace .647 3.050® 6.000 10.000 .058 .647
Wilks' Lambda .353 3.050® 6.000 10.000 .058 .647
Hotelling's Trace 1.830 3.050® 6.000 10.000 .058 647
Roy's Largest Root 1.830 3.050® 6.000 10.000 .058 .647
b.
Design: Intercept
Within Subjects Design: injection+time+injection*time
Mauchly's Test of Sphericity
Measure: intensity






injection .929 1.026 2 .599 .934 1.000 .500
time .592 7.203 5 .207 .737 .871 .333
Injection * time .072 33.600 20 .033 .619 .849 .167
Tests the null hypothesis that the error covariance matrix of the orthonormallzed transformed dependent variables Is 
proportional to an identity matrix.
a- May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed In 
the Tests of Within-Subjects Effects table, 
b.
Design: Intercept
Within Subjects Design: lnjectlon+time+injection*tlme
Tests of Within-Subjects Effects
Measure: intensity
Source
Type III Sum 
of Squares df Mean Square F SIg.
Partial Eta 
Squaredinjection Sphericity Assumed 61.454 2 30.727 13.201 .000 .468
Greenhouse-Geisser 61.454 1.868 32.898 13.201 .000 .468
Huynh-Feldt 61.454 2.000 30.727 13.201 .000 .468
Lower-bound 61.454 1.000 61.454 13.201 .002 .468
Error(injectlon) Sphericity Assumed 69.829 30 2.328
Greenhouse-Geisser 69.829 28.021 2.492
Huynh-Feldt 69.829 30.000 2.328
Lower-bound 69.829 15.000 4.655
time Sphericity Assumed 59.597 3 19.866 7.967 .000 .347
Greenhouse-Geisser 59.597 2.212 26.938 7.967 .001 .347
Huynh-Feldt 59.597 2.612 22.819 7.967 .000 .347
Lower-bound 59.597 1.000 59.597 7.967 .013 .347
Error(time) Sphericity Assumed 112.202 45 2.493
Greenhouse-Geisser 112.202 33.186 3.381
Huynh-Feldt 112.202 39.176 2.864
Lower-bound 112.202 15.000 7.480
Injection * time Sphericity Assumed 31.189 6 5.198 2.415 .033 .139
Greenhouse-Geisser 31.189 3.716 8.394 2.415 .064 .139
Huynh-Feldt 31.189 5.091 6.126 2.415 .043 .139
Lower-bound 31.189 1.000 31.189 2.415 .141 .139
Error(injection*time) Sphericity Assumed 193.715 90 2.152
Greenhouse-Geisser 193.715 55.735 3.476
Huynh-Feldt 193.715 76.367 2.537
Lower-bound 193.715 15.000 12.914
Tests o f W ith in -S ubjects  C ontrasts
Measure: intensity
Source injection time
Type III Sum 
o f Squares df Mean Square F Siq.
Partial Eta
injection Linear 8.201 1 8.201 3.617 .077 .194
Quadratic 53.253 1 53.253 22.301 .000 .598
Error(injection) Linear 34.011 15 2.267
Quadratic 35.818 15 2.388
time Linear .509 1 .509 .138 .716 .009
Quadratic 2.876 1 2.876 2.285 .151 .132
Cubic 56.212 1 56.212 22.207 .000 .597
Error(time) Linear 55.349 15 3.690
Quadratic 18.885 15 1.259
Cubic 37.969 15 2.531
injection * time Linear Linear 1.388 1 1.388 .314 .583 .021
Quadratic 1.531 1 1.531 2.269 .153 .131
Cubic 1.661 1 1.661 1.136 .303 .070
Quadratic Linear 1.160 1 1.160 .444 .516 .029
Quadratic 2.568 1 2.568 1.325 .268 .081
Cubic 22.881 1 22.881 12.642 .003 .457
Error(injection*time) Linear Linear 66.205 15 4.414
Quadratic 10.121 15 .675
Cubic 21.932 15 1.462
Quadratic Linear 39.241 15 2.616
Quadratic 29.067 15 1.938
Cubic 27.149 15 1.810




Type III Sum 
of Squares df Mean Square F Siq.
Partial Eta 
SquaredIntercept 4556.178 1 4556.178 183.862 .000 .925
Error 371.707 15 24.780




injection Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound1 5.497 .383 4.681 6.312
2 4.127 .411 3.251 5.002
3 4.991 .381 4.179 5.802
Pairwise Comparisons
Measure: intensity
(1) injection (J) injection
Mean
Difference
(l-J) Std. Error Sig.a
95% Confidence Interval for 
Difference3
Lower Bound Upper Bound
1 2 1.370* .239 .000 .727 2.014
3 .506 .266 .230 -.211 1.223
2 1 -1.370* .239 .000 -2.014 -.727
3 -.864* .301 .035 -1.674 -.054
3 1 -.506 .266 .230 -1.223 .211
2 .864* .301 .035 .054 1.674
Based on estimated marginal means
*• The mean difference is significant at the .05 level.
a- Adjustment for multiple comparisons: Bonferroni.
M ultivariate Tests
Value F Hypothesis df Error df Sig.
Partial Eta 
SguaredPillai's trace .687 15.391a 2.000 14.000 .000 .687
Wilks' lambda .313 15.391a 2.000 14.000 .000 .687
Hotelling's trace 2.199 15.391a 2.000 14.000 .000 .687
Roy's largest root 2.199 15.391a 2.000 14.000 .000 .687
Each F tests the multivariate effect of injection. These tests are based on the linearly independent 
pairwise comparisons among the estimated marginal means.
a- Exact statistic
3. injection * time
Measure: intensity
injection time Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 1 5.594 .525 4.475 6.712
2 5.056 .594 3.791 6.322
3 5.638 .459 4.659 6.616
4 5.700 .447 4.747 6.653
2 1 4.656 .568 3.445 5.867
2 2.388 .435 1.459 3.316
3 5.294 .452 4.331 6.257
4 4.169 .616 2.856 5.481
3 1 5.250 .458 4.273 6.227
2 4.556 .469 3.558 5.555
3 5.563 .538 4.415 6.710
4 4.594 .511 3.505 5.683
Profile Plots
Estimated Marginal Means of intensity
time 
—  1


































Mean Std. Deviation N
unp_int_1 4.7500 2.54296 16
unp_int_2 4.0000 2.75681 16
unp_int_3 5.2500 2.01660 16
unp_int_4 4.6875 1.95683 16
unp_sub_1 3.6875 2.08866 16
unp_sub_2 1.8125 2.07264 16
unp_sub_3 5.0625 2.32289 16
unp_sub_4 3.4375 1.93111 16
unp_mus_1 4.6250 2.21736 16
unp_mus_2 3.1875 2.19754 16
unp_mus_3 5.3750 1.99583 16
unpl_mus_4 3.1875 2.04022 16
Multivariate T e s ti1
Effect Value F Hypothesis df Error df Siq.
Partial Eta 
Squaredinjection Pillai's Trace .507 7.212s 2.000 14.000 .007 .507
Wilks’ Lambda .493 7.212s 2.000 14.000 .007 .507
Hotelling's Trace 1.030 7.212s 2.000 14.000 .007 .507
Roy's Largest Root 1.030 7.212s 2.000 14.000 .007 .507
time Pillai's Trace .722 11.245s 3.000 13.000 .001 .722
Wilks' Lambda .278 11.245s 3.000 13.000 .001 .722
Hotelling's Trace 2.595 11.245s 3.000 13.000 .001 .722
Roy's Largest Root 2.595 11.245s 3.000 13.000 .001 .722injection * time Pillai's Trace .438 1.298s 6.000 10.000 .341 .438
Wilks' Lambda .562 1,298s 6.000 10.000 .341 .438
Hotelling's Trace .779 1.298s 6.000 10.000 .341 .438
Roy's Largest Root .779 1.298s 6.000 10.000 .341 .438
b.
Design: Intercept
Within Subjects Design: injection+time+injection*time
Mauchly's Test of Sphericity
Measure: unpleasantness





Huynh-Feldtinjection .925 1.091 2 .579 .930 1.000 .500
time .645 6.011 5 .306 .774 .924 .333
injection * time .186 21.521 20 .382 .612 .835 .167
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables Is 
proportional to an Identity matrix.
a- May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in 
the Tests of Within-Subjects Effects table, 
b.
Design: Intercept
Within Subjects Design: injection+time+injection*time
Tests of Within-Subjects Effects
Measure unpleasantness
Source
Type III Sum 
of Squares df Mean Square F Siq.
Partial Eta 
Squaredinjection Sphericity Assumed 43.948 2 21.974 5.648 .008 .274
Greenhouse-Geisser 43.948 1.860 23.622 5.648 .010 .274
Huynh-Feldt 43.948 2.000 21.974 5.648 .008 .274
Lower-bound 43.948 1.000 43.948 5.648 .031 .274
Error(injection) Sphericity Assumed 116.719 30 3.891
Greenhouse-Geisser 116.719 27.907 4.182
Huynh-Feldt 116.719 30.000 3.891
Lower-bound 116.719 15.000 7.781
time Sphericity Assumed 127.557 3 42.519 12.276 .000 .450
Greenhouse-Geisser 127.557 2.322 54.923 12.276 .000 .450
Huynh-Feldt 127.557 2.773 45.994 12.276 .000 .450
Lower-bound 127.557 1.000 127.557 12.276 .003 .450
Error(time) Sphericity Assumed 155.859 45 3.464
Greenhouse-Geisser 155.859 34.837 4.474
Huynh-Feldt 155.859 41.601 3.747
Lower-bound 155.859 15.000 10.391
injection time Sphericity Assumed 27.427 6 4.571 1.759 .117 .105
Greenhouse-Geisser 27.427 3.672 7.469 1.759 .155 .105
Huynh-Feldt 27.427 5.011 5.474 1.759 .132 .105
Lower-bound 27.427 1.000 27.427 1.759 .205 .105
Error(lnjectlon*tlme) Sphericity Assumed 233.906 90 2.599
Greenhouse-Geisser 233.906 55.085 4.246
Huynh-Feldt 233.906 75.158 3.112
Lower-bound 233.906 15.000 15.594
Tests of With In-Subjects Contrasts
Measure: unpleasantness
Source injection time
Type III Sum 
of Squares df F Siq.
Partial Eta
injection Linear 10.695 1 10.695 2.302 .150 .133
Quadratic 33.253 1 33.253 10.604 .005 .414
Error(injection) Linear 69.680 15 4.645
Quadratic 47.039 15 3.136
time Linear .551 1 .551 .118 .736 .008
Quadratic .130 1 .130 .066 .800 .004
Cubic 126.876 1 126.876 33.680 .000 .692
Error(time) Linear 69.899 15 4.660
Quadratic 29.453 15 1.964
Cubic 56.507 15 3.767
injection * time Linear Linear 4.064 1 4.064 .671 .426 .043
Quadratic 1.758 1 1.758 1.220 .287 .075
Cubic 7.014 1 7.014 3.658 .075 .196
Quadratic Linear 4.901 1 4.901 2.408 .142 .138
Quadratic .753 1 .753 .480 .499 .031
Cubic 8.938 1 8.938 3.478 .082 .188
Error(injection’ time) Linear Linear 90.911 15 6.061
Quadratic 21.617 15 1.441
Cubic 28.761 15 1.917
Quadratic Linear 30.524 15 2.035
Quadratic 23.539 15 1.569
Cubic 38.554 I 15 2.570




Type III Sum 
of Squares df Mean Square F Siq.
Partial Eta 
SquaredIntercept 3209.505 1 3209.505 134.447 .000 .900
Error 358.078 15 23.872




injection Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 4.672 .445 3.723 5.621
2 3.500 .359 2.734 4.266
3 4.094 .409 3.222 4.965
Pairwise Comparisons
Measure: unpleasantness
(1) injection (J) injection
Mean
Difference
(W> Std. Error Sig.a
95% Confidence Interval for 
Difference3
Lower Bound Upper Bound
1 2 1.172* .299 .004 .366 1.977
3 .578 .381 .450 -.448 1.604
2 1 -1.172* .299 .004 -1.977 -.366
3 -.594 .361 .362 -1.566 .378
3 1 -.578 .381 .450 -1.604 .448
2 .594 .361 .362 -.378 1.566
Based on estimated marginal means
• The mean difference is significant at the .05 level. 
a - Adjustment for multiple comparisons: Bonferroni.
Multivariate Tests
Value F Hypothesis df Error df Sig.
Partial Eta 
SquaredPillai's trace .507 7.212a 2.000 14.000 .007 .507
Wilks' lambda .493 7.212a 2.000 14.000 .007 .507
Hotelling's trace 1.030 7.212a 2.000 14.000 .007 .507
Roy's largest root 1.030 7.212a 2.000 14.000 .007 .507
Each F tests the multivariate effect of injection. These tests are based on the linearly independent 
pairwise comparisons among the estimated marginal means.
a- Exact statistic
2. time
3. in jection * tim e
Measure: unpleasantness
injection time Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 1 4.750 .636 3.395 6.105
2 4.000 .689 2.531 5.469
3 5.250 .504 4.175 6.325
4 4.688 .489 3.645 5.730
2 1 3.688 .522 2.575 4.800
2 1.813 .518 .708 2.917
3 5.063 .581 3.825 6.300
4 3.438 .483 2.408 4.467
3 1 4.625 .554 3.443 5.807
2 3.188 .549 2.017 4.358
3 5.375 .499 4.311 6.439
4 3.188 .510 2.100 4.275
Profile Plots











D escriptive S tatistics
Mean Std. Deviation N
1 1 Tinti T_int1 36.7500 13.34416 16
2 T_int2 T_int2 27.9375 12.70941 16
3 T_int3 T_int3 35.1875 15.50148 16
4 T_int4 T_int4 27.0625 13.61112 16
2 1 T_sub1 T_sub1 42.8750 11.27165 16
2 T_sub2 T_sub2 36.0000 13.42138 16
3 T_sub3 T_sub3 44.5000 12.73316 16
4 T_sub4 T_sub4 37.1875 17.15505 16
3 1 T_mus1 T_mus1 46.8750 13.84136 16
2 T_mus2 T_mus2 47.0000 16.00833 16
3 T_mus3 T_mus3 43.6875 10.93446 16
4 T_mus4 T_mus4 42.6875 14.50388 16
Multivariate Test#
Effect Value F Hypothesis df Error df Sig.
Partial Eta 
Squaredinjection Pillai’s Trace .577 9.532a 2.000 14.000 .002 .577
Wilks' Lambda .423 9.532“ 2.000 14.000 .002 .577
Hotelling's Trace 1.362 9.532“ 2.000 14.000 .002 .577
Roy's Largest Root 1.362 9.532“ 2.000 14.000 .002 .577
time Pillai's Trace .241 1.374“ 3.000 13.000 .295 .241
Wilks' Lambda .759 1.374“ 3.000 13.000 .295 .241
Hotelling's Trace .317 1.374" 3.000 13.000 .295 .241
Roy's Largest Root .317 1.374“ 3.000 13.000 .295 .241injection * time Pillai's Trace .324 .799“ 6.000 10.000 .592 .324
Wilks' Lambda .676 .799“ 6.000 10.000 .592 .324
Hotelling's Trace .479 .799“ 6.000 10.000 .592 .324
Roy's Largest Root .479 .799“ 6.000 10.000 .592 .324
b.
Design: Intercept
Within Subjects Design: injection+time+injection*time
Mauchly's Test of Sphericity
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the Tests of Within-Subjects Effects table.
Design: Intercept
Within Subjects Design: injection+time+injection*time
Tests of Within-Subjects Effects
Measure: timetopeakvas
Source
Type III Sum 
of Squares df Mean Square F
Partial Eta
5813.948 2 2906.974 13.851 .000 4ftn
Greenhouse-Geisser 5813.948 1.775 3276.231 13.851 .000 .480
Huynh-Feldt 5813.948 1.996 2913.305 13.851 .000 .480
Lower-bound 5813.948 1.000 5813.948 13.851 .002 .480Error(injection) Sphericity Assumed 6296.052 30 209.868
Greenhouse-Geisser 6296.052 26.619 236.527
Huynh-Feldt 6296.052 29.935 210.325
Lower-bound 6296.052 15.000 419.737
t'me Sphericity Assumed 1434.042 3 478.014 2.071 .117 121
Greenhouse-Geisser 1434.042 2.676 535.812 2.071 .125 .121
Huynh-Feldt 1434.042 3.000 478.014 2.071 .117 .121
Lower-bound 1434.042 1.000 1434.042 2.071 .171 .121Error(time) Sphericity Assumed 10387.792 45 230.840
Greenhouse-Geisser 10387.792 40.146 258.752
Huynh-Feldt 10387.792 45.000 230.840
Lower-bound 10387.792 15.000 692.519
injection * time Sphericity Assumed 809.802 6 134.967 .997 .432 062
Greenhouse-Geisser 809.802 4.276 189.390 .997 .419 .062Huynh-Feldt 809.802 6.000 134.967 .997 .432 062
Lower-bound 809.802 1.000 809.802 .997 .334 062Error(injection time) Sphericity Assumed 12182.865 90 135.365
Greenhouse-Geisser 12182.865 64.138 189.948
Huynh-Feldt 12182.865 90.000 135.365
Lower-bound 12182.865 15.000 812.191
Tests o f Within-Subjects Contrasts
Measure: timetopeakvas
Source injection time
Type III Sum 
of Squares df F Sig.
Partial Eta I
injection Linear 5684.445 1 5684.445 20.177 .000 .574
Quadratic 129.503 1 129.503 .938 .348 .059
Error(injection) Linear 4225.930 15 281.729
Quadratic 2070.122 15 138.008
time Linear 570.417 1 570.417 2.901 .109 .162
Quadratic 1.021 1 1.021 .005 .947 .000
Cubic 862.604 1 862.604 3.183 .095 .175Error(time) Linear 2949.683 15 196.646
Quadratic 3373.479 15 224.899
Cubic 4064.629 15 270.975
injection * time Linear Linear 14.102 1 14.102 .160 .695 .011
Quadratic 6.570 1 6.570 .052 .823 .003
Cubic 553.164 1 553.164 3.397 .085 .185
Quadratic Linear 56.376 1 56.376 .260 .617 .017
Quadratic .128 1 .128 .002 .961 .000
Cubic 179.463 1 179.463 1.080 .315 .067
Error(injection*time) Linear Linear 1321.773 15 88.118
Quadratic 1901.805 15 126.787
Cubic 2442.711 15 162.847
Quadratic Linear 3251.549 15 216.770
Quadratic 772.497 15 51.500
Cubic 2492.529 15 166.169




Type III Sum 
of Squares df Mean Square F Sig.
Partial Eta 
SquaredIntercept 291720.083 1 291720.083 763.476 .000 .981
Error 5731.417 15 382.094




injection Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 31.734 2.019 27.431 36.038
2 40.141 2.023 35.828 44.453
3 45.063 2.087 40.613 49.512
Pairw ise Com parisons
Measure: timetopeakvas
(1) injection (J) injection
Mean
Difference
c-J) Std. Error Sig.a
95% Confidence Interval for 
Difference3
Lower Bound Upper Bound
1 2 -8.406* 2.449 .011 -15.003 -1.809
3 -13.328* 2.967 .001 -21.321 -5.335
2 1 8.406* 2.449 .011 1.809 15.003
3 -4.922 2.208 .124 -10.869 1.025
3 1 13.328* 2.967 .001 5.335 21.321
2 4.922 2.208 .124 -1.025 10.869
Based on estimated marginal means
*• The mean difference is significant at the .05 level. 
a- Adjustment for multiple comparisons: Bonferroni.
M ultivariate Tests
Value F Hypothesis df Error df Sig.
Partial Eta 
SquaredPillai's trace .577 9.532a 2.000 14.000 .002 .577
Wilks' lambda .423 9.532a 2.000 14.000 .002 .577
Hotelling's trace 1.362 9.532a 2.000 14.000 .002 .577
Roy's largest root 1.362 9.532a 2.000 14.000 .002 .577
Each F tests the multivariate effect of injection. These tests are based on the linearly independent 
pairwise comparisons among the estimated marginal means.
a- Exact statistic
2. time
3. injection * tim e
Measure: timetopeakvas
injection time Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound1 1 36.750 3.336 29.639 43.861
2 27.938 3.177 21.165 34.710
3 35.188 3.875 26.927 43.448
4 27.063 3.403 19.810 34.315
2 1 42.875 2.818 36.869 48.881
2 36.000 3.355 28.848 43.152
3 44.500 3.183 37.715 51.285
4 37.188 4.289 28.046 46.329
3 1 46.875 3.460 39.499 54.251
2 47.000 4.002 38.470 55.530
3 43.688 2.734 37.861 49.514
4 42.688 3.626 34.959 50.416
Profile Plots












































Mean Std. Deviation N
A60_int1 281.7533 119.22889 15
A60_int2 247.7467 144.38024 15
A60_int3 271.4800 116.08545 15
A60_int4 288.6867 118.85930 15
A60_sub1 198.1267 111.67750 15
A60_sub2 92.2667 95.11626 15
A60_sub3 230.0867 101.52957 15
A60_sub4 192.9400 136.50066 15
A60_mus1 188.3533 103.57024 15
A60_mus2 161.0733 106.77591 15
A60_mus3 220.7067 127.65094 15
A60_mus4 156.1667 112.69460 15
Multivariate Tests?1
Effect Value F Hypothesis df Error df Sig.
Partial Eta 
Squared
injection Pillai's T race .815 28.697“ 2.000 13.000 .000 .815
Wilks’ Lambda .185 28.697a 2.000 13.000 .000 .815
Hotelling's Trace 4.415 28.697“ 2.000 13.000 .000 .815
Roy's Largest Root 4.415 28.697a 2.000 13.000 .000 .815
time Pillai's T race .593 5.834a 3.000 12.000 .011 .593
Wilks' Lambda .407 5.834“ 3.000 12.000 .011 .593
Hotelling's Trace 1.459 5.834a 3.000 12.000 .011 .593
Roy's Largest Root 1.459 5.834“ 3.000 12.000 .011 .593
injection * time Pillai's Trace .465 1.305a 6.000 9.000 .345 .465
Wilks' Lambda .535 1.305a 6.000 9.000 .345 .465
Hotelling's Trace .870 1 .305“ 6.000 9.000 .345 .465
Roy's Largest Root .870 1.305“ 6.000 9.000 .345 .465
a- Exact statistic 
b.
Design: Intercept
Within Subjects Design: injection+time+injection*time
Mauchly's Test of Sphericity
Measure: A60





Huynh-Feldtinjection .932 .921 2 .631 .936 1.000 .500time .667 5.143 5 .400 .775 .938 .333
injection * time .189 19.601 20 .501 .628 .887 .167
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is 
proportional to an identity matrix.
a May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in 
the Tests of Within-Subjects Effects table, 
b.
Design: Intercept
Within Subjects Design: injection+time+injection*time
Tests of Within-Subjects Effects
Measure: A60
Source
Type III Sum 
of Squares df Mean Square F
Partial Eta
Sphencity Assumed 342203.479 2 171101.739 23.099 .000 .623
Greenhouse-Geisser 342203.479 1.872 182801.178 23.099 .000 .623
Huynh-Feldt 342203.479 2.000 171101.739 23.099 .000 .623
Lower-bound 342203.479 1.000 342203.479 23.099 .000 .623Errorflnjection) Sphericity Assumed 207409.160 28 7407.470
Greenhouse-Geisser 207409.160 26.208 7913.971
Huynh-Feldt 207409.160 28.000 7407.470
Lower-bound 207409.160 14.000 14814.940
time Sphericity Assumed 133167.560 3 44389.187 5.887 .002 .296
Greenhouse-Geisser 133167.560 2.325 57288.091 5.887 .005 .296
Huynh-Feldt 133167.560 2.815 47304.399 5.887 .002 .296Lower-bound 133167.560 1.000 133167.560 5.887 .029 .296Error(time) Sphericity Assumed 316665.892 42 7539.664
Greenhouse-Geisser 316665.892 32.543 9730.590
Huynh-Feldt 316665.892 39.412 8034.824
Lower-bound 316665.892 14.000 22618.992
injection * time Sphericity Assumed 81265.163 6 13544.194 1.579 .163 101
Greenhouse-Geisser 81265.163 3.765 21583.729 1.579 .196 .101Huynh-Feldt 81265.163 5.323 15267.813 1.579 .173 .101Lower-bound 81265.163 1.000 81265.163 1.579 .230 .101Error(injection*time) Sphericity Assumed 720720.285 84 8580.003
Greenhouse-Geisser 720720.285 52.712 13672.905
Huynh-Feldt 720720.285 74.517 9671.885
Lower-bound 720720.285 14.000 51480.020
Tests o f W ithin-Subjects Contrasts
Measure: A60
Source injection time
Type III Sum 
of Squares df Mean Square F Sig.
Partial Eta 
Squared
injection Linear 247566.252 1 247566.252 41.177 .000 .746
Quadratic 94637.227 1 94637.227 10.751 .005 .434
Error(injection) Linear 84171.502 14 6012.250
Quadratic 123237.658 14 8802.690
time Linear 4216.338 1 4216.338 .358 .559 .025
Quadratic 8542.222 1 8542.222 1.915 .188 .120
Cubic 120409.000 1 120409.000 18.841 .001 .574
Error(time) Linear 164748.521 14 11767.752
Quadratic 62448.113 14 4460.579
Cubic 89469.258 14 6390.661
injection * time Linear Linear 2488.399 1 2488.399 .117 .737 .008
Quadratic 14676.620 1 14676.620 3.129 .099 .183
Cubic 8083.542 1 8083.542 1.489 .243 .096
Quadratic Linear 7015.991 1 7015.991 1.072 .318 .071
Quadratic 9528.540 1 9528.540 1.318 .270 .086
Cubic 39472.070 1 39472.070 6.236 .026 .308
Error(injection*time) Linear Linear 297597.100 14 21256.936
Quadratic 65664.499 14 4690.321
Cubic 76003.011 14 5428.786
Quadratic Linear 91586.820 14 6541.916
Quadratic 101246.956 14 7231.925
Cubic 88621.899 14 6330.136




Type III Sum 
of Squares df Mean Square F Siq.
Partial Eta 
Squared
Intercept 7997246.137 1 7997246.137 106.159 .000 .883
Error 1054661.625 14 75332.973




injection Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 272.417 23.930 221.091 323.742
2 178.355 21.577 132.077 224.633
3 181.575 21.546 135.363 227.787
P airw ise C om parisons
Measure: A60
(1) injection (J) injection
Mean
Difference
(l-J) Std. Error Sig.a
95% Confidence Interval for 
Difference3
Lower Bound Upper Bound
1 2 94.062* 15.211 .000 52.721 135.402
3 90.842* 14.157 .000 52.368 129.316
2 1 -94.062* 15.211 .000 -135.402 -52.721
3 -3.220 17.577 1.000 -50.990 44.550
3 1 -90.842* 14.157 .000 -129.316 -52.368
2 3.220 17.577 1.000 -44.550 50.990
Based on estimated marginal means
*■ The mean difference is significant at the .05 level. 
a- Adjustment for multiple comparisons: Bonferroni.
M ultivariate Tests
Value F Hypothesis df Error df Sig.
Partial Eta 
Squared
Pillai's trace .815 28.697a 2.000 13.000 .000 .815
Wilks' lambda .185 28.697a 2.000 13.000 .000 .815
Hotelling's trace 4.415 28.697a 2.000 13.000 .000 .815
Roy's largest root 4.415 28.697a 2.000 13.000 .000 .815
Each F tests the multivariate effect of injection. These tests are based on the linearly independent 
pairwise comparisons among the estimated marginal means.
a- Exact statistic
2. time
3. in jection * tim e
Measure: A60
injection time Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 1 281.753 30.785 215.727 347.780
2 247.747 37.279 167.792 327.702
3 271.480 29.973 207.194 335.766
4 288.687 30.689 222.865 354.509
2 1 198.127 28.835 136.282 259.972
2 92.267 24.559 39.593 144.940
3 230.087 26.215 173.861 286.312
4 192.940 35.244 117.348 268.532
3 1 188.353 26.742 130.998 245.709
2 161.073 27.569 101.943 220.204
3 220.707 32.959 150.016 291.397
4 156.167 29.098 93.758 218.575
Profile Plots




































Mean Std. Deviation N
AR_int1 702.1200 348.94487 15
AR_int2 566.9733 336.29282 15
AR_int3 643.2667 281.57130 15
AR_int4 633.1533 257.24708 15
AR_sub1 651.6267 337.97205 15
AR_sub2 282.3800 252.99994 15
AR_sub3 697.2200 272.53295 15
AR_sub4 513.0133 358.57342 15
AR_mus1 623.0000 340.47502 15
AR_mus2 470.9667 280.51496 15
AR_mus3 689.6467 331.49488 15
AR_mus4 435.0800 317.43825 15
Multivariate TestsP
Effect Value F Hypothesis df Error df Sig.
Partial Eta 
Squared
injection Pillai's Trace .400 4.326a 2.000 13.000 .036 .400
Wilks' Lambda .600 4.326a 2.000 13.000 .036 .400
Hotelling's Trace .666 4.326a 2.000 13.000 .036 .400
Roy's Largest Root .666 4.326“ 2.000 13.000 .036 .400
time Pillai's Trace .651 7.456“ 3.000 12.000 .004 .651
Wilks' Lambda .349 7.456“ 3.000 12.000 .004 .651
Hotelling's Trace 1.864 7.456“ 3.000 12.000 .004 .651
Roy's Largest Root 1.864 7.456“ 3.000 12.000 .004 .651
injection * time Pillai's Trace .646 2.739“ 6.000 9.000 .085 .646
Wilks' Lambda .354 2.739“ 6.000 9.000 .085 .646
Hotelling's Trace 1.826 2.739“ 6.000 9.000 .085 .646




Within Subjects Design: injection+time+injection*time
Mauchly's Test of Sphericity
Measure: AR






injection .964 .473 2 .789 .965 1.000 .500
time .437 10.543 5 .062 .768 .928 .333
injection * time .099 27.260 20 .140 .506 .662 .167
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is 
proportional to an identity matrix.
a. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in 
the Tests of Within-Subjects Effects table.
b.
Design: Intercept
Within Subjects Design: injection+time+injection*time
Tests of Within-Subjects Effects
Measure: AR
Source
Type III Sum 
of Squares df Mean Square F Sig.
Partial Eta 
Squared
injection Sphericity Assumed 341718.624 2 170859.312 4.266 .024 .234
Greenhouse-Geisser 341718.624 1.931 176967.724 4.266 .026 .234
Huynh-Feldt 341718.624 2.000 170859.312 4.266 .024 .234
Lower-bound 341718.624 1.000 341718.624 4.266 .058 .234
Error(injection) Sphericity Assumed 1121439.616 28 40051.415
Greenhouse-Geisser 1121439.616 27.034 41483.298
Huynh-Feldt 1121439.616 28.000 40051.415
Lower-bound 1121439.616 14.000 80102.830
time Sphericity Assumed 1704479.110 3 568159.703 11.287 .000 .446
Greenhouse-Geisser 1704479.110 2.304 739841.004 11.287 .000 .446
Huynh-Feldt 1704479.110 2.784 612324.136 11.287 .000 .446
Lower-bound 1704479.110 1.000 1704479.110 11.287 .005 .446
Error(time) Sphericity Assumed 2114267.276 42 50339.697
Greenhouse-Geisser 2114267.276 32.254 65550.886
Huynh-Feldt 2114267.276 38.971 54252.724
Lower-bound 2114267.276 14.000 151019.091
injection * time Sphericity Assumed 659602.900 6 109933.817 2.130 .058 .132
Greenhouse-Geisser 659602.900 3.035 217349.656 2.130 .110 .132
Huynh-Feldt 659602.900 3.969 166187.684 2.130 .090 .132
Lower-bound 659602.900 1.000 659602.900 2.130 .166 .132
Error(injection*time) Sphericity Assumed 4335001.907 84 51607.166
Greenhouse-Geisser 4335001.907 42.487 102032.296
Huynh-Feldt 4335001.907 55.566 78014.896
Lower-bound 4335001.907 14.000 309642.993
Tests of Within-Subjects Contrasts
Measure: AR
Source injection time
Type III Sum 
of Squares df Mean Square F Sip.
Partial Eta 
Squared
injection Linear 200271.211 1 200271.211 4.275 .058 .234
Quadratic 141447.413 1 141447.413 4.253 .058 .233
Error(injection) Linear 655843.978 14 46845.998
Quadratic 465595.638 14 33256.831
time Linear 56807.545 1 56807.545 .877 .365 .059
Quadratic 53841.065 1 53841.065 2.780 .118 .166
Cubic 1593830.501 1 1593830.501 23.842 .000 .630
Error(time) Linear 907211.556 14 64800.825
Quadratic 271178.986 14 19369.928
Cubic 935876.733 14 66848.338
injection * time Linear Linear 17249.554 1 17249.554 .122 .733 .009
Quadratic 97099.852 1 97099.852 3.349 .089 .193
Cubic 111839.915 1 111839.915 5.082 .041 .266
Quadratic Linear 28047.382 1 28047.382 .693 .419 .047
Quadratic 75507.410 1 75507.410 1.374 .261 .089
Cubic 329858.786 1 329858.786 15.550 .001 .526
Error(injection*time) Linear Linear 1987486.976 14 141963.355
Quadratic 405903.402 14 28993.100
Cubic 308128.728 14 22009.195
Quadratic Linear 566938.859 14 40495.633
Quadratic 769566.273 14 54969.019
Cubic 296977.670 14 21212.691




Type III Sum 
















injection Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 636.378 61.508 504.456 768.301
2 536.060 62.754 401.466 670.654
3 554.673 63.603 418.259 691.088
P airw ise C om parisons
Measure: AR
(1) injection (J) injection
Mean
Difference
(l-J) Std. Error Sig.a
95% Confidence Interval for 
Difference3
Lower Bound Upper Bound
1 2 100.318* 33.545 .029 9.151 191.486
3 81.705 39.516 .173 -25.690 189.100
2 1 -100.318* 33.545 .029 -191.486 -9.151
3 -18.613 36.309 1.000 -117.292 80.065
3 1 -81.705 39.516 .173 -189.100 25.690
2 18.613 36.309 1.000 -80.065 117.292
Based on estimated marginal means
*■ The mean difference is significant at the .05 level, 
a- Adjustment for multiple comparisons: Bonferroni.
M ultivariate Tests
Value F Hypothesis df Error df Sig.
Partial Eta 
Squared
Pillai's trace .400 4.326a 2.000 13.000 .036 .400
Wilks' lambda .600 4.326a 2.000 13.000 .036 .400
Hotelling's trace .666 4.326a 2.000 13.000 .036 .400
Roy's largest root .666 4.326a 2.000 13.000 .036 .400
Each F tests the multivariate effect of injection. These tests are based on the linearly independent 
pairwise comparisons among the estimated marginal means.
a- Exact statistic
2. time
3. in jection * tim e
Measure: AR
injection time Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 1 702.120 90.097 508.881 895.359
2 566.973 86.830 380.741 753.206
3 643.267 72.701 487.338 799.196
4 633.153 66.421 490.695 775.612
2 1 651.627 87.264 464.464 838.789
2 282.380 65.324 142.273 422.487
3 697.220 70.368 546.296 848.144
4 513.013 92.583 314.442 711.585
3 1 623.000 87.910 434.451 811.549
2 470.967 72.429 315.623 626.311
3 689.647 85.592 506.071 873.222
4 435.080 81.962 259.289 610.871
Profile Plots






Short form McGill Pain Questionnaire 
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5 EXCRUCIATING ©  R. Melzack, 1984
Fig 1 The short-form McGill Pain Questionnaire (SF-MPQ). Descriptors 1-11 represent the sensory 
dimension of pain experience and 12-15 represent the affective dimension. Each descriptor is ranked on 
an intensity scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The Present Pain Intensity (PPI) of the 
standard long-form McGill Pain Questionnaire (LF-MPQ) and the visual analogue (VAS) are also 
included to provide overall intensity scores.
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